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1.0 Introduction to Blood Groups
Around 1900 Landsteiner noticed that plasma from some individuals agglutinated
with the red cells of others.1 This notion led the way to discovery of blood groups.
The ABO blood group system was discovered by both Landsteiner2 (A, B and C
(later named O), groups) and Decastello and Sturli3 (AB group) in 1901 and 1902
respectively, which made blood transfusion feasible. After this discovery more blood
groups were identified. Nowadays 29 blood group systems are known with a total of
243 system antigens. Some systems contain only 1 antigen (e.g. P system) where-
as others contain as much as 43 (MNS system) or 49 (Rh system) antigens.
The Rh blood group system was first described by Levine and Stetson in 1939. They
investigated a hemolytic transfusion reaction in a woman transfused with her hus-
band’s red cells after giving birth to a stillborn baby. They found that an agglutinin in
the woman’s serum agglutinated her husband’s red cells and those of 80% of ABO-
compatible donors. Therefore, they suggested that the woman was immunized by a
fetal antigen of paternal origin and that the hemolytic transfusion reaction was cau-
sed by the maternal agglutinin reacting with that antigen on the transfused red cells
of her husband.4 The following year, Landsteiner and Wiener found that sera from
rabbits (later guinea pigs) immunized with red cells from Rhesus monkeys aggluti-
nated 85% of human red cells.5 The antibody responsible was named anti-Rh. In that
same year Wiener and Peters found an apparently identical antibody in the sera of
patients who experienced a transfusion reaction after receiving ABO-compatible red
cells.6 Initially it was thought that the human and animal antibody recognized a com-
mon factor on both Rhesus monkey and human red cells. However, in 1942 Fisk and
Foord demonstrated that the human and animal anti-Rh were not identical and 20
years later it was demonstrated that human and animal anti-Rh do not recognize the
same antigen.7 The antigen defined by the animal anti-Rh was renamed ‘LW’ (after
its’ founders Landsteiner and Wiener). Not long after the discovery of RhD, the other
major antigens of the Rh system (C, c, E and e) were identified.8,9
1.1 Blood Group Systems
The discovery of the ABO system made blood transfusions feasible and the disco-
very of RhD unravelled the mechanism of Hemolytic Disease of the Fetus and
Newborn (HDFN) and facilitated the immunoprophylactic prevention of HDFN. The
ABO and Rh systems are clinically the most relevant systems. However, many other
blood group antibodies are capable of causing transfusion reactions and HDFN. A
blood group system may be defined as a genetically discrete group of antigens con-
trolled by a single gene or by a cluster of two or more closely linked homologous
genes with virtually no recombination occurring between them.10 Each system is
genetically discrete from every other blood group system. Any two systems may be
13
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shown to be different either by demonstrating that the genes segregate at meiosis
through the analysis of families, or by the gene loci being allocated to different chro-
mosomes or to clearly ditinct parts of the same chromosome.10 Allmost all genes
holstering blood group systems (except the P antigen) have been cloned and
sequenced, providing more insight in the molecular mechanisms causing serologi-
cal complexities like point mutations, gene conversions and unequal crossing over.
Although most antigens belong to one of the 29 blood group systems, both low fre-
quency antigens, or the 700 series,11 like Batty (incidence of less than 1% in most
populations tested) and high frequency antigens, or the 901 series,11 like Langereis
(incidence of at least 99%) can not always be assigned to a particular system. Also
blood group collections have been introduced to harbour sets of genetically, bioche-
mically or serologically related antigens that could not achieve the system status for
various reasons (like the unability to shown a genetical distinction from all existing
systems).10 At the present time, five blood group collections are defined (e.g. the
Cost collection).
1.1.1 Molecular Basis of Blood Group Systems
Every blood group system is encoded by a single gene or a cluster of two or more
highly homologous genes. Once a gene is experimentally shown to encode a pro-
tein that carries a blood group, focused genotyping of blood from donors with
serologically defined antigen profiles is used to determine the molecular basis of the
encoded protein (antigen). Blood group antigens of a certain system are encoded by
different alleles of the gene coding for that particular blood group. Therefore, the
diversity of alleles of that gene determines the number of different antigens of a sys-
tem. Different genetic biological mechanisms account for the molecular diversity of
blood groups systems like nucleotide substitutions, crossing over, alternative RNA-
splicing, deletion of nucleotides, exons or genes, insertion of nucleotides, exons or
genes and exon duplication events.12 However, most bloodgroups are encoded by
Single Nucleotide Polymorphisms (or SNP’s), which means that a single nucleotide
difference in the whole gene determines which blood group antigen is expressed on
the protein of the red cell.
1.1.2 Blood Group Antigen Structure and Function in Red Cells
Most blood groups are synthesized by the red cell. Biochemical and molecular gene-
tic studies have revealed most polypeptide antigen structures. The chemical nature
of carbohydrate antigens (like ABO, Hh, Lewis and P) has been known for some time
but the glycosyltransferases that direct the synthesis of these molecules have only
been characterized more recently. Generally, blood group gene products can be
classified into five functional categories: a) membrane transporters and channels, b)
receptors for exogenous ligands, viruses, bacteria and / or parasites, c) adhesion
molecules, d) enzymes and e) structural proteins. However, some molecules may fit
14
Chapter 1
110094_Binnen  08-11-2005  09:15  Pagina 14
into more than one specified category (e.g. Band 3 is an anion exchanger, plays a
role in membrane structure and also plays a role in the cytoadherence of P.
Falciparum infected RBC’s to the vascular endothelium). Most blood group systems
have “null phenotypes”, phenotypes in which the antigens of the system are not
expressed. Null phenotypes are generally caused by inactivating mutations in the
encoding gene. Therefore the protein is not present in any tissue, although excepti-
ons are known (like the FY-GATA mutation which only hampers Fy antigen
expression on red cells). Only a few null phenotypes are known to be associated
with a clinical syndrome (like the Rhnull, McLeod and Leach null phenotypes) which,
if present, is often mild or of low severity.13
Ad a) Blood group system antigens that function as membrane transporters and/or
channels usually are polytopic and have an even number of -helical membrane
spanning domains of about 21 amino acids each and have both termini inside the
cytosol. They facilitate the transport of biologically important molecules into or out of
the cell. This category includes the Band 3 anion exchanger (Diego system),14 the
water channel AQP1 (Colton system)15 and the urea transporter Kidd.16
Ad b) Some red cell surface proteins appear to function as receptors for exogenous
ligands, viruses, bacteria and/or parasites. The biological significance of the interac-
tion between microorganisms and red cells is unknown, except for some parasitic
infections with a intra-erythrocytic stage of development (like malaria). Many
microorganisms recognize sialic acid, a charged monosaccharide present on cell
glycoconjugates and abundantly present on glycophorin A.17 An example of a micro-
bial interaction with an other carbohydrate structure is the parvovirus B19 that uses
the P blood group glycolipid to infect human erythrocyte progenitor and in most
cases causes benign anemia.18,19
Ad c) Other red cell surface proteins function as adhesion molecules and most of
these proteins carry blood group activity. Cell adhesion molecules are involved in the
adhesion of cells to other cells and to the extracellular matrix. CD44 is a wide-spre-
ad glycoprotein which carries the Indian (Ina/Inb) polymorphism and possibly also
the high frequency antigen AnWj.10 CD44H, the standard form of the molecule, is
present on red cells and leukocytes. AnWj most probably is an isoform of the CD44
glycoprotein.20 On epithelial cells, AnWj appears to be a receptor for Heamophilus
Influanzae, a major cause of bacterial meningitis in young children.21 Also the
Lutheran (Lu) and LW antigens display adhesion activity. The Lu glycoprotein binds
laminins (a family of ECM glycoproteins, present in all basement membranes)22 and
the LW antigens (expressed on the red cell membrane glycoprotein CD242 or ICAM-
4) form a ligand for intergrins.23
Ad d) Blood group antigens may also be dependent on enzymatic activity that syn-
thesizes the antigen. Typical examples of this are the glycosyltransferases
responsible for the biosynthesis of carbohydrate antigens (ABO, Hh, Lewis, etc.).
The Yt (Cartwright) glycoprotein represents acetylcholinesterase (AChE, a serine
15
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hydrolase). Besides its GPI linked presence on red cells, AChE is also present in
patients with PNH (Paroxysmal Nocturnal Haemoglobinuria) who are unable to cou-
ple GPI anchors.24 The Kell glycoprotein protein is an endopeptidase capable of
cleaving the biologically inactive big endothelin (40 amino acids) into the smaller
active vasoconstrictor endothelin (21 amino acids).25
Ad e) Some blood group molecules are involved in the structure of red blood cells.
The red cell architecture is maintained by the membrane skeleton, a network of gly-
coproteins beneath the plasma membrane. Red cell membrane glycoproteins that
link the membrane with its’ skeleton are Band 3 (also a red cell transporter), the
Diego antigen and glycophorin C and its’ isoform glycophorin D (carrying the
Gerbich blood group antigens). Mutations in the genes of the above mentioned
blood group antigens result in abnormally shaped erythrocytes. The Rh system also
relates to the red cell shape by being firmly linked to the red cell membrane skele-
ton.26,27 Although GPA and GPB are major erythrocyte membrane components, they
are not critical to red cell membrane integrity.
1.1.3 Blood Group Immunogenicity
Transfused red cells are regarded as incompatible if their survival in the recipient’s
circulation is limited by antibodies. Incompatible transfused red cells may cause a
hemolytic transfusion reaction. A distinction is made between an immediate hemo-
lytic transfusion reaction (IHTR), in which destruction begins during transfusion, and
a delayed hemolytic transfusion reaction (DHTR), in which destruction begins only
after there has been an immune response, provoked by the transfusion. Almost all
DHTR’s are caused by secondary immune responses.28
Red cell destruction is classified as either intravascular, characterized by the ruptu-
re of red cells within the blood stream and liberation of Hb into the plasma, or as
extravascular, characterized by phagocytosis of red cells by macrophages with sub-
sequent liberation of bilirubin into the plasma.29 Antibody-mediated intravascular red
cell destruction is caused by the sequential binding of the complement components
C1 through C9 following the formation of antibody-antigen complexes. This type of
cell destruction is usually seen following a transfusion of major-side ABO incompa-
tible blood. With extravascular red cell destruction, the abnormal (IgG or C3) coating
of the red cell acts as a signal to macrophages that attempt to remove the abnormal
protein from the red cell membrane. The macrophage activity may result in phago-
cytic destruction of the red cell within the liver and the spleen. However, if the
macrophage succeeds in removing the IgG or C3 coating from the red cell, it also
removes a part of the cell membrane creating a spherocyte.30
Hemolytic disease of the fetus and newborn (HDFN) is a condition in which the life
span of the infant’s red cells is shortened by the action of specific antibodies deri-
ved from the mother by placental transfer.28 The immunoglobulin involved in HDFN
is IgG which binds to the Fc receptor on the plasma membrane of the placenta.31
16
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Although the commonest IgG red cell antibodies in human serum are anti-A and
anti-B, anti-D is involved in most cases of moderate to severe HDFN.28 The mecha-
nism of HDFN due to anti-D is described in 1.2.4.
1.2 The Rh Blood Group System
1.2.1 Molecular Basis of the Rh System
The RHD and RHCE genes, encode the RhD and RhCcEe proteins respectively.
Each gene consists of 10 exons with a total of 417 amino acids. The RHD and
RHCE genes face each other with their 3’-end at the RH locus on chromosome
1p36.13-p34.3. The RHD gene is flanked by the upstream Rh box (5’-end) and the
downstream Rh box (3’-end). Situated in between the downstream Rh box and
RHCE is the SMP1 (Small Membrane Protein 1) gene of which the exact function is
not known (figure 1A).
1.2.1.1 RhD-negativity
RhD-negative RBC’s usually lack the entire RhD protein on the erythrocyte surface
due to an RHD gene deletion. This deletion is proposed to have occurred through a
mechanism of unequal crossing over at the RH locus, triggered by the homology of
the Rh boxes (figure 1B).32
Figure 1. The structure of the RH locus (A) and the proposed mechanism of unequal crossing over (B)
causing a RHD negative RH locus (C).
As a result of this unequal crossing over, the RHD negative RH locus carries a so
called hybrid Rh box, with its’ 5’-end identical to the upstream Rh box and its’ 3’-end
identical to the downstream Rh box. About 15% of the European population is RhD-
negative whereas in blacks only 5% carry the RhD-negative phenotype and in
Asians RhD-negativity is even more rare (<1%).33 In whites, the RHD gene deletion
is the major form of RhD-negativity. In blacks, RhD-negativity is frequently caused
by either the RHD allele or the r’s (or (C)cdes) allele. The RHD allele is characte-
rized by a 37 bp duplication of the intron 3/exon 4 boundary causing a frame shift
17
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and a premature translation termination codon in exon 4, 609G>A, 654G>C and
667T>G missense mutations in exon 5 and 674C>T missense and 807T>G nonsen-
se mutations in exon 6 and has a frequency of 0.0714 in blacks.34 The r’s is a hybrid
RHD allele characterized by the presence of RHCE exons starting from nt. 455
(exon 3) to exon 7. The r’s allele gives rise to a weak expression of RhC and has a
frequency of 0.036 in blacks.35,36 Figure 2 shows some of the most frequent forms
of RHD negativity.37
Figure 2. Different forms of RHD-negativity 
1.2.1.2 Weak D Expression
Normal RhD-positive cells carry an antigen density ranging from 15,000 to 33,000
sites per cell (from R1r to R2R2). However, phenotypes have been identified with
(type-specific) antigen densities between 70 and 5200 RhD antigens per cell. These
phenotypes are called weak D and are caused by amino acid substitutions on the
intracellular and transmembraneous segments of the RhD protein. RBC’s with the
weak D phenotype carry a presumably intact RhD antigen and occur in 0.2% to 1%
of whites. Until now, 40 different weak D alleles have been identified at the molecu-
lar level38 of which weak D types 1 and 2 are most frequent (70% and 18% of all
weak D’s, respectively) and types 1 to 3 represent the vast majority of all weak D.39
In Asians, a very weak form of RhD is frequent among the RhD-negative typed
population, called Del. The RhD-Del expression can only be detected by the adsorp-
tion/elution technique which is not a standard diagnostic procedure in most
laboratories.
Since the weak D phenotype carries a presumably intact RhD antigen alloanti-D for-
mation is not likely. However, one case of weak D type 15 has been reported to have
alloanti-D and the weak D type 4.2 is functionally identical to the DAR partial RhD
and known for its alloanti-D formation.40 Additionally, an anti-D was observed after a
RhD-positive transfusion in an individual with the weak D type 1 pheno- and geno-
18
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type.41 Therefore, the distinction between partial and weak D cannot be made on
alloanti-D production. For the prediction of anti-D immunization risk in weak D
Wagner et al. have developed the Rhesus index. This index is based on the antigen
density of several different MoAb’s and may theoretically range from 1.0 (low immu-
nization risk, e.g. normal RhD) to 0.0 (high immunization risk, e.g. partial RhD
lacking many epitopes). Weak D types 4.2 and 15 indeed show Rhesus indexes of
0.21, which is lower than all other weak D’s with the single exception of weak D type
7 (Rhesus index of 0.03).40 However, it has been shown that the Rhesus index is not
only dependent on the quantity of the antigen but also on the affinity of the anti-
body.42
1.2.1.3 Partial RhD Expression.
The Rh system is highly diverse. This diversity is probably caused by the tandem
arrangement of the RHD and RHCE genes (figure 3). This genetic configuration has
led to the frequent creation of aberrant RH alleles caused by unidirectional replace-
ment of RHD or RHCE gene fragments with their RHCE or RHD counterparts,
leading to the formation of RHD-CE-D or RHCE-D-CE alleles, respectively.
Templated mutations, probably also caused by very short gene conversions, in
which an isolated RHD or RHCE nucleotide is replaced by its RHCE or RHD speci-
fic counterpart have been found frequently. Finally, single point mutations in the
RHD/CE genes that do not match the RHD/CE homologs have been described.
These three mechanism have led to a large number of variant alleles. These alleles
have mostly been described in non-White populations and give rise to an altered Rh
protein.10,43 Mutated RHD alleles cause altered RhD antigens, usually missing one
or more epitopes (therefore this category is also referred to partial RhD). Sometimes
new Rh antigens are expressed due to the different protein loop configuration.
Figure 3. Tandem arrangement of the RHD and RHCE genes, leading to RHD(1-2)RHCE(3-8)D(9-10).
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Carriers of a partial RhD protein most often produce anti-D antibodies against the
RhD epitopes missing on their own RhD protein, when they are exposed to the com-
plete RhD protein. The extant knowledge of the molecular basis of partial and weak
D phenotypes enabled the development of the phylogeny of RHD in humans in
which most “African” alleles are represented with the representative “Eurasian”
(European-Asian) alleles (figure 4).44,45,46
Figure 4. Phylogeny of RHD in humans. 
1.2.2 Structure of the Rh Complex in Red Cells
The Rh blood group system antigens are part of a larger Rh complex in the red cell
membrane.The RhD and RhCcEe polypeptides display an almost identical membra-
ne organization. Both polypeptides consist of twelve membrane spanning domains
20
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and their NH2 and COOH domains are situated intracellular which results in six
extracellular domains to which immune responses are directed (figure 5).47,48 The
RhD and RhCcEe polypeptides are encoded by the homologous RHD and RHCE
genes (figure 5).49
Figure 5. Schematic representation of chromosomal arrangement of the RH locus, the RHD and RHCE
genes and the RhD and RhCE polypeptides.
In the membrane, the Rh proteins are closely associated with the Rh associated gly-
coprotein RhAG. Despite being genetically discrete, the Rh protein and RhAG share
a 36% homology and adopt a very similar configuration in the red cell membrane.
RhAG has a single N-glycan on its first extracellular loop50 whereas Rh proteins are
not glycosylated. Studies with Rhnull cells, a rare phenotype in which the Rh pepti-
des are deficient, have shown the involvement of the Rh proteins with other proteins.
The expression of the LW antigens is more pronounced RhD-positive cells than on
RhD-negative cells. Monoclonal anti-LW coprecipitates LW glycoprotein and the Rh
polypeptide.51 This suggests a close association with the Rh proteins. The Fy5 anti-
gen (Duffy system) is absent on Rhnull cells and its expression is reduced on D-- cells
(cells not expressing RhCcEe proteins). Glycophorin B (GPB) expression is reduced
with 60-70% on Rhnull cells, reflected in reduced expression of the S, s and U anti-
gens.52 The association between GPB and Rh complex is also reflected in the
coprecipitation of GPB with anti-RhAG.53 RhAG of GPB deficient red cells is more
heavily glycosylated than normal. Due to the absence of GPB, which may facilitate
transport of RhAG to the cell surface, RhAG stays in the intracellular membrane sys-
tem longer, permitting more glycosylation.54 CD47 (or integrin-associated protein
IAP) expression is reduced with 75% on Rhnull cells compared to normal. CD47 may
function as a marker of self on red cells by binding signal regulatory protein (SIRP)
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on macrophages, generating a negative signal that prevents phagocytosis of the red
cells.55 Cotransfection experiments have shown an association between Band 3
(Diego antigen) and Rh in which Band 3 enhances the expression of D, c, E and
endogenous RhAG.56 The Rh proteins and their associated and accessory proteins
are present as a protein cluster in the red cell membrane.52,54 The Rh complex con-
sists of a tetrameric core of two RhAG and two RhD/CcEc proteins, accompanied by
LW, GPB and CD47. Only RhAG appears to be a requirement for the expression of
Rh polypeptides.
1.2.3 Function of the Rh Complex in Red Cells
DNA sequencing revealed that the erythroïd Rh homologous RhD/RhCE and espe-
cially RhAG share a significant sequence similarity to the Mep/Amt family of
polytopic proteins which span the membrane 10-12 times and function as ammoni-
um transporters.57 Recently, the non-erythroïd Rh homologous RhBG and RhCG
have been described, which seemed to be the missing link in the ammonium trans-
porter phylogenetic tree.58,59 RhAG and RhCG have been shown to promote
ammonium ion transport when transfected into yeast.60 It was also shown that
RhAG, transfected into Xenopus oocyte, or yeast cell, functions as an importer of
ammonium.60,61 That the Rh complex exports ammonium from human red blood
cells was recently described.62 The ammonium import was measured during the
incubation of normal RBC’s, Rhnull amorph cells (expressing 33-38% RhAG) and
Rhnull regulator cells in a solution containing a radiolabelled analogue of NH4Cl (14C-
methyl-NH3Cl). It was shown that Rhnull regulator cells accumulated the
radiolabelled methyl-ammonium ions to significantly higher levels than normal
RBC’s. Subsequently, Rhnull amorph cells accumulated an intermediate amount of
methyl-ammonium ions. To show that the accumulation of methyl-ammonium was
due to a decreased export, the release of intracellular methyl-ammonium ions was
measured. Normal RBC’s were shown to release 87% of the methyl-ammonium ions
within 30 seconds, whereas Rhnull regulator cells released only 46% and Rhnull
amorph cells showed an intermediate pattern.62 The ammonium transport function
of the Rh proteins could serve as a protection for the RBC in an environment with
high ammonium levels, such as in the kidney during the excretion of acids.62 It has
also been postulated that Rh/RhAG proteins mediate movement of CO2, based on
the observation that expression of RH1, one of the two Rh-like proteins in blue green
algea, increased when cells were grown in 3% CO2 and decreased when these cells
were shifted to air.63 However, more than 2000 genes were induced in blue green
algea when shifted to grow in CO2, RH2 did not show this effect and no direct evi-
dence for RH1-mediated movement of CO2 has been demonstrated. A recent
publication shows that RhAG facilitates CH(3)NH(2)/NH(3) movement across the
RBC membrane and represents a potential example of a gas channel in mammali-
an cells.64 It is also hypothesized that RhAG serves as an ammonium or ammonia
22
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scavenger, keeping the total blood ammonia (NH4+ + NH3) level low by trapping
ammonium (NH4+) inside the RBC.43 The mechanism of ammonia transport by
Amt/MEP was recently demonstrated by elucidating the structure of AmtB. This
study describes that the AmtB protein is the first structure of a transmembrane chan-
nel family that can conduct unhydrated molecules that in isolation would be
gasseous.65
1.2.4 Immunogenicity of the Rh System
The Rh system comprises 49 antigens. The major Rh antigen from a clinical point of
view is RhD, followed by Rhc. Eighty percent of RhD-negative individuals who recei-
ve RhD-positive blood will produce anti-D antibodies after the first encounter66 and
only 7-8% of RhD-negative individuals remain complete non-responders.67
Antibodies against RhD are known to cause hemolytic disease of the fetus and
newborn (HDFN), hemolytic transfusion reactions and are involved in autoimmune
hemolytic anemia. Even after the introduction of RhD immunoglobulin, maternal sen-
sitization occurs in 0.8-1.5% of RhD-negative mothers due to failure of prophylaxis,
or during pregnancy as a result of fetomaternal hemorrhage.68 Of the 200 cases of
HDFN per year in The Netherlands, 170 cases of HDFN are due to RhD antago-
nism.69 Hemolytic transfusion reactions due to anti-Rh alloantibodies (especially
anti-D antibodies) are rare in countries were patient and donor are matched for the
ABO and RhD antigens. Hemolytic transfusion reactions due to anti-D alloantibodies
are usually severe. In autoimmune hemolytic anemia, warm autoantibodies with a
broad Rh-specificity are usually found in the patients serum and eluate, causing the
shortened RBC lifespan.
1.2.5 Weak D, Partial RhD and Transfusion Practice
The molecular mutations in weak D are by definition situated in those parts of the
RHD gene that encode for the transmembrane or intracellular regions of the RhD
protein. However, as described in 1.2.1.2, some of the less fequent weak D pheno-
types have been described to provoke an anti-D reaction when they encounter
normal RhD. Therefore, when a weak D phenotype is serologically indicated the
initial transfusion policy, pending further type characterization, should be RhD-nega-
tive. When further (molecular) analysis shows the presence of weak D types 1, 2 or
3, it is advisable to convert the transfusion policy to RhD-positive since in these
weak D phenotypes no immunization has ever been described and the stock of
RhD-negative blood is usually limited. In all other cases RhD-negative transfusions
are still recommended.70
Most aberrant RHD alleles encode RhD proteins that lack the expression of one or
more RhD epitopes.Therefore, they are prone to form an anti-D against the RhD epi-
tope(s) that they miss. For this reason, partial RhD phenotypes are always
transfused with RhD-negative blood. Most partial RhD are present in non-White
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populations except for the DVI phenotype which occurs with a incidence of 0.015%
in the European population and is highly immunogenic.71 Therefore, the Dutch con-
sensus for RhD serotyping in patients recommends the use of an anti-D reagent that
does not agglutinate the DVI protein so that the patient is typed RhD-negative and
will therefore receive RhD-negative blood. However, in newborns, the DVI protein
should be recognized as RhD-positive regarding the administration of anti-D immun-
oprophylaxis to the mother.72
1.3 Ethnic Diversity
The most recent ancestor of the human species and the chimpanzee lived approxi-
mately 5 to 6 million years ago in sub-Saharan Africa. The earliest members of the
human-like (hominid) lineage, the australopithecine, remained confined to Africa.
One of these australopithecines evolved into the first species of the genus Homo
about 2.5 to 2 million years ago.The H. ergaster/ erectus, the first uncontested mem-
ber of this genus, is believed to be the first hominid to have spread out of Africa
about less than 2 million years ago. This spread is chronicled by the presence of H.
erectus-like fossils. These fossils were found in the Middle east about 1.7 million
years ago, in East Asia possibly 1.9 but certainly 1.1 million years ago and in
Southeast Asia probably 1.8 million years ago. The H. erectus-like fossils found in
Western Europe are not older than 1.0 million years. From this data a migration route
could be reconstructed. Later, due to unknown reasons however a connection with
the Ice Age has been postulated, a different branch of H. erectus evolved and spre-
ad from the Middle East to Europe. During the period of expansion, the species
differentiated into distinct variants, leading to disagreement between paleoanthropo-
logists about the identity of the H. erectus in different regions. What happened after
the expansion is heavily disputed. The hominid fossil records (of the last 1.5 million
years) have been interpreted in three different hypotheses, the candelabra hypothe-
sis, the multiregional hypothesis and the uniregional hypothesis.73
1.3.1 The Candelabra Hypothesis
The Candelabra hypothesis (figure 6) was postulated by CS Coon in 1963.74 He
postulated that the different populations of H. erectus in the different regions evol-
ved into subspecies of a new species, H. sapiens, independently of each other. The
subspecies correspond to the four main geographical races. This model postulates
an unprecedented mode of species origin. Instead of diversification in different spe-
cies, isolated populations evolve towards subspecies of the same new species.
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Figure 6. The Candelabra hypothesis as proposed by Coon.73,74
Independent emergence of H. sapiens from H. erectus in four different regions by parallel evolution.
The appearance of characteristics shared by the subspecies and specific for the
new species is explained by the fact that all the mutations responsible for the appea-
rance of these characteristics arose independently at least four times and were also
fixed independently in each of the four populations. Therefore, this model implies an
extraordinary form of parallel evolution.
1.3.2 The Multiregional Hypothesis
The multiregional hypothesis (figure 7) was developed by AG Thorne and MH
Wolpoff in 1992.75 This hypothesis postulates the emergence of the same species,
H. sapiens, from the same ancestor, H. erectus, in the four different geographical
races. It differs from the Candelabra model in that this hypothesis requires a conti-
nuous gene flow among the populations and therefore abolishes the requirement for
parallel evolution. The explanation for the existence of two types of characteristics,
those that differentiate the populations in the various regions from one another and
those that are shared by the different populations but distinguish H. sapiens from H.
erectus, is that regional differences are the result of mutations that arose locally and
then remained limited to the population of each region and that the shared, H.
sapiens-specific characters are the result of mutations that arose in one population
and than spread by gene flow to all the other regional populations. Because each of
the mutations arose only once, its fixation in the different populations does not repre-
sent parallel evolution. Multiregionalists believe in a evolution in which one species
(H. erectus) evolves gradually, without splitting into a single new species (H.
sapiens).
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Figure 7. The multiregional hypothesis as postulated by Thorne and Wolpoff.73,75
The evolution of H. sapiens from H. erectus in four geographical regions by spreading of H. sapiens-
specific characteristics from the population of their origin to all other populations. At the same time,
characteristics responsible for regional continuity have remained restricted to the population of their
origin.
1.3.3 The Uniregional Hypothesis
The uniregional hypothesis (figure 8) was postulated by Stringer and Andrews in
1988.76 They divided the same sets of fossils in each of the regions into two catego-
ries, one related to H. erectus and one to H. sapiens.They interpret the first category
as illustrative of the spread of H. erectus in the different regions, a spread that pro-
duced different forms, that all became extinct. The second category was seen as the
product of a process in which the H. ergaster evolved in Africa into H. sapiens and
then spread (less that 200,000 years ago) into the regions previously occupied by
the descendants of H. erectus, as well as Australia and America. Thus, there was
only one region in which the H. Sapiens originated and that this region was Africa.
Therefore, this hypothesis is often referred to as the “Out of Africa” model.
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Figure 8. The uniregional (Out of Africa) hypothesis as postulated by Stringer and Andrews.73,76
Lineages founded by H. erectus became extinct in all regions except in Africa. The
African lineage gave rise to H. sapiens which spread to all regions previously inha-
bited by H. erectus and its’ descendants.
The main differences between the multiregional and the uniregional hypotheses are
that the multiregional hypothesis postulates that H. sapiens evolved simultaneously
from different populations in several regions, and that during its evolution genes flo-
wed from one population to the other whilst the uniregional hypothesis postulates
that H. sapiens evolved from a single population in one region and than expanded
to other regions. Furthermore, the multiregional hypothesis postulates that the evo-
lution of H. sapiens began less that 2 million years ago whereas the uniregional
hypothesis postulates a much more recent evolution of the H. Sapiens, about
200,000 years ago. However, various uniregionalists differ in their opinion about
what happened in Europe.
1.3.4 Phylogenetics
Since paleoanthropologists can not agree on how the fossil data should be interpre-
ted, non-paleoanthropological data is sought that could give more insight into
evolutionary pathways. Despite the fact that in the present time all lineages other
than H. sapiens are extinct, it is still possible to gain information about the extinct
ancestors by molecular analysis of especially the differentiated regions in the DNA
of H. sapiens itself. By sequencing large stretches of DNA in different populations,
mutation patterns will be found. Some mutations will be shared by different popula-
tions. The degree of sharing reflects the extend to which the DNA sequences are
related just as the sharing of substitutions reflects phylogenetic relationships among
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species. Therefore, the “ancestor of all ancestors” has none of the mutations that dif-
ferentiate the living individuals.
The first tree of human populations was published in 1964, based on gene frequen-
cy data of five blood group systems (ABO, Rh, MN, Diego and Duffy) totalling 20 loci
from 15 populations from different continents. Due to the low number of loci studied
and the fact that the genes involved were all coding for blood group antigens (which
probably are subject to the distorting influence of natural selection) the first tree was
not perfect. However, in 1982 Nei et al. produced another tree of human populations
based on gene frequencies of multiple protein encoding genes as well as blood
group genes (figure 9).73 They place the first split of H. sapiens approximately
110,000 years ago and the second split 41,000 years ago. Overall they conclude that
all existing populations of H. sapiens are derived from an ancestral population that
existed in Africa. Because the African population is the oldest population it had the
most time to accumulate genetic differences.
Figure 9. Tree of human populations by Nei and Roychoudhury in 1982.73
In 1987 a paper was published by Cann et al.77 They conducted PCR-R(estriction)
F(ragment) L(ength) P(olymorphism) analyses on mitochondrial DNA (mtDNA, does
not recombine and is passed on strictly by the maternal lineage) of 147 individuals
from five different populations (African, Asian, Australian, Caucasian and New
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Guinean) with 12 restriction enzymes (totalling 467 sites). The tree they constructed
consisted of two main branches, one with only African samples and the other with
all remaining samples including some African samples. The researchers postulated
that all mtDNA analysed stemmed from one woman that must have lived some
200,000 years ago, probably in Africa and that all populations, except the African
population, had multiple origins. The postulated ancestral African woman is often
referred to as “Black Eve”, and released a genuine media spectacle. However, later
studies conducted on the Y-chromosome indicate not only an African origin but also
a bi-directional population movement and studies on the X-chromosome are in con-
cordance with the multiregional hypothesis.78,79 Studies conducted on microsatellite
loci and on a different source, organic molecules or biomarkers, may give a new and
deeper insight into the human evolution.
1.3.5 Hominid Speciation
To emerge as a new species, a group of individuals –the founding population– must
somehow disengage itself from its parental population and begin an existence of its
own (a population comprising the ancestral species is split in two). According to the
founder effect hypothesis a species arisis from a pair or from very few individuals
that have become isolated from the parental population. The founding period is ref-
fered to as the bottleneck phase. The rival hypothesis interprets the transition from
one species to another as a gradual proces without radical reduction in population
size. It believes that it is the accumulation of small changes in the gene pool which
differentiate and eventually isolate it from all other pools. According to the cladoge-
netic hypothesis, there are two modes of species formation, allopatric speciation
(spatial) in which in order to diverge, the sisterpools must become separated by a
barrier formed by long geographical distance and sympatric speciation (temporal) in
which species that live in the same place diverge to form distinct species. However,
the anagenetic (phyletic) hypothesis assumes a linear transformation from one
population to another without a population splitting. Both modes of speciation exist.73
Multiregionalists will argue that H. erectus originated by a founder effect during a
bottleneck phase some 2 milione years ago. Uniregionalists will also explain the
emergence of H. sapiens via a bottleneck, which they date much later in time. While
cladogenesis in the formation of hominid species is now the preffered hypothesis,
not so long ago hominid evolution was generally interpreted in terms of anagenesis.
Still, multiregionalists see the transformation of H. erectus into H. sapiens from an
anagenetic point of view.
1.3.6 Evolutionary Aspects of RH
Until the discovery of the sequence related RHAG homologues in vertebrates it was
believed that the Rh proteins were erythroïd-specific and were only present in hig-
her vertebrates. The RHAG homologues were found as 2 different RHAG-like genes
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in Caenorhabditis elegans (a nematode) and as 1 RHAG-like gene in Geodia cydo-
nium (a marine sponge), with amino acid identities of 46%, 39% and 47%
respectively, as compared to human RhAG.80,81 RHAG counterparts were also found
in mouse and macaque.82 The highest homology between RhAG and Rh is found in
the transmembraneous parts of the protein, suggesting a conserved functional role
for the RhAG protein family. RH orthologs were found in chimpanzees, gorillas,
orang-utans, gibbons, baboons, macaques, New World monkeys, mice and
cows.83,84 The invertebrate homologues resemble RHAG more strongly than RH.
Therefore it is postulated and widely accepted that the RH gene is a duplication of
the RHAG gene and subsequently that this duplication event occurred during prima-
te evolution (about 250- to 346 million years ago).85 However it is also estimated by
phylogenetic analysis that the time of coalescence of mammalian Rh cDNA sequen-
ces is 100 million years.86 RHCE is believed to represent the ancestral gene while
the RHD gene is the result of a duplication event that took place about 8 to 11 mil-
lion years ago.87
Southern Blot experiments with human Rh cDNA probes have shown that only three
species carry more than one RH gene; chimpanzees, gorillas and humans.88
However, most rhesus monkeys and one among ten gorillas investigated so far were
also found to carry small Rh-related 5’-fragments which correspond, most probably,
to truncated RH genes. These truncated RH genes may be the result of either a par-
tial duplication or they may be left over from an ancestral, partially deleted gene.89,90
Recently the physical structure of the RH locus was revealed. RHD is flanked by two
highly homologous sequences (98.6%) of approximately 9000 bp, dubbed upstream
and downstream Rhesus boxes (Rh boxes). The downstream Rh box is followed by
the SMP1 gene and RHCE, antidromically. Deletion of RHD is proposed to have
occurred via a mechanism of unequal crossing-over within a stretch of 1463 bp in
which the Rhesus boxes share an identical sequence (identity region).32
The mouse orthologue of human Rh is Rhced. In mice, no sequences were found
homologous to either the human Rh boxes or an additional RH gene. The mouse
orthologue of SMP1 is located antidromically at the 3’-end of the Rhced gene (the
same as in humans except that in the human 3’-untranslated region both genes par-
tially overlap).91
The Rh system now knows eight haplotypes which were formed by a series of dupli-
cation, mutation and recombination events (figure 10). Dce is the ancestral
haplotype. Deletion or inactivation of RHD then created the dce haplotype. The DCe
haplotype may have been the result of a non-reciprocal recombination of RHD exon
2 sequences into the ce allele of RHCE and DcE would have arisen from a point
mutation in the ce allele. Then, dCe arose from a recombination between DCe and
cde, dcE from recombination between DcE and dce, and DCE from recombination
between DCe and DcE. The very rare dCE haplotype must have arisen from recom-
bination between the also rare haplotypes dcE and dCe.10,46
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Figure 10. Schematic representation of the proposed derivation of the 7 different haplotypes from the
ancestral Dce haplotype.46
1.4 Scope of this Thesis
The aim of the research described in this thesis was to gain insight into the ethnic
variability of the Rh blood group system with the ultimate goal of developing typing
methods that reliably predict the Rh blood group in a multiracial society in such a
way that the effectivity of the present prevention-policy standards are guaranteed. To
achieve this, we compared serological data with data obtained by molecular assays
regarding RHCc typing and investigated the discrepancies. A new RHC/RHc geno-
typing strategy was developed that proved to generate reliable results in different
ethnic groups (chapter 3).
During the course of the study the exact RH locus and the mechanism causing RhD-
negativity in whites became known, enabling the molecular determination of RHD
zygosity. This triggered us to study the RHD zygosity at the RH locus and the
mechanism causing RhD-negativity in non-White persons (chapter 2). We also had
the opportunity to investigate RhD-negativity and RHD-zygosity in Chinese HAN
population (chapter 4).
The recently proposed phylogeny of RHD in humans shows 4 main clusters (figure
4).45 Each of the African clusters is characterized by a specific animo acid substituti-
on relative to the Eurasian RHD allele. Because of its proposed evolutionary and
clinical importance we further analyzed the RHD(201R, 223V) cluster which includes
the main part of the weak D type 4 and DIVa clusters, in five ethnic groups (chapter
5).
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To prevent maternal synthetization of anti-D due the maternal-fetal RhD-incompati-
bility IVIG-RhD is administered to all RhD-negative pregnant women in the 30th week
of gestation in The Netherlands. IVIG-RhD is biological material and is becoming
scarce as RhD immunization is prevented. Thus, unnecessary use of IVIG-RhD
should be avoided, like administering IVIG-RhD to RhD-negative women carrying an
RhD-negative fetus. Therefore, we developed a molecular assay to test for RHD
positivity with respect to the RhD-negative RHD alleles (RHD alleles that do not give
rise to an RhD protein due to various underlying molecular mechanisms) and eva-
luated the use of this strategy on cell-free fetal DNA derived from maternal plasma
(chapter 6).
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Chapter 2
The highly variable RH locus in nonwhite persons hampers
RHD zygosity determination but yields more insight into 
RH-related evolutionary events
Martine GHM Grootkerk-Tax, Petra A Maaskant-van Wijk, Judith van Drunen and C Ellen van der
Schoot. The highly variable RH locus in nonwhite persons hampers RHD zygosity determination but
yields more insight into RH-related evolutionary events. Transfusion 2005;45:327-337.
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Abstract
Background: Knowledge about paternal RHD hemi or homozygosity is of clinical
interest in alloimmunized pregnant women. D negativity in white persons is usually
caused by deletion of the RHD gene. Recently, the physical structure of the RH locus
and the mechanism cusing the deletion of the RHD gene have been explored, ena-
bling RHD zygosity determination in white persons by specific detection of a hybrid
Rhesus box characteristic for the RHD- locus
Study design and methods: RHD zygosity was determined in 402 samples from
five different ethnic groups by polymerase chain reaction (PCR)-restriction fragment
length polymorphism and by a newly developed real-time quantitative PCR. The
Rhesus boxes of samples showing discrepancies between both tests were cycle
sequenced.
Results: In nonwhite persons, several mutated Rhesus boxes exist that hamper
zygosity determination by detection of the RHD- locus. Such mutated Rhesus boxes
in D+ RHD homozygous black persons have a frequency of 0.22. In white persons,
no mutated Rhesus boxes were encountered so far.
Conclusions: Owing to the high frequency of the mutated Rhesus boxes, zygosity
determination by detection of the RHD- locus is not feasible in nonwhite persons.
The cosegregation of variant RHD genes (RHD and (C)cdes) with specific mutated
Rhesus boxes yields more insight into the evolutionary events concerning variant
RHD genes and mutated Rhesus boxes.
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Introduction
The Rh system is a highly complex blood group system in which the Rh antigens are
located on D and CE polypeptides. The polypeptides are encoded by the RHD and
RHCE genes, respectively. D is involved in hemolytic transfusion reactions and
hemolytic anemia. D mismatch is the major cause of hemolytic disease of the fetus
and newborn (HDFN). Even after the introduction of D immunoglobulin, maternal
immunization occurs in 0.8 to 1.5 percent of D- mothers owing to failure of prophy-
laxis or during pregnancy as a result of fetomaternal hemorrhage.1
Information about the RHD hemi- or homozygosity is of value for paternal testing
when D antibodies are found in a D- pregnant woman. The risk of an affected child
is 100 percent with a homozygously RHD+ father, but is only 50 percent when the
father is hemizygous for RHD. Furthermore, RHD zygosity determination may be of
value for preconception counseling when a previous pregnancy is complicated by
severe HDFN attributed to D antibodies. The D- phenotype in white persons is main-
ly caused by RHD gene deletion, although 14 different D- RHD alleles have been
described with low frequencies (1:1500) in Caucasian persons.2 In the Japanese
population, a D- RHD gene is found in 6 percent of the D- alleles, but D negativity
in the Japanese population is rare (only 0.5% of the total population).3 In other ethnic
groups (especially in black persons), D negativity is frequently caused by the aber-
rant RHD genes RHD (allele frequency 0.0714)4 and/ or (C)cdes (r’s, allele
frequency 0.036).5,6 In both cases, RHD-specific sequences are present but due to
the presence of a translation termination codon (RHD) or the substitution of RHD-
specific sequences by RHCE-specific sequences ((C)cdes), no detectable D
epitopes are present on the red blood cell (RBC) surface. Several methods have
been described for RHD zygosity measurement, such as a simple guess based on
phenotypic features, D antigen density and linkage disequilibrium, and associating
D-negativity with polymorphisms in RHCE.7,8 These approaches, however, are indi-
rect and are therefore not very reliable. It is also possible to directly determine the
extent of the RHD expression by quantitative polymerase chain reaction (PCR) or by
classical endpoint PCR.9,10 With these approaches, however, the aberrant RHD alle-
les should be taken into account. Recently, Wagner and Flegel11 have elucidated the
organization of the RH gene locus and proposed a model for the mechanism cau-
sing the RHD- haplotype in white persons. In this model, RHD negativity is caused
by an unequal crossing-over event, triggered by the high homology between the
upstream and downstream Rhesus boxes that flank the RHD gene (Fig. 1A). The
Rhesus boxes have a length of approximately 9000 bp in identical orientation and
share a 98.6 percent homology. The region in which the RHD deletion takes place
(breakpoint region) is located within a stretch of 1463 bp in which both Rhesus
boxes have an identical sequence (identity region). The Rhesus box resulting from
the unequal crossing-over event therefore carries characteristics of both the upstre-
am and the downstream Rhesus boxes (in 5’-end to 3’-end order) and is called the
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hybrid Rhesus box. Wagner and Flegel11 suggested two different PCR methods for
RHD zygosity determination by specific detection of the RHD- genotype. One of
those methods is based on the PCR-restriction fragment length polymorphism
(RFLP) technology. With a consensus forward primer and a downstream specific
reverse primer, both hybrid and downstream Rhesus boxes are amplified. The PCR
is followed by enzymatic digestion that distinguishes between the hybrid Rhesus
box and the downstream Rhesus box at the 5’-part of the breakpoint and/or identity
region (Fig. 1B). Three recently conducted studies are known to investigate RHD
zygosity based on the PCR-RFLP method,12-14 of which two studies were conducted
on a nonwhite population.12,14 None of these studies, however, have made a direct
comparison between zygosity determination on a quantitative level, directly on the
RHD gene, and on the presence of the RHD- locus. In this study, RHD zygosity was
determined in 402 donors from five different ethnic groups. Results of the PCR-
RFLP were compared with results obtained with a newly developed real-time
quantitative PCR specific for RHD exon 7, combined with an assay on a reference
gene, for RHD zygosity determination. Discrepant samples were further analyzed by
cycle sequencing of the Rhesus boxes.
Figure 1. RH locus and proposed mechanism of unequal crossing-over causing the RHD- haplotype in
white persons. (Top) Physical structure of the RH locus. (A) The RHD gene is flanked by the highly
homologous upstream (U, GenBank Accession Number AJ252311) and downstream (D, GenBank
44
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Accession Number AJ252312) Rhesus boxes depicted by black and gray triangles, respectively. The
downstream Rhesus box is followed by the SMP1 gene (white arrow) and, in the opposite direction,
the RHCE gene (gray arrow). (B) Triggered by their high homology, the proposed unequal crossing-
over takes place between the upstream and downstream Rhesus boxes. (C) The result of the unequal
crossing-over event, the RHD - RH locus with a hybrid Rhesus box (UD, GenBank Accession Number
AJ252313) as found in white persons.11 (Bottom) PCR-RFLP. Both the downstream and the hybrid
Rhesus boxes are amplified with primers rez7 (consensus) and rnb31 (downstream specific) as
depicted by the line with hatched marks, indicating the Pst I digestion sites. Owing to the Pst I digesti-
on site present in the part preceding the identity region of only the upstream Rhesus box (present in
the amplified hybrid Rhesus box), the RHD + and RHD - locus are distinguished.11
Materials and methods
Samples 
From five different ethnic groups, 263 D + and 139 D- ethylenediaminetetraacetate-
anticoagulated blood samples were obtained. D + samples comprised 52 white per-
sons from the Netherlands (9 ccDEe, 35 CcDee, 7 ccDee, and 1 CCDee
phenotypes), 84 South African black persons (73 ccDee, 3 ccDEe, and 8 CcDee
phenotypes), 47 South African Asian persons (2 ccDee, 8 ccDEe, 31 CcDee, 1
CcDEe, 3 CCDee, and 2 CCDEe phenotypes), 49 black persons from Ethiopia (18
ccDee, 5 ccDEe, 18 CcDee, 3 CcDEe, 4 CCDee, and 1 CCDEe phenotypes), and
31 black persons from Curaçao (13 ccDee, 4 ccDEe, 9 CcDee, 2 CcDEe, and 3
CCDee phenotypes). D- samples comprised 10 white persons from the Netherlands
(8 ccdee, 1 ccdEe, and 1 Ccdee phenotypes), 10 South African black persons (6
ccdee and 4 Ccdee phenotypes), 17 South African Asian persons (16 ccdee and 1
Ccdee phenotypes), 13 black persons from Ethiopia (12 ccdee and 1 Ccdee pheno-
types), and 89 black persons from Curaçao (73 ccdee, 1 ccdEe, and 15 Ccdee
phenotypes). Based on their phenotypic features and the prevalence of haplotypes
among the ethnic backgrounds, all nonwhite D + samples were expected to be
homozygous for RHD.15 Samples of the white group were selected for hemizygosi-
ty based on their phenotypic features; as a control sample, one RHD homozygous
sample was included (CCDee).
Serology 
RBCs were Rh phenotyped according to standard serologic protocols with an immu-
noglobulin (Ig) M monoclonal antibody (MoAb) anti-D (GAMA401, D epitope 6/ 7), a
polyclonal IgG anti-D, and IgM MoAbs (from Gamma Biologicals, Houston, TX)
recognizing C (MS24), c (MS33), E (GAMA402), and e (MS16, MS21, MS63
(blend)).
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Genomic DNA analyses 
Genomic DNA was isolated from peripheral white blood cells by a salting-out
method according to standard protocol.16 Oligonucleotide sequences of all primers
(Invitrogen, Carlsbad, CA) used in this study are listed in Table 1. PCR procedures
were performed in a thermal cycler (Model 9700, Applied Biosystems, Nieuwerkerk
aan de IJssel, the Netherlands).
For detection of the RHD deletion, the PCR-RFLP method as previously described
by Wagner and Flegel was performed.11 Primers rez7 and rnb31 were used for
amplification of the downstream and hybrid Rhesus boxes (Table 1). Primer annea-
ling was at 660C. The enzymatic digestion pattern indicates the presence of a hybrid
Rhesus box (RHD gene deleted) and/or a downstream Rhesus box (RHD gene pre-
sent) (Fig. 1B).
The RHD multiplex (MPX) PCR was performed as described by Maaskant-van Wijk
and coworkers.17 Minor modifications were the use of high-performance liquid chro-
matography-purified primers and PCR master mix (AmpliTaq, Applied Biosystems).
With this MPX PCR, RHD exons 3, 4, 5, 6, 7, and 9 are amplified simultaneously.
For the detection of RHD, an allele-specific primer amplification was developed
with primers Rex5Ws and Rex5Was (Table 1) specific for nucleotide 654C (RHD)
and nucleotide 674T (RHD), respectively. As internal control primer set, ßACTs
and ßACTas (b-actin gene) were used. PCR procedures were performed on 200 ng
of genomic DNA in a total reaction volume of 50 uL. The reaction mixture contained
100 ng of primers Rex5Ws and Rex5Was, 50 ng of primers bACTs and bACTas, 5
mmol per uL of each dNTP, 2 U of Taq DNA polymerase (Promega, Madison, WI) in
the appropriate buffer, and 2 U of Taq DNA polymerase antibody (Becton Dickinson,
San Jose, CA), supplemented with 1.5 mmol per uL MgCl2. Amplification conditions
were 1-minute denaturation at 950C, 1- minute primer annealing at 600C, and 1
minute extension at 720C.
The RHC/c/hex3 MPX PCR followed by intron 4/exon 7 MPX PCR as described by
Tax and associates18 was used for the detection of (C)cdes, DIIIa, and DIVa alleles.
When a hybrid exon 3 was detected by the RHC/c/hex3 MPX PCR, both DIIIa and
DIVa alleles were distinguished from a (C)cdes allele by the intron 4/exon 7 MPX
PCR.
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Table 1. Oligonucleotide primer sequence and specificity 
Primer Name Specificity Nucleotide sequence*
Rex5Ws RHD CGCCCTCTTCTTGTGGATC (F)
Rex5Was RHD TGGACTTCTCAGCAGAGCAA (R)
bACTs ß-Actin gene ccttcctgggcatggagtcctg (F)17
bACTas ß-Actin gene ggagcaatgatcttgatcttc (R)17
940S RHD exon 7 GGGTGTTGTAACCGAGTGCTG (F)
1064R RHD exon 7 CCGGCTCCGACGGTATC (R)
968 RHD exon 7 cccacagctccatcatgggctacaa (P)
Alb-F Albumin tgaaacatacgttcccaaagagttt (F)
Alb-R Albumin ctctccttctcagaaagtgtgcatat (R)
Alb-T72 Albumin tgctgaaacattcaccttccatgcaga (P)
Rez7 Consensus Rhesus box cctgtccccatgattcagttacc (F)11
Rnb31 Downstream Rhesus box cctttttttgtttgtttttggcggtgc (R)11
CBRF04 Consensus Rhesus box tgcactgccctggcagagg (F)
CRBR02 Consensus Rhesus box agaaatttgcatgagtaacaggag (R)
Rhbox5070 Consensus Rhesus box ctacaggcccatgagagtccaaa (F)12
Rhbox5571 Consensus Rhesus box agtgcaagccccaagccttgaca (R)12
CRBF06 Consensus Rhesus box gttaatatgggtggctggc (F)
CRBR08 Consensus Rhesus box cattaagagatacgcacagg (R)
* Uppercase and lowercase characters represent coding and noncoding sequences, respectively.
Bold characters represent RHD-specific nucleotides, underlined characters represent downstream
Rhesus box-specific nucleotides, and italic characters represent primer mismatches.
In parentheses: P = RQ-PCR probe; F = forward orientation of the primer; R = reverse orientation of
the primer.
RHD zygosity determination by real-time quantitative PCR
For RHD zygosity determination a real-time quantitative PCR (RQ-PCR) was deve-
loped (Model 7700 sequence detector, Applied Biosystems).19 In a single well, RHD
exon 7 (primers 940S and 1064R [RHD specific]) and albumin (reference gene, pri-
mers Alb-F and Alb-R) were amplified. RHD was detected by a FAM fluorescently
labeled RHD-specific probe (probe 968, Table 1), and albumin was detected simul-
taneously by a VIC fluorescently labeled albumin-specific probe (probe Alb-T72,
Table 1). Primers were used in a final concentration of 900 nmol per uL for RHD and
300 nmol per uL for albumin, and both probes were used in a final concentration of
100 nmol per uL in a total volume of 25 uL of universal master mix (TaqMan, Applied
Biosystems). The best results were obtained with a genomic DNA input between 50
and 100 ng. Each sample was tested in triplicate, and for each test the ratio between
RHD and albumin was calculated by dividing the RHD gene quantity by the albumin
gene quantity based on a standard curve. RHD zygosity of each sample was deter-
mined by taking the median of the three ratios. When hemizygous for RHD, the
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median is approximately 0.5, when homozygous for RHD the median is approxima-
tely 0.9 (Fig. 2). With the above-described method, 149 samples were analyzed. In
114 samples, RHD zygosity was determined with RHD and albumin in separate
wells because both probes carried the same (FAM) fluorescent label.
Sequencing analyses of the Rhesus boxes
The position of all primers used for Rhesus box sequencing and the PCR-RFLP are
depicted in Fig. 3. PCR products obtained with primers rez7/rnb31 were cycle-
sequenced (ABI-Prism 377, DNA sequencer, Applied Biosystems) with primers
Rhbox5070, Rhbox5571, CRBF04, CRBR02, and CRBF06 with cycle sequencing
chemistry (Big Dye terminator, Applied Biosystems). PCR products obtained with
primers CRBF06 and CRBR08 were sequenced with primer CRBF06. Reference to
nucleotide positions is given corresponding to the published downstream Rhesus
box sequence (GenBank Accession Number AJ252312).
Results
RHD zygosity determination of D+ samples 
The RHD zygosity of 263 D+ samples from five different ethnic groups was determi-
ned by PCR-RFLP and RQ-PCR. In white persons, no discrepancies between both
methods were found. Of the 52 samples, 51 samples showed hemizygosity by PCR-
RFLP and RQ-PCR and 1 sample showed homozygosity for RHD with both assays.
In all nonwhite groups, discrepancies between PCR-RFLP and RQ-PCR were found
(61 of 211). In 58 cases, the PCR-RFLP indicated the presence of a hybrid Rhesus
box, suggestive for an RHD gene deletion (RHD+/RHD-), whereas by RQ-PCR 2
RHD genes were demonstrated (RHD+/RHD+) (Table 2). One sample showed only
hybrid Rhesus boxes by PCR-RFLP (RHD-/RHD-) and one RHD gene by RQ-PCR
(RHD+/RHD-) (Table 2B).
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Table 2. RHD zygosity determination by PCR-RFLP versus RQ-PCR in four
different ethnic groups* 
RQ-PCR
PCR-RFLP RHD +/RHD + RHD +/RHD- 
A. Ethiopian black persons 
RHD +/RHD + 26 0 
RHD +/RHD- 7 16 
RHD-/RHD- 0 0
B. South African black persons 
RHD +/RHD + 23 1a
RHD +/RHD- 42 17
RHD-/RHD- 0 1b
C. Curaçao black persons 
RHD +/RHD + 14 1a
RHD +/RHD- 8 8 
RHD-/RHD- 0 0
D. South African Asian persons 
RHD +/RHD + 11 0
RHD +/RHD- 1 35 
RHD-/RHD- 0 0
* Fifty-eight samples show a hybrid Rhesus box by PCR-RFLP (RHD+/RHD-) and two RHD genes by
RQ-PCR (RHD+/RHD+) (7 Ethiopian black persons, 42 South African black persons, 8 Curaçao black
persons, and 1 South African Asian person, all in bold). Two samples show two RHD genes by PCR-
RFLP and only one RHD gene by RQ-PCR, both indicated by a superscript lowercase “a” (B and C).
Further analysis of these samples revealed one (C)cdes allele (South African black person) and one
DIVa allele (Curaçao black person), both hampering zygosity determination by RQ-PCR. One South
African black person showed only hybrid Rhesus boxes by PCR-RFLP and one RHD gene by RQ-PCR
(B, indicated by superscript lowercase “b”). Sequencing analysis showed that this sample carried a
mutated downstream Rhesus box as described by Matheson and Denomme.12
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Figure 2. RQ-PCR analysis on RHD exon 7. Box-whisker graph of samples analyzed for RHD zygosity
with the RQ-PCR on RHD exon 7 (n = 149). Of each sample the median of the ratio of RHD divided by
albumin was calculated from triplicate samples. Of each experiment the median of the ratio of RHD of
the samples are calculated relative to the RHD homozygous control. The whiskers represent the range
and the boxes represent the mean ± standard deviation per group. Based on the RQ-PCR results, 100
samples were determined to be hemizygous for RHD and 49 samples were determined to be homozy-
gous for the RHD gene. 
Two samples showed no hybrid Rhesus boxes by PCR-RFLP (RHD+/RHD+) and
only 1 RHD gene by RQ-PCR (RHD+/RHD-) (Tables 2B and 2C). Because the RQ-
PCR is specific on RHD exon 7 and therefore does not recognize the variant RHD
alleles (C)cdes and DIVa, all 263 samples were analyzed for the presence of such
alleles with the RHC/c/hex3 MPX PCR followed by the intron 4/exon 7 MPX PCR. In
only 2 cases, the presence of a (C)cdes allele (South African black person) and a
DIVa allele (Curaçao black person) was demonstrated, which explained the RQ-
PCR hemizygosity, although PCR-RFLP did not indicate the presence of a hybrid
Rhesus box.
Sequence analysis of the RH locus in samples showing a hybrid Rhesus
box by PCR-RFLP and two RHD genes by RQ-PCR.
To elucidate why the PCR-RFLP indicated a deletion of the RHD gene, while RQ-
PCR indicated the presence of two RHD genes, PCR-RFLP products (primers rez7
and rnb31, amplifying both the hybrid and the downstream Rhesus boxes) of 40 dis-
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crepant samples were sequenced with forward primer Rhbox5070 and reverse pri-
mer Rhbox5571 (Rhbox primers), spanning a domain including nt. 5275, G>A (PstI
restriction site) and nucleotide 5447, 5465, and 5526, T>C, A>C, and A>G from
upstream to downstream Rhesus box sequence, respectively (Fig. 4, URH and
DRH).We expected to find only downstream sequences because the RQ-PCR infers
the presence of two downstream Rhesus boxes. Six samples showed the presence
of a mutated downstream box (nucleotides 5164C, 5275G, 5447C/T, 5465C, and
5526G) as described by Matheson and Denomme,12 causing PstI digestion in the
PCR-RFLP (4 of 26 South African black persons, 1 of 6 Curaçao black persons, and
1 of 7 Ethiopian black persons).
Figure 3. Primer positions and specificity on the Rhesus box. Primer rnb31 is downstream sequence
specific; all other primers are consensus (they anneal on the upstream, downstream, and hybrid
Rhesus boxes). The upstream sequence of nucleotide (nt) 5275 forms the discriminating PstI digesti-
on site.
A mutated downstream Rhesus box as described by Matheson and Denomme was
also found in the sample showing two hybrid Rhesus boxes by PCR-RFLP and one
RHD gene by RQ-PCR (Table 2B).12 One sample (South African black person)
showed a deletion-insertion in one of the sequences hampering further analyses. Of
the remaining 33 samples, normal upstream (URH) and downstream (DRH) Rhesus
box sequences were found in the 5’-part preceding the identity region, compared
with an RHD hemizygous control sample (white person). This is in concordance with
the hemizygous restriction pattern in the PCR-RFLP. Of these, 7 showed upstream
and downstream sequences in a 1URH:1DRH ratio (6 of 26 South African black per-
sons and 1 of 6 Curaçao black persons), and 26 showed the upstream and
downstream sequence in a 1URH:2DRH ratio (15 of 26 South African black persons,
1 of 1 South African Asian persons, 4 of 6 Curaçao black persons, and 6 of 7
Ethiopian black persons). Because the RQ-PCR indicated the presence of two RHD
genes, we postulated that the upstream sequence amplified in the 5’-part preceding
the identity region could not be derived from a hybrid Rhesus box but from either a
mutated upstream or a mutated downstream Rhesus box.To further analyze this, the
51
RH locus is highly variable in nonwhite persons
110094_Binnen  08-11-2005  09:15  Pagina 51
3’-part following the identity region was analyzed in 21 samples (6 1URH:1DRH and
15 1URH:2DRH) by sequencing PCR products obtained with primers CRBF06 and
CRBR08 (consensus) with primer CRBF06. In five cases (all 1URH:1DRH in the 5’-
part preceding the identity region), the absence of a normal upstream Rhesus box
sequence indicated the presence of a mutated upstream Rhesus box. The presen-
ce of a PstI digestion site in the PCR product obtained with the downstream Rhesus
box primer rnb31 can thus be explained by the homozygous presence of a mutated
upstream box causing the annealing of primer rnb31 in the 3’-part following the iden-
tity region of the mutated upstream Rhesus box. In four of these five samples (three
South African black persons and one Curaçao black person), the mutated upstream
box (further assigned as URH1, Fig. 4) showed transition from URH to DRH
between nucleotide 7416 and nucleotide 7649. In one of the five samples (South
African black person), a homozygous presence of a different mutated upstream
Rhesus box, assigned URH2 (transition from URH to DRH between nucleotide 7381
and nucleotide 7416), was postulated.
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Figure 4. Sequences of mutated upstream, downstream, and hybrid Rhesus boxes found in black per-
sons. The boxes URH and DRH represent the upstream (white squares) and downstream sequence
(gray squares) Rhesus boxes, respectively, as previously described.11 Nucleotide (nt) 7403 was found
to be nonspecific for upstream or downstream sequences and is therefore denoted as P (polymor-
phic, dotted squares). URH1 and URH2 are mutated upstream Rhesus boxes and DRH1 to DRH5 are
mutated downstream Rhesus boxes as found in nonwhite research populations. UDRH is the hybrid
Rhesus box as previously described in white persons and in this study is predominantly found in white
persons and South African Asian persons. UDRH1 and UDRH2 are the two deviant hybrid Rhesus
boxes as found in black persons. 
The sequences of the PCR products obtained with consensus primers CRBF06 and
CRBR08 of the other discrepant samples were also analyzed for the possible pre-
sence of the URH1 and URH2 mutated Rhesus boxes. In the samples showing
1URH:2DRH in the 5’-part preceding the identity region, the presence of either
URH1 (n = 11) or URH2 (n = 4) boxes was found, next to a normal upstream
sequence as expected from the 1URH:2DRH ratio. The interpretation of these
sequences was less clear, however, because of the presence of additional mutati-
ons in the 3’- part following the identity region (discussed later). In one sample
(1URH:1DRH), sequence analyses showed that the discrepant results between RQ-
PCR and PCR-RFLP could be explained by the presence of a mutated downstream
Rhesus box, because sequencing of the consensus PCR product (primers CRBF06
and CRBR08) showed three upstream and one downstream sequence in the 5’-end
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region and sequencing with the Rhbox primers (on the product obtained with pri-
mers rez7 and rnb31) showed a 1URH:1DRH ratio. The PstI digestion site in the
PCR-RFLP product was present in a mutated downstream Rhesus box assigned
DRH1 (Fig. 4, transition from URH to DRH between nucleotide 7649 and nucleotide
7678). The DRH1 was found next to two normal URH and one normal DRH, causing
the 1URH:1DRH ratio with Rhbox primer sequencing. As indicated previously, the
sequence analysis of the consensus PCR product from the 3’-part following the
identity region showed more nucleotide changes than could be explained by the
assigned Rhesus boxes (URH, URH1, URH2, DRH, DRH1). In particular, the diffe-
rences in sequence peak height suggested the presence of additional mutated
Rhesus boxes. Therefore, sequence analysis of the 3’-part following the identity
region with CRBF06 was also performed on products obtained with primers rez7
and rnb31 (downstream Rhesus box specific) on the 21 selected samples. All
sequences could be explained by the presence of one of three newly identified
mutated downstream boxes (DRH2, DRH3, DRH4, Fig. 4).These mutated downstre-
am Rhesus boxes showed normal downstream- specific sequences in the 5’-part
preceding the identity region and therefore do not hamper zygosity determination by
PCR-RFLP. The DRH2 box was found in five samples next to a URH1, DRH3 in six
samples next to a URH1, and DRH4 in one sample homozygously next to a URH1.
No mutated DRH boxes were found in the five samples in which the URH2 caused
the PstI digestion by PCR-RFLP. In the other four samples, only normal downstream
Rhesus boxes were found. Table 3 shows the number of discrepant samples per
ethnic group and per phenotype. No association between RHCE haplotypes and
mutated Rhesus boxes could be established. It has previously been suggested that
a cytosine at nucleotide position 7403 was specific for the upstream Rhesus box
sequence.11 In most of the analyzed downstream and hybrid Rhesus boxes, howe-
ver, and especially in black persons but also in white persons, a guanine at
nucleotide position 7403 was encountered. Because of this polymorphism, it is not
possible to indicate this nucleotide in the newly identified mutated Rhesus boxes
(Fig. 4).
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Table 3. Mutated Rhesus boxes, phenotype association, and occurrence of
RHD and (C)cdes alleles in D+ samples*
Phenotype
Ethnic group ccDee ccDEe CcDee CcDEe CCDee CCDEe
South African black persons 408 (33) 11 (2) 1 (71) NT† NT NT
South African Asian persons 0 (2) 0 (8) 1 (30) 0 (1) 0 (3) 0 (2)
Ethiopian black persons 3 (15) 1 (4) 3 (15) 0 (3) 0 (4) 0 (1)
Curaçao black persons 53 (8) 1 (3) 21 (71) 0 (2) NT 0 (3)
* The number outside the parentheses represents the number of samples carrying a mutated Rhesus
box hampering zygosity determination by PCR-RFLP analyses per phenotype and between parenthe-
ses is the number samples tested without a mutated Rhesus box hampering zygosity determination
by PCR-RFLP analyzes per phenotype. Superscript characters represent the number of RHD alleles
detected and subscript characters represent the number of (C)cdes alleles detected. † NT = not tes-
ted.
Furthermore, we found nucleotide 7354A encoding upstream and nucleotide 7354G
encoding downstream sequences in all samples (also in samples without a mutated
upstream Rhesus box) and this is therefore included as such in Fig. 4.
Analyses of the RHD gene-negative RH locus.
A total of 139 D- samples were analyzed by PCR-RFLP and by RHD MPX PCR (to
identify the presence of the RHD gene and/or (C)cdes allele). PCR-RFLP showed
the presence of homozygous RHD gene deletion sites in 105 D- samples. In 32 sam-
ples, the presence of both a hybrid and a downstream Rhesus box was
demonstrated, indicative for the presence of one RHD gene. In 26 of these samples,
the presence of either the nonfunctional RHD gene (15 samples, ccdee) or the
nonfunctional (C)cdes allele (11 samples, Ccdee) was demonstrated, all in black
persons from South Africa, Curaçao, and Ethiopia. In 4 samples (3 South African
black persons and 1 Curaçao black person, Ccdee) both the RHD and the (C)cdes
allele were found. In these samples, the PCR-RFLP falsely indicated the presence
of a hybrid Rhesus box. Two samples (Ethiopian black persons, ccdee) carried the
DAU2 RHD variant allele and were initially typed D- owing to the very low antigen
density.20 In two samples (black persons from Curaçao and South Africa, phenoty-
pe Ccdee), the presence of only downstream Rhesus box sequences was
demonstrated, indicative for the presence of two RHD genes. In both samples, the
presence of homozygous (C)cdes alleles was demonstrated. Except for the four
samples with RHD and (C)cdes alleles there was complete concordance between
PCR-RFLP and RHD MPX PCR analyses. Because in all RHD- samples the hybrid
Rhesus box was detected by PCR-RFLP, this deletion has most probably occurred
in all ethnic groups by a similar mechanism. To investigate this in more detail, hybrid
Rhesus boxes of four nonwhite groups were sequenced. To analyze the region
between the PstI digestion site (nucleotide 5275) in the 5’-part preceding the identi-
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ty region and the identity and/or breakpoint region, PCR products obtained with pri-
mers rez7 and rnb31 of 47 homozygous RHD- samples (9 South African Asian
persons, 9 Curaçao black persons, 10 Ethiopian black persons, 9 South African
black persons, and 10 white persons) were sequenced with primers CRBF04 and
CRBR02. In all cases, the 3 upstream-specific nucleotides (5447, 5465, and 5526)
between the upstream-specific nucleotide 5275 (conducting the PstI restriction site)
and the identity and/ or breakpoint region were found. Additionally, in 2 samples the
nucleotide changes 5629C>T (white person) and 5734C>T (South African black per-
son) were found. This indicates that at least in all tested 74 ce-alleles from nonwhite
persons the RHD deletion has not occurred upstream from the identity and/or break-
point region. To study the hybrid Rhesus boxes in the 3’-part following the identity
region, 27 homozygous RHD- samples were sequenced with primer CRBF06 on a
PCR product obtained with primers CRBF06 and CRBR08 (8 South African Asian
persons, 9 Curaçao black persons, and 10 Ethiopian black persons; no South
African black persons were analyzed because in this group only samples with at
least 1 nonfunctional RHD gene were present). All Asian samples showed downstre-
am sequences indicating 2 normal hybrid Rhesus boxes. Of the black persons, 6
samples showed only downstream sequences, 3 samples showed downstream
sequences with a 7403G>C change, 5 samples showed upstream and downstream
sequences at nucleotides 7287, 7381, and 7403 and continued downstream, and 5
samples showed upstream and downstream sequences at nucleotides 7287, 7381,
7403, and 7416 and continued downstream. These sequence results indicate the
presence of two mutated hybrid Rhesus boxes (Fig. 4, UDRH1 and UDRH2) in black
persons. Both the UDRH1 (once) and the UDRH2 (three times) boxes were also
found in D+ samples hemizygous for RHD (n = 6) next to a normal upstream and
downstream Rhesus box. To study the prevalence of the UDRH1 and UDRH2 boxes
in white persons, 42 RHD- samples were sequenced with primer CRBF06 on the
PCR product obtained with primers CRBF06 and CRBR08. Thirty-eight samples
showed only downstream sequences and 4 samples showed downstream sequen-
ces with a heterozygous 7403G>C polymorphism. Neither UDRH1 nor UDRH2
boxes are prevalent in a white population.
Sequence analyses of RHD + and/or (C)cdes+ samples.
As shown in Table 3, the (C)cdes allele is only found in samples without a mutated
Rhesus box that results in a discrepant result in the PCR-RFLP, whereas the RHD
gene is exclusively found in samples carrying such a mutant Rhesus box. This sug-
gests that the RHD cosegregates with a mutated Rhesus box and that (C)cdes
alleles never cosegregate with a mutated Rhesus box that interferes with the PCR-
RFLP assay. Therefore, 30 samples (14 hemizygous RHD, 5 RHD, and (C)cdes;
6 hemizygous (C)cdes; and 5 homozygous (C)cdes) were amplified with primers rez7
and rnb31 and sequenced with primer CRBF06. The sequence results showed that
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the RHD cosegregates with the URH1 (n = 13) or URH2 (n = 1) box indicating that
the RHD has originated from an RH locus with a mutated upstream Rhesus box.
The (C)cdes allele cosegregates with a normal upstream Rhesus box and a muta-
ted downstream Rhesus box (Fig. 4, DRH5). This mutated downstream Rhesus box
was not encountered in any of the previously sequenced samples without (C)cdes
alleles.
Hybrid Rhesus boxes with the exact same sequence in the downstream part
(UDRH2) were frequently found (4 of 9 analyzed Curaçao black persons and 1 of 10
analyzed Ethiopian black persons).
Discussion
Despite the availability of Rh immunoprophylaxis, D mismatch is still the major cause
of HDFN. In a pregnancy complicated by the presence of maternal anti-D, the RHD
zygosity status of the father determines the chance of a fetus being either positive
or negative for D. New insights into the RH locus and the mechanism causing the
gene deletion in the RHD- haplotype in white persons have made it possible to dis-
criminate RHD-hemizygous from RHD-homozygous individuals by detection of the
RHD- RH locus.11 In this study, RHD zygosity was determined in five different ethnic
groups. Results of the PCR-RFLP were compared to results obtained by a newly
developed RQ-PCR in D+ samples (n = 263). In all nonwhite ethnic groups, discre-
pancies were found between both methods (61 discrepancies in 211 D+ samples).
Sequencing analyses of parts of the Rhesus boxes of 40 discrepant samples show-
ed the presence of previously described mutated downstream Rhesus boxes in 6
samples.12 These boxes, as described by Matheson and Denomme12 in a study on
284 D+ samples (201 samples were from black descent as determined by the GATA-
1 mutation at the FY locus), show two different sequence patterns. The most
frequently found pattern (3 of 4 sequenced samples) was: nucleotide 5164C, nucle-
otide 5275G, nucleotide 5447C, nucleotide 5465C, and nucleotide 5526G. In this
study, this sequence was found in 6 of 40 discrepant D+ samples.The other sequen-
ce pattern as found by Matheson and Denomme in 1 sample was nucleotide 5164C,
nucleotide 5275G, nucleotide 5447T, nucleotide 5465C, and nucleotide 5526G and
was also found once in our sequenced population. New mutated upstream and
downstream Rhesus boxes were encountered with a very high frequency in black
persons. By sequencing samples typed hemizygous for RHD by PCR-RFLP and
homozygous for RHD by RQ-PCR, the physical structure of the mutated Rhesus
boxes was elucidated. We found two mutated upstream Rhesus boxes (URH1 and
URH2) and five mutated downstream Rhesus boxes (DRH1 to DRH5). Furthermore,
two mutated hybrid Rhesus boxes were found (UDRH1 and UDRH2). Although
DRH2 to DRH5 do not influence zygosity determination by PCR-RFLP, they do show
that the RH locus is highly variable. Mutated Rhesus boxes affecting the PCR-RFLP
assay (URH1, URH2, and DRH1) have a frequency of 0.22 in D+ homozygous black
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persons, rendering zygosity determination by PCR-RFLP impossible in a nonwhite
population. PCR-RFLP, however, always correctly indicates the presence of a down-
stream Rhesus box. Also, in samples known to have an RHD- RH locus, the
presence of a hybrid Rhesus box was always demonstrated. This may explain why
no discrepancies are found in studies concerning RHD- samples. A recent study
conducted by Perco and coworkers13 based on a white population consisting of 83
D+, 13 D-, and 37 weak-D samples, showed an altered downstream Rhesus box in
a stretch of 2917 bp of a weak-D type 29 sample.13 This result was not confirmed by
this study. Mutated Rhesus boxes have no effect on the RQ-PCR, and given the fre-
quency of the mutated boxes the latter assay is a better tool for RHD zygosity
determination in nonwhite persons. The RQ-PCR has a much lower false typing rate
than the PCR-RFLP. In case of an RHD, however, the sample will be typed false-
positive for D.Therefore, in nonwhite persons, the RQ-PCR should be combined with
an assay indicating the presence of the RHD, like the allele-specific primer ampli-
fication described in this study for detection of RHD. When a D+ sample shows an
RHD, the sample carries one RHD gene and one RHD and may for paternal ana-
lyses be regarded as hemizygous for RHD. Another option would be to use an
RQ-PCR that does not amplify the RHD (like the assay developed by Finning et
al.21) and to use such an assay in a quantitative way. In some cases, however, it may
be preferred to at least recognize the presence of an RHD. Other RHD genes
known with RHD exon 7 nucleotide changes are D category IV (nucleotide
1048G>C) and DBT types I and II (RHD exon 7 is substituted by RHCE exon 7).
Furthermore, in Europeans RHD-gene-positive, Dantigen- negative variants have
been described that may interfere with RHD zygosity determination.2 Regarding the
fact that these variants are exceedingly rare, the RQ-PCR remains the best assay
for zygosity determination.
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Figure 5. Schematic representation of the evolution of different Rhesus boxes and their cosegregation
with RHD and (C)cdes alleles. With the acceptance that the RH locus originally carries URH and
DRH, the RHD has evolved in an RH locus already expressing URH1 (considering the existence of
URH1 without RHD but not vice versa) and the (C)cdes allele and DRH5 have evolved in close asso-
ciation on the same RH locus.
*The UDRH and UDRH1 have evolved from an unequal crossing-over event between a URH and a
DRH. The UDRH2 may have evolved from an unequal crossingover event between a URH and a
DRH5 or may be the result of a gene conversion event between UDRH and DRH5.
Apart from RHD zygosity determination of the father to calculate the risk of the fetus
being D+, it is now possible to directly determine the RHD status of the fetus on cell-
free fetal DNA that can be derived from maternal plasma and serum.22,23
Contamination of maternal DNA (of D- RHD genes or genes causing a very weak D
expression), however, might lead to false-positive results, and scarcity of fetal DNA
may result in a false-negative prediction of D (recently reviewed by van der Schoot
et al.24). The RHD cosegregates mainly with the mutated upstream Rhesus box
URH1 but was also found once in cosegregation with URH2. Both the URH1 and the
URH2 boxes are also present in samples not carrying an RHD, indicating that the
mutations in the RHD gene that lead to the RHD have been introduced on an RH
locus with a mutated upstream Rhesus box. The presence of one RHD with an
URH2 box may be due to recombination of the two at a later time point (Fig. 5).
Owing to the cosegregation of the RHD with a mutated URH box that causes
(false) indication of a hybrid Rhesus box in the PCR-RFLP, the phenotypic predicti-
on (D-) is correct. In a study concerning the RHD allele distribution in 58 African
persons of Mali, it was also found that all D+ samples carrying an RHD allele show-
ed a hybrid Rhesus box by PCR-RFLP (n = 5).14 These results are in concordance
with the results of this study, and further molecular analyses of these samples will
most probably reveal cosegregation with the URH1 or URH2 box. The (C)cdes alle-
le cosegregates with a DRH5 box and the DRH5 is not found in samples without the
(C)cdes. Therefore, it may be postulated that the DRH5 box and the (C)cdes allele
were formed in close association on the same RH locus (Fig. 5). Whether UDRH1
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and UDRH2 are the result of an unequal crossing-over event that has taken place
further downstream of the breakpoint and/or identity region or that the unequal cros-
sing-over has taken place within the breakpoint region but between a URH and
mutated DRH box cannot be elucidated from our data. Given the cosegregation of
the (C)cdes allele with DRH5 and the similarity between UDRH2 and DRH5, howe-
ver, it is possible that either UDRH2 has evolved from a gene conversion event
between DRH5 and UDRH or UDRH2 has its origin from an unequal crossing-over
event involving an URH and the DRH5 box (Fig. 5). The latter possibility implies that
in black persons, two RHD gene deletion events may have taken place, one in a nor-
mal RH locus and one in an RH locus with a (C)cdes allele and a DRH5 box. The
recent elucidation of the physical structure of the RH locus have made it possible to
propose a model for the deletion of the RHD gene via a mechanism of unequal cros-
sing-over from the RH locus in white persons.11 The results of this study indicate that
the RHD gene deletion via this same mechanism has also occurred in Asian per-
sons from South Africa and black persons from South Africa, Curaçao, and Ethiopia.
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Abstract
Background: RH genotyping assays are mainly based on research in whites.These
assays may not be reliable in a multiracial society because of the genetic variation
in RH among ethnic groups.
Study design and methods: Five groups from different ethnic backgrounds were
serologically typed for C and c and were genotyped on nucleotide C48 and intron 2
for RHC and RHc on nucleotides C178 and C307.
Results: RHc genotyping with both methods proved to be reliable. RHC genotyping
on C48 is not reliable because of a 48G>C mutation in the RHce allele (false-posi-
tive prediction of C). This mutation was found in every ethnic group and does not
affect c or e expression. RHC genotyping on intron 2 is unreliable because of r’s
((C)cdes) alleles (a false-negative prediction of C). This allele was found in whites
and blacks from Curaçao and South Africa. Reactions of r’s cells with anti-C are
weaker, but no negative reactions with various MoAbs were found. A new method
(RHC/c/hex3-intron 4/exon 7 multiplex PCRs) was developed based on intron 2 and
r’s hybrid exon 3 characteristics (RHC) and C307 (RHc).
Conclusions: Reliable RHC and RHc genotyping is possible in different ethnic
groups with the RHC/c/hex3- intron 4/exon 7 multiplex PCR approach.
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Introduction
The Rh blood group system is of clinical interest because it is involved in HDN,
hemolytic transfusion reactions, and autoimmune hemolytic anemia. The most
important Rh antigens are D, C, c, and E, e. These antigens are encoded by two
highly homologous genes, RHD and RHCE, both located on chromosome 1p34.3-
p36.1. RHCE encodes for both the polypeptides that carry C and c and E and e,
whereas RHD encodes for the D polypeptide. Comparing the RHc and RHC alleles,
there are six nucleotide (nt) differences, four of which result in amino acid substitu-
tions in the corresponding polypeptides.1,2 These substitutions are 48G>C leading to
W16C encoded by exon 1 and 178 C>A, 203 A>G, and 307 C>T leading to L60I,
N68S, and P103S, respectively, encoded by exon 2 (in c to C order). Studies with
cells of nonhuman primates suggested that of the four amino acids that might be cri-
tical for expression of Rhc, P103, the only polymorphic site that is extracellular, plays
an important role in expression of c.3,4 Moreover, we recently described that a sin-
gle point mutation 307 T>C leading to S103P in RHD resulted in expression of c on
the D polypeptide, independent of the presence of W16, L60, and N68.5 For C
expression, the system is more complex. Although S103 is critical, C antigenicity has
to be determined by other amino acids as well, as S103 is also present in the D poly-
peptide. K562 transfection studies clearly showed the importance of C16 in C
expression.6 It has been suggested that the interaction with the third extracellular
loop is probably also required for some C epitopes. This would explain the weak
expression of C by the r’s allele, a variant RHD in which part of exon 3 to exon 7 of
RHD is replaced by sequences derived from RHCE.7 Several RHC genotyping
assays have been developed. For RHC genotyping assays based on coding sequen-
ces, the polymorphism in exon 1 has to be used and for RHc genotyping the
polymorphisms in exon 2 has to be used. In addition, RHC genotyping assays can
be based on a 109-bp insert in intron 2, which is only present in RHC.8 Avent9 deve-
loped an RHC genotyping assay based on the 109-bp insertion in intron 2 of RHC,
and Faas et al.7 developed an RHC genotyping assay based on the C48 polymor-
phism in exon 1. However, the sequences of RH genes may vary with the ethnic
background of a person. It is important to be aware of the differences in genetic
sequences in order to develop genotyping methods that are reliable in a multiracial
society. Therefore, in this article, the previously described RHC and RHc genotyping
assays were tested on large panels of serologically typed donors from different
ethnic backgrounds. For RHc typing, both assays (based on C178 and C307) were
found to be reliable on all donors tested. Both RHC genotyping assays, based on
C48 and the 109-bp insert in RHC intron 2, resulted in high numbers of discrepant
results. However, by analyzing these discrepancies, we were able to develop a geno-
typing method for RHC in combination with typing for RHc that predicted the correct
c phenotype in 100 percent and that predicted the correct C phenotype in 99.8 per-
cent of the total research population (n = 1071).
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Materials and methods
Samples
A total of 1071 EDTA blood samples were obtained from five different ethnic groups;
that is, 250 whites from the Netherlands (collected by Bloodbank Rotterdam,
Rotterdam, the Netherlands), 250 African blacks, and 250 African Asians (both col-
lected by The South African Blood Transfusion Service, Johannesburg, South
Africa), 170 blacks from Ethiopia (collected by The Ethiopian Red Cross Society
Transfusion Service, Addis Ababa, Ethiopia), and 151 blacks from Curaçao (collec-
ted by The Red Cross Bloodbank Curaçao, Willemstad, Curaçao). All donors were
chosen randomly, except for the blacks from Curaçao, which were partly selected to
obtain D- samples.
Serology
RBCs of all donors were phenotyped for D, C, c, E, and e according to standard
serologic protocols with an IgM anti-D MoAb (GAMA401), a polyclonal IgG anti-D
reagent, and an IgM MoAb (Gamma Biologicals, Houston, TX) recognizing C
(MS24), c (MS33), E (GAMA402), and e (MS16, MS21, MS63 [blend]). Expression
of C was studied with MoAbs CM216-1 (Gamma Biologicals), CB250A1 (Ortho
Diagnostics, Turnhout, Belgium), 8-36216 (CLB, Amsterdam, the Netherlands), C-
93/44 (National Hematological Scientific Center, Moscow, Russia), 388F3
(Dominion Biologicals, Dartmouth, Nova Scotia, Canada), MS23, MS273, and
MS257 (IGRI, Oslo, Norway), P3x25513G8, and DGC02 (Diagast Laboratories,
Lille, France). The expression of c was studied with MS33 (IGRI), BS240 (Biotest
AG, Dreieich, Germany), 951 (CRTS de Bordeaux, France), BB7.D4 (Institut
National de Transfusion Sanguine, Paris, France), and POQ/3D2 (Laboratoire
Immunologie Moleculaire, Toulouse, France) according to the five epitope hypothe-
sis.5 The expression of e and E was studied with MS16, MS21, and MS63 (IGRI),
MS62, and MS69 (Serologicals Corp., Edinburgh, Scotland), and DGPE01 (Diagast
Laboratories). Expression of f (RH6) was studied with a polyclonal IgG patient serum
(phenotyped CcDEe).
Genomic DNA isolation
Genomic DNA was isolated from peripheral blood WBCs by a salting-out method
according to standard protocol.10 Oligonucleotide sequences of all primers used in
this study are listed in Table 1.
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Table 1. Primers 
Primer Sequence (from 5’ to 3’)* Location † Specificity Reference‡ 
R31 CGCTGCCTGCCCCTCTGC Exon 1 (F) RHC 7 
R147 TTGATAGGATGCCACGAGCCCC Exon 1 (R) RHD/CE 7 
R-15 tatctagagacggacacaggATGAGC Exon 1 (F) RHD/CE 7 
R159A TCTGACCGTGATGGCGCCCC Exon 2 (F) RHc 5 
R348 CTGAACAGTGTGATGACC Exon 2 (R) RHD/CE 5 
R637 GCCCTCTTCTTGTGGATG Exon 5 (F) RHD/CE 5 
R768 TGACCCTGAGATGGCTGT Exon 5 (R) RHD/CE 5 
C/rev gaacatgccacttcactccag Intron 2 (R) RHC 9 
C/for cagggccaccaccatttgaa Intron 2 (F) RHD/CE 9 
c/rev TGATGACCACCTTCCCAGG Exon 2 (R) RHc 9 
c/for TCGGCCAAGATCTGACCG Exon 2 (F) RHD/CE 9 
R364 TCGGTGCTGATCTCAGTGGA Exon 3 (F) RHD 12 
R474mmC ACTGATGACCATCCTCATGG Exon 3 (R) RHCE 
R581 ACGGAGGATAAAGATCAGAG Exon 4 (F) RHCE 23 
R667 CTCAGCAGAGCAGAGTTGAC Exon 5 (R) RHCE 23 
R973 AGCTCCATCATGGGCTACAA Exon 7 (F) RHCE 
R1068mmC ATTGCCGGCTCCGACGGCATG Exon 7 (R) RHD 
RHDin2F tcctggctctccctctct Intron 2 (F) RHD 13 
RH3R aggtccctcctccagcac Intron 3 (R) RHD/CE 13 
RHCE1F atagacaggccagcacag 38-End promoter (F) RHCE 
Rhin1R tgggggaatctttttcctt Intron 1 (R) RH 
RHD1F atagagaggccagcacaa 38-End promoter (F) RHD 13 
Rhin7DF ctggaggctctgagaggttgag Intron 7 (F) RHD
Rhin8R tatgtgatcctcagggaaggag Intron 8 (R) RH 
* Uppercase letters represent coding sequences and lowercase letters represent noncoding
sequences. 
† (F) denotes a forward primer and (R) denotes a reverse primer. 
‡ Reference number if primer sequence has been published previously. 
RHC and RHc allele-specific primer amplification assays
The RHC and RHc allele-specific primer amplification (ASPA) assays have been
described before.5,7 The ASPA for RHC was performed with primers R31 (RHC spe-
cific on nt C48) and R147. To avoid false-negative results, an internal control PCR
was included by adding consensus primer R-15, which would always yield a product
in combination with R147. The ASPA for RHc was performed with primers R159A,
RHc specific on nt C178, and R348. To avoid false-negative results, primers R637
and R768 were included, which amplify a PCR product from exon 5 of all RH alle-
les. PCR products were size separated by electrophoresis on a 12-percent
acrylamide gel and were visualized by ethidium bromide staining.
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RHC/c multiplex PCR
RHC typing was performed with primers C/rev, specific on the 109-bp insert in intron
2, and C/for. RHc typing was performed with primers c/rev (RHc specific on nt C307)
and c/for, as developed by Avent.9 Because both PCRs are performed in the same
tube, no extra internal control PCR was included. PCR products were separated
according to their size by electrophoresis on a 1-percent agarose gel.
RHC/c/hex3 multiplex PCR
A PCR was developed that amplifies the hybrid (RHD-RHCE) exon 3 (hex3) as
found in an r’s ((C)cdes) allele. This PCR was performed with primers R364, RHD
specific on nt A383, and R474mmC, RHCE specific on nt C455. The hex3 primers
were added to the original RHC/c multiplex (MPX) PCR. PCR products were sepa-
rated by size in electrophoresis on an 8-percent acrylamide gel.
Intron 4/exon 7 MPX PCR 
The previously described hex3 primer pair is not specific for an r’s allele but will also
yield a product from other variant RHD (i.e., DIIIa and DIVa type 1).11 Therefore, an
MPX PCR that yields PCR products of these variant RHD was developed. Because
the presence of a hybrid exon 3 combined with an RHD intron 4 in an RHCE envi-
ronment (G602 in exon 4 and G667 in exon 5) is specific for the detection of a DIIIa
gene, primers R581, RHCE specific on nt G602, and R667, RHCE specific on nt
G667, were used. For DIVa type 1 detection, primers R973, RHD specific on nt
A992, and R1068mmC, RHCE specific on nt C1048, were included, as the presen-
ce of a hybrid exon 3 combined with 1048G>C mutation in RHD exon 7 is specific
for the detection of this variant gene. No additional control PCR was added becau-
se primer pair R581/R667 always yields a product from RHCE. PCR products were
separated by size in electrophoresis on a 2-percent agarose gel.
RHD-specific MPX PCR
RHD exons 3, 4, 5, 6, 7, and 9 were amplified with RHD sequence specific primers
in a one-reaction mixture as described before.12 Minor modifications were the use of
high-performance liquid chromatography-purified primers instead of desalted and
the use of Amplitaq (Perkin Elmer/Roche, Nieuwerkerk aan de IJssel, the
Netherlands).
PCR conditions
All primers used in this study were desalted unless mentioned otherwise and were
obtained from Invitrogen (Carlsbad, CA). All PCRs were performed in a thermal
cycler (model 9700, Applied Biosystems, Nieuwerkerk aan de IJssel, the
Netherlands) on 200 ng of genomic DNA in a total reaction volume of 50 mL.
Reaction mixtures contained 100 ng of each primer (except for primer pairs C/for
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and C/rev and R364 and R474mmC, 200 ng; R31- R147-R-15 and c/for-c/rev, 75
ng), 5 mM of each dNTP, 2 U of Taq DNA polymerase (Promega, Madison, WI) in
the appropriate buffer and 2 U of Taq DNA polymerase antibody (Becton &
Dickinson, San Jose, CA), supplemented with 1.5 mM of MgCl2. All PCRs started
with one cycle of denaturation at 950C for 5 minutes and were completed with one
cycle of 5 minutes at 720C to complete extension. The PCR conditions were 35
cycles of 1 minute at 950C for denaturation, 1 minute at 600C (RHC ASPA) or 530C
(RHc ASPA) or 650C (RHC/c MPX PCR) or 660C (RHC/c/hex3 MPX PCR) or 590C
(intron 4/exon 7 MPX PCR) for annealing and 1 minute at 720C or 45 seconds at
720C (intron 4/exon 7 MPX PCR) for extension.
Nla IV digestion
PCR products of RHD exon 3 were obtained with primers RHDin2F, RHD specific in
intron 2, and RH3R.13 A 10-µL PCR product was digested with restriction endonuc-
lease Nla IV (MBI Fermentas, GMBH, St. Leon-Rot, Germany) in a 15-µL reaction
mixture containing 5 U of enzyme in the appropriate buffer supplemented with 1-per-
cent BSA. Nla IV digestion is RHCE specific on the last polymorphic site of exon 3
(C455).
Sequence analyses
RHD exon 3 was amplified with primers RHDin2F and RH3R. RHCE exon 1 was
amplified with primers RHCE1F, RHCE specific in 3’-end promoter region, and
Rhin1R in intron 1. RHD-specific exon 1 was amplified with primers RHD1F, RHD
specific in 3’-end promoter region, and Rhin1R. RHD-specific exon 8 was amplified
by using primers Rhin7DF in intron 7 and Rhin8R in intron 8. PCR products were
purified (concert rapid PCR purification system, Invitrogen) and cycle sequenced by
using big dye terminator chemistry (ABI-PRISM 377, DNA sequencer, Applied
Biosystems).
Results
RHC and RHc ASPAs and RHC/c MPX PCR analysis
Serologically determined phenotypes for C and c of 125 donors of each ethnic group
were compared with results of the RHC-ASPA (specific on C48) and the RHc-ASPA
(specific on C178) and with results of the RHC/c MPX PCR (specific on the 109-bp
insert in intron 2 and on C307, respectively). For RHc genotyping, no discrepancies
between serologically determined phenotypes and the RHc- ASPA nor the RHC/c
MPX PCR were found (results not shown). For RHC genotyping, two kinds of discre-
pancies were found (Table 2). A total of 43.3 percent of serologically typed C- donors
(n = 337) gave false-positive results with the C48- specific RHC-ASPA. No false-
negative results were obtained (n = 288).
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Table 2. RhC phenotyping compared with RHC genotyping with RHC-ASPA
and with RHC/c MPX PCR approaches
RHC genotype PCR*
C+ RHC-ASPA RHC/c MPX 
Donor origin phenotype (% false positive)† (% false negative)‡
Whites, Netherlands 77 80 (6.3) 76 (1.3)
Blacks, South Africa 21 91 (67.3) 14 (33.3)
Blacks, Ethiopia 54 88 (47.9) 54 (0)
Blacks, Curaçao 32 71 (41.9) 18 (43.8)
Asians, South Africa 104 105 (4.8) 104 (0)
Total population 288 435 (43.3) 267 (7.3)
* One hundred twenty-five donors of each ethnic group were tested, totaling 625 donors
† False positivity is calculated by dividing the number of false-positive typed samples by the total
number of serologically negative samples times 100%.
‡ False negativity is calculated by dividing the number of false-negative typed samples by the total
of number of serologically positive samples times 100%.
The presence of 48G>C in RHc has previously been described by Wolter et al.14 and
was stated to be the result of exon replacement. According to our results, this
48G>C mutation occurs in all ethnic groups considered here, although the prevalen-
ce is highest in blacks. These results are in concordance with the results from Faas
et al.,7 who found this mutation to be present in a ce-like allele, predominantly in
blacks. Of the serologically typed C+ donors (n = 288), 7.3 percent gave false-nega-
tive results for RHC with the RHC/c MPX PCR. No false-positive results were
obtained (n = 337). No discrepancies were found among people of Ethiopian and
Asian origin. All RHC-discrepant samples in the RHC/c MPX PCR showed accor-
ding to the RHC-ASPA the presence of a C48 (encoding Cys16) in the absence of
a normal RHC allele. A false-negative prediction of the C phenotype by using the
RHC/c MPX PCR may be caused by presence of r’s ((C)cdes), an RHD variant
hybrid D-CE-D gene of which exons 1 and 2 and part of exon 3 (first three polymor-
phic sites) are derived from RHD as well as exons 8, 9, and 10 and the 3’-noncoding
region. The region in between is derived from RHCE. The r’s gene leads to a weak
expression of C on the RBC surface but will not be detected by the RHC/c MPX PCR
because of the absence of the RHC intron 2. Therefore, it was investigated in one of
the discrepant samples (D- Curacao donor without RHD according to the RHD
MPX PCR) whether the false-negative C prediction was due to the presence of r’s.
Sequencing analyses of RHD exon 3 revealed that the first three polymorphic sites
were derived from RHD (nts T361, T380, and A383), the last polymorphic site from
RHCE (C455), and a nucleotide substitution 410 C>T leading to A137V, which all
have previously been described to be present in an r’s hybrid gene.7,15 Sequencing
analyses of RHD exon 8 specifically amplified with intronic primers (GenBank
accession numbers AB035194 and AB035196) revealed an RHD exon.16 Therefore,
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we screened the 21 RHC discrepant samples for presence of r’s.
Nla IV digestion and RHD MPX PCR analyses
Of the 21 C+ samples that were negative for RHC intron 2 with RHC/c MPX PCR
analyses, exon 3 was amplified, followed by an RHCE-specific digestion of the last
polymorphic site (C455) with endonuclease Nla IV. All 21 donors were shown to
carry the hybrid exon 3, as in all cases, at least part of the PCR product was dige-
sted. Of the 14 Curacao donors who were typed false negative for RHC, 12 samples
were completely digested, and two samples were partly digested. Samples from six
out of seven South African donors who were typed false negative for RHC were part-
ly digested, and one sample was completely digested. All 21 samples were
screened for presence of RHD exons 3, 4, 5, 6, 7, and 9 by RHD MPX PCR analy-
ses. In case of an r’s gene next to an RHD deletion, only RHD exon 9 will be
amplified, and in case of an RHD next to an r’s gene, all RHD exons except exon
5 will be amplified.Two samples that were partly digested by Nla IV and were D- car-
ried an RHD next to an r’s gene (one Curaçao and one South Africa donor). Six
samples that were partly digested and were D+ (one Curaçao and five South Africa
donors) showed no deviation of RHD and probably carry a normal RHD next to an
r’s gene. Indeed, 12 samples (all D- Curaçao donors) that were completely digested
showed only exon 9 by RHD MPX PCR analysis. One sample that was completely
digested and was D+ (South Africa donor) was missing RHD exons 3, 4, and 5 and
turned out to carry a DIIIa variant RHD by intron 4/exon 7 MPX PCR analyses next
to an r’s gene.
RHC/c/hex3 and intron 4/exon 7 MPX PCR analyses
Because all samples discrepant for RHC in the RHC/c MPX PCR showed an r’s
hybrid gene, a primer pair specific for the RHD-RHCE hybrid exon 3 characteristic
for the r’s variant was added to the RHC/c MPX PCR (RHC/c/ hex3 MPX PCR; Fig.
1). When a product is yielded for the hybrid exon 3, there may be four possible vari-
ant genes underlying: an r’s, a DIIIa,17 a DIVa type 1,18 or an RN. Only one of the
three published RN variant RHCE will yield a hybrid exon 3-specific PCR product
with the RHC/c/ hex3 MPX PCR.19 However, as RN does encode the RHC-specific
109-bp insert in intron 2, it will already be typed as C+ in the RHC/c/hex3 MPX PCR.
To discriminate between different RHD variant genes (r’s, DIIIa, and DIVa type 1)
and, therefore, to avoid false-positive typing for RHC, an intron 4/exon 7 MPX PCR
was developed that yields a product in case of DIIIa (intron 4) or DIVa type 1 (exon
7) (Fig. 2). If a hybrid exon 3-positive sample is also positive for DIIIa or DIVa type
1, the sample should be typed C-.
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Figure 1. RHC/c/hex3 MPX PCR. Results of the RHC/c/hex3 MPX PCR. Lane 1, CCDee sample, an
RHC-specific product of 320 bp is amplified; Lane 2, CcDEe sample, an RHC-specific product of 320
bp and an RHc-specific product of 177 bp are amplified; Lane 3, ccdee sample, an RHc-specific pro-
duct of 177 bp is amplified; Lane 4, (C)cdes, r’s sample, both the RHc and the hex3 product of 111
bp are amplified; Lane 5, water control.
The RHC/c/hex3 MPX PCR was tested on all samples previously tested with both
ASPAs, and the RHC/c MPX PCR and was tested on an additional 125 whites, 45
blacks from Ethiopia, 26 blacks from Curaçao, 125 blacks from South Africa, and
125 Asians from South Africa and compared with serologic results. All samples that
showed a hybrid exon 3 product in absence of a normal RHC allele (characterized
by 109-bp insert in intron 2) were also tested with the intron 4/exon 7 MPX PCR.
Genotyping results obtained with the RHC/c/hex3 MPX PCR and intron 4/exon 7
MPX PCR compared with serologic typing are shown in Table 3. The distribution of
r’s, DIIIa, and DIVa type 1 genes in the groups from different ethnic backgrounds is
shown in Table 4. All samples (except one) that gave false-negative results in the
RHC/c MPX PCR are now typed correctly. The discrepant sample (South African
donor, phenotype CcDee) was typed false negative for C because of the presence
of both an r’s variant gene and a DIIIa variant gene, as was shown by RHD MPX
PCR analyses. One sample (Curaçao donor, phenotype ccdee) was typed false
positive. This sample was false positive in the RHC ASPA (C48), positive for the
hybrid exon 3 (hex3), and negative for both DIIIa and DIVa type 1 variant genes, and
it lacks the expression of the C protein. Sequencing analyses of RHD exon 3 show-
ed the same hybrid exon 3 as in r’s and a normal RHD exon 3. Because this sample
shows only one (nonfunctional) RHD (RHD, according to RHD MPX PCR analy-
ses) on the RH locus by RHD breakpoint PCR-RFLP analyses20 (results not shown),
the hybrid exon 3 is most likely located in RHce.
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Figure 2. Intron 4/exon 7 MPX PCR. Lane 1, r’s sample, the 1180-bp product of RHCE intron 4 is
amplified; Lane 2, DIIIa sample, the 529 bp of RHD intron 4 is amplified with RHCE-specific primers;
Lane 3, DIVa type 1 sample, the 90- bp product shows the presence of C1048; Lane 4, water control;
Lane 5, DNA marker (100 bp). The 1180-bp product is also functioning as an internal control. The
1180-bp amplicon is not visible in Lane 2 because of competition. 
The positive and negative predictive values of both the RHC/c MPX PCR and the
RHC/c/hex3-intron 4/exon 7 MPX PCR analyses (Table 5) show that the new appro-
ach has a better diagnostic value for RHC and RHc genotyping in different ethnic
groups.
Frequency of r’s gene and 48G>C RHce alleles in different Rh phenotypes 
Our results indicate that the 48G>C mutation is most likely associated with RHce
(Table 6) and is found in both R0 (cDe) and r (cde) haplotype. Of the Curaçao donors
(which were partly selected to be D-), 28 of the 39 samples carrying the 48G>C muta-
tion were found to be RhD negative. In the Ethiopian population, 3 out of 33 samples
carrying the 48G>C mutation were found to be D-. Furthermore, we found that in all
donors in whom the RhC expression was derived from an r’s gene (n = 34) and that
in all D- donors carrying an RHD (as confirmed by sequencing analysis of exon 4 of
all samples missing exon 5 by RHD MPX PCR analysis) (n = 17 in analyzed group of
1071), the 48G>C mutation was present, which suggests that the mutation is present
in cis RHce alleles. Table 4 shows the distribution of r’s, DIIIa, and DIVa type 1 vari-
ant RHD genes as found in this study. We found one r’s gene to be present among
whites from the Netherlands and none of the variant genes to be present in blacks
from Ethiopia. In blacks from South Africa, both r’s and DIIIa genes are highly fre-
quent. DIVa type 1 genes are only found in blacks from in which r’s genes are also
highly frequent. One DIIIa gene was found among the Asians from South Africa.
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Table 3. RhC phenotyping compared with RHC genotyping RHC/c/hex3 MPX
PCR and intron 4/exon 7 MPX PCRs 
C+ RHC + Percentage of Percentage of 
Donor origin phenotype RHC/c/hex3 false-negative false-positive
C typing C typing 
Whites, Netherlands (n = 250) 170 170 0 0 
Blacks, South Africa (n = 250) 47 46 2.1 0 
Blacks, Ethiopia (n = 170) 70 70 0 0 
Blacks, Curaçao (n = 151) 37 38 0 0.9 
Asians, South Africa (n = 250) 214 214 0 0 
Total population (n = 1071) 538 538* 0.19 0.19 
* This number includes one sample typed as false positive for C and one sample typed as false
negative for C and, therefore, shows no difference from the total C+ phenotypes.
Table 4. Distribution of r’s, DIIIa, and DIVa type 1 variant genes among 
different ethnic groups 
Number of donors with phenotype (gene) 
Donor origin r’s (C)cdes* DIIIa* DIVa type 1* 
Whites, Netherlands (n = 250) 1 0 0 
Blacks, South Africa (n = 250) 18 30 0 
Blacks, Ethiopia (n = 170) 0 0 0 
Blacks, Curaçao (n = 151) 15 0 2 
Asians, South Africa (n = 250) 0 1 0 
* Designation of phenotypes of variant r’s, DIIIa, and DIVa type 1 was based on genomic PCR
results. All samples were tested in the following assays: RHD MPX PCR, RHC ASPA, RHc ASPA,
RHC/c/hex3 MPX PCR, and intron 4/exon 7 MPX PCR. All samples from African blacks are also
analyzed with all DAR PCRs.22
Table 5. Positive and negative predictive values* for RHC genotyping with
RHC/c MPX PCR (RHC intron, 2 RHc C307) and RHC/c/hex3-intron 4/exon 7
MPX PCR analyses 
RHC/c MPX PCR† RHC/c/hex3-intron 4/exon 7 MPX PCR 
Positive predictive Negative predictive Positive predictive Negative predictive 
value value value value 
Whites, Netherlands (n = 250) 1 0.9796 1 1 
Blacks, South Africa (n = 250) 1 0.9369 1 0.9951 
Blacks, Ethiopia (n = 170) 1 1 1 1 
Blacks, Curaçao (n = 151) 1 0.8692 0.9737 1 
Asians, South Africa (n = 250) 1 1 1 1 
* Positive and negative predictive values are calculated as described by Altman.28
† This assay was tested on only 125 donors of each ethnic group. 
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Table 6. Phenotype associations* 
Ccdee CcDee CcDee ccdee ccDee ccDee ccDEe CcDEe 
r’s/48G>C (n = 1071) 14/14 2/2 14/14 4/4
DIIIa/48G>C (n = 1071) 3/3 27/23 1/1 
DIVa type 1/48G>C (n = 1071) 2/2
48G>C+ (n = 625) 21 10 93 9 
* Number of genes/number of RHce alleles with 48G>C mutation associated with gene. 
† Number of RHce alleles with 48G>C mutation not associated with r’s, DIIIa, or DIVa type 1 genes in
n = 625 donors. 
Serologic analysis of r’s genes and 48G>C RHce alleles
Serologic analysis by titration studies of C expression encoded by r’s on RBCs of three
donors (Ccdee) with MoAbs CM216-1, CB250A1, and 8-36216 gave an identical weak
expression comparable with the earlier described r’s reaction pattern by the same labo-
ratory (results not shown).7 All three r’s samples showed a titer of 4, 64, and 32,
respectively (controls showed a titer of 16, 64, and 64, respectively), and showed
between 60 percent and 65 percent antigen expression as compared with a CcDee cell
(100%). Furthermore, to investigate whether C expression is altered when encoded by
r’s, C expression was studied with MoAbs C-93/44, 388F3, MS23, MS257, MS273,
P3x25513G8, and DGC02. No differences in reactivity between control and donor cells
were observed (results not shown).To investigate whether the 48G>C mutation leading
to W16C on the RHce allele has an effect on c expression on the RBC, we amplified
and cycle-sequenced RHCE exon 2 of all samples of the Curaçao donors and serolo-
gically tested three samples that were found to be homozygous for the 48G>C mutation
(all ccDee). MoAbs MS33 (epitope 1, according to the proposed 5 epitope model for
c5), BS240 (epitope 2), 951 (epitope 3), POQ/3D2 (epitope 4), and BB7.D4 (epitope 5)
were used with CCDee, ccdee, and Ccdee controls (Table 7). Herewith, no altered reac-
tion pattern between donor and control cells was observed, and therefore, the 48G>C
mutation in RHce does not affect the expression of c. To investigate whether expressi-
on of e and f (RH6) are affected by 48G>C when encoded on the same allele, we
serologically tested the previously described samples and an additional three ccDEe
samples (one white and two South African donors) expressing the 48G>C mutation.To
determine e expression, MoAbs as well as polyclonal antibodies were used (Table 7).
No differences in reactivity were observed with MoAbs between donor and control cells.
MS16 gave a very weak to no reaction with both control and donor cells. After enzyme
treatment, the reactions with MS16 were stronger (2+), but again, no difference was
observed between control and donor cells. For reactivity of the donor cells with anti-f, a
polyclonal IgG anti-f patient serum was used with control cells ccdee, and ccdEe
Titration studies showed no difference between donor and control cells; therefore, the
reactivity of RHce carrying the 48G<C mutation with polyclonal anti-f is not affected.
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* Scoring system is based on 0 (negative), vw (very weak), w (weak), to 4 (strongly positive) scale. 
† Polyclonal antibody. 
‡ RBCs pretreated with bromelain. 
Discussion 
Because RHD is highly variable, it is difficult to design genotyping methods for cor-
rect prediction of D expression from RHD. Variant RHD have different gene
frequencies among different ethnic groups. RHCE, however, seems to be less vari-
able; at least, fewer RHCE variants are described in literature. Because C and c
cover fewer epitopes, it might be less complex to design reliable genotyping assays
for RHC and RHc. In this article, the variability in RHC and RHc between different
ethnic groups was studied, which may disturb reliable genotyping. Based on the
observed variant genes, an RHC/c genotyping assay was developed that is reliable
in different ethnic groups. Serologic analysis of the RBCs expressing Rh polypepti-
des encoded by the variant genes showed that C and c antigen expression of the
cells is not affected qualitatively. In all ethnic groups, RHce and RHcE alleles seem
to be strongly preserved for the mutations in exon 2 that are specific for c expressi-
on. This was expected for P103, as this amino acid is essential for c expression, but
it also seems to be the case for L60. We tested 543 c+ donors for the presence of
C178 and found no discrepancies.Therefore, genotyping for RHc is possible on both
C178 and C307, but because of the recent report by Faas et al.5 of a variant RHD
with Rhc expression caused by a 307 T>C mutation, this position is theoretically pre-
ferred for RHc genotyping. RHC/c polymorphisms were first described by Mouro et
al.1 and by Simsek et al.2 They both found a W at amino acid position 16 (G48) on
the RHc allele derived from white donors. Also, in the white population in this study,
RHc with G48 is the predominant genotype. However, 3 out of 125 white donors
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Table 7. Reactivity of c and e with polyclonal antibodies and MoAbs and RH6 (f) 
reactivity with anti-f patient serum* 
Donor POQ/ BB7.Polyc DGP DGP Anti-f 
number Phenotype MS33 BS240 951 3D2‡ D4 Rhe† MS16 MS16‡ MS62 MS69 MS69‡ MS63 MS21 E01 E01‡ serum 
980717 ccDee 4 4 4 NT 1 4 vw 2 3 1 3 3 3 w 3 3 
980736 ccDee 4 4 3 3 1 4 0 2 3 1 3 4 3 w 3 3 
980762 ccDee 4 4 4 4 1 4 vw 2 3 1 3 3 3 1 3 3 
970063 ccDEe NT NT NT NT NT 4 0 2 3 1 3 3 3 0 2 3 
980121 ccDEe NT NT NT NT NT 4 0 2 3 1 3 3 3 0 2 3 
980135 ccDEe NT NT NT NT NT 4 0 2 3 1 2 3 3 0 2 3 
Control ccdee 4 4 4 4 1 4 w 3 3 2 3 4 3 2 3 3 
Control ccdEe NT NT NT NT NT 4 0 2 3 w 3 3 3 vw 2 3 
Control ccDEE NT NT NT NT NT 0 0 w 0 0 0 0 0 0 0 NT 
Control Ccdee 4 4 3 NT 1 NT NT NT NT NT NT NT NT NT NT NT 
Control CCDee 0 0 0 0 0 NT NT NT NT NT NT NT NT NT NT NT 
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were found to carry an RHce allele with a 48G>C mutation. Furthermore, our results
show that the 48G>C mutation in exon 1 of the RHc allele in the absence of an RHC
allele is highly frequent in blacks (67.3% in South Africans, 47.9% in Ethiopians, and
41.9% in Curaçao). Our results show that the 48G>C mutation is associated with the
RHce allele and is present in both the RHD+ as in RHD- haplotypes and, therefore,
is not only associated with the R0 (cDe) haplotype, as suggested by Westhoff et al.,21
but is also seen with the r (cde) haplotype, especially in black populations (2.4% in
Ethiopian donors and 22.4% in Curaçao donors). Although C16 is involved in C
expression,6 clearly other conformation determining factors are also required for the
expression of C. However, it is highly unlikely that this variant RHce is immunogenic
for transfusion recipients and/or mothers lacking this gene. Serologic analysis with
MoAbs directed against each of the five different c epitopes as described by Faas et
al.5 showed that the 48G>C mutation does not interfere with the expression of any
of the c epitopes. The possible effect of the 48G>C mutation on e and f (RH6)
expression was serologically analyzed with polyclonal antibodies and MoAbs. None
of the reactions differed between the donor cells and the control cells, not even after
enzyme treatment. This is in contrast with the results of Westhoff et al.,21 who found
that the 48G>C mutation induced the loss of reactivity with (among others) MoAbs
MS16 and MS69, which were reported to be strongly positive (4+) on enzyme-trea-
ted control cells. In our hands, both antibodies were weakly reactive with both control
cells (2+) and enzyme-treated cells of six donors carrying the 48G>C mutation (2+)
(Table 7). We might have missed the decreased e expression due to low titers in our
batches of MoAbs. Genotyping for RHC is more complicated because the only RHC-
specific nucleotide in the coding part, C48, is not usable as described previously
here. Intron 2 of RHCE differs between RHC and RHc. However, our results show
that because of the presence of the variant RHD gene r’s ((C)des), which encodes
an Rh polypeptide that weakly expresses C and which lacks the RHC specific intron
2, this polymorphism is also not usable; the r’s gene was found in 0.4 percent of whi-
tes, 9.9 percent of blacks from Curaçao, and 7.2 percent of blacks from South Africa.
All samples that were typed false negative for C with the RHC/c MPX PCR, which is
specific for RHC specific in intron 2, appeared to carry an r’s gene. In blacks from
South Africa and Curaçao in approximately 40 percent of the phenotypically C+
donors, C expression was the result of this variant RHD. The expression of the C
polypeptide encoded by an r’s gene was tested with MoAbs. None of the antibodies
gave weaker reactions with the donor cells compared with the control cells.
Therefore, it seems that r’s genes do not give rise to altered C. However, there is one
report in which an alloanti-C was found in a patient carrying an r’s gene.22 We first
published about the r’s gene in 1997 and suggested that r’s genes cosegregate with
an RHce allele with the 48G>C mutation.7 The results of this study are in agreement
with this hypothesis (Table 6). An MPX PCR was developed in which RHc is detec-
ted specifically on C307 and RHC is detected specifically on both the 109-bp
79
RHC and RHc genotyping in different ethnic groups
110094_Binnen  08-11-2005  09:15  Pagina 79
insertion in RHC intron 2 and on the hybrid exon 3 as found in an r’s gene. Because
this hybrid exon 3 is also present in DIIIa and DIVa type 1 variant RHD genes, an
exclusion intron 4/exon 7 MPX PCR was developed that is positive for both DIIIa and
DIVa type 1 genes, which can be used in a second phase when a hybrid exon 3 is
detected in the absence of a normal RHC. If a sample is positive for either DIIIa
and/or DIVa type 1, the sample should be typed negative for C. If a sample is nega-
tive for both DIIIa and DIVa type 1, the sample should be typed positive for C (Fig.
3). A false-negative prediction of the C phenotype may still be encountered becau-
se of the presence of an r’s gene with a DIIIa, a DIVa type 1, or a DAR23 gene in
trans. This was found in one case in this study and concerned a black person from
South Africa. Based on the on the frequencies of r’s, DIIIa, and DIVa type 1 genes
as found in this study (Table 4), we can predict that the probability to find a black
South African donor carrying an r’s gene and a DIIIa or a DIVa type 1 gene will be
0.2 percent. This will be lower in all other ethnic groups, as the frequencies of both
r’s, DIIIa, and DIVa type 1 genes are much lower. The probability of carrying an r’s
gene with a DAR gene in trans in a black South African donor will be 0.18 percent,
based on a gene frequency of 0.025 for the DAR variant gene. However, all samples
from African blacks were also tested with the DAR-specific PCRs (results not
shown). Herewith, we identified one sample that was typed DIIIa by RHC/c/hex3-
intron 4/exon 7 MPX PCR analyses to be positive for a DAR variant gene. This
sample did not carry an RHC and did not express C on the RBC surface.
Furthermore, r’s alleles with a weak D type 4.0 or 4.124 in trans will also give rise to
a false-negative prediction of C. However, these alleles are rare. The other mutati-
ons found in an r’s gene, 410 C>T and 733CG, may also be used for specific
detection of an r’s allele. Recently, Wagner et al.25 have described an ASPA specific
on G733 (V245) in an RHCE environment resulting in VS positivity. The presence of
both the RHD-RHCE hybrid exon 3 (hex3) and G733 is indicative for an r’s allele.
However, this approach also will not be conclusive because the L245V polymor-
phism has been identified in VS+, C- donors without an r’s gene.15 The 410 C>T
mutation is present in a DIII type 4 allele and may be present in other alleles.24 A
false positive prediction of the C phenotype was made in one case. Here, a hybrid
exon 3 as found in an r’s gene is most likely present in the RHce allele. It could not
be determined whether the RHD-specific mutations in this allele have influence on
the expression of c or e because of the presence of a normal RHce allele in trans.
Because this sample also carries the G48C mutation, analysis with the C48-ASPA
(which we found never to be false-negative) is not informative.
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Figure 3. Flow diagram for RHC and RHc genotyping by RHC/c/hex3-intron 4/exon 7 MPX PCR analy-
sis. This diagram indicates the decisions to be made when genotyping with the RHC/c/hex3 MPX
PCR. Hex3- indicates the absence of an RHD-RHCE hybrid exon 3, and hex3+ indicates the presence
of an RHD-RHCE hybrid exon 3. According to the diagram, genotyping for both RHc and RHC can be
done by one single assay, except when a hybrid RHD-RHCE exon 3 is present in an RHC- sample. In
that case, further analyses to determine the origin of the hybrid exon 3 is necessary. When the hybrid
exon 3 originates neither from DIIIa, nor DIVa type 1, the sample should be typed C+; otherwise, the
sample should be typed as C-. 
With the RHC/c/hex3 genotyping method, it is now possible to type reliably for RHC
and RHc in different ethnic groups. With the new approach, 1071 of the 1071 sam-
ples were correctly typed for c, and 1069 of the 1071 samples were correctly typed
for C. The only positive and negative predictive values lower than 1.0 for the RHC/c/
hex3 MPX PCR in combination with the intron 4/exon 7 MPX PCR are 0.97 (blacks
from Curaçao) and 0.99 (blacks from South Africa), respectively. A false-positive pre-
diction of the phenotype can form a health hazard when typing blood transfusion
recipients, as they will be transfused with antigen-positive cells and being antigen-
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negative themselves, the recipient may produce allo-antibodies against the donor
cells. False-negative prediction of the phenotype can form a health hazard when
typing blood donors, as their cells will actually be antigen-positive and given to a
antigen-negative recipient, and in prenatal diagnosis, as the fetus of an antigen-
negative pregnant woman will be incorrectly typed negative and therefore the
pregnancy will not be monitored while the mother may produce antibodies to anti-
gen of the child. Genotyping may be the only diagnostic tool in cases in which direct
phenotyping is not possible (e.g., prenatal diagnosis or recently transfused patients).
After anti-D, anti-c is the most important RBC alloantibody that can cause HDN.26 A
correct prediction of the C phenotype is also valuable because anti-G may be res-
ponsible for HDN.27
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Chapter 4
Systemic analysis and zygosity determination of the RHD gene
in a D-negative Chinese Han population reveals a novel 
D-negative RHD gene 
X Qun, MGHM Grootkerk- Tax, PA Maaskant-van Wijk, CE van der Schoot. Systemic analysis and
zygosity determination of the RHD gene in a D-negative Chinese Han population reveals a novel D-
negative RHD gene. Vox Sanguinis 2005;88:35-40.
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Abstract
Background: The aim of this study was to systemically analyse the genetic back-
ground of D negativity in a Chinese Han population.
Study design and methods: DNA of 74 D-negative samples was analysed by
using an RHD multiplex polymerase chain reaction (MPX PCR) for the presence of
RHD and by PCR-restriction fragment length polymorphism (PCR-RFLP) for RHD
zygosity determination. Sixty-five samples were additionally analysed by using real-
time quantitative PCR on RHD exon 7. RHD exon-specific sequencing was
performed on discrepant samples.
Results: Forty-six samples (62%) showed the absence of RHD-specific exons by
RHD MPX PCR and homozygous RHD negativity by PCR-RFLP. Twenty-two sam-
ples (30%) showed a 1227G>A mutation, characteristic for the Del phenotype. Five
(7%) samples showed all characteristics of the RHD(1-2)-CE(3-9)-D(10) hybrid
gene. One sample (1.4%) showed a novel 933C>A nonsense mutation in RHD exon
6, which resulted in a premature stop codon.
Conclusions: The RHD gene deletion, RHD-CE-D hybrid genes and one novel
93C>A mutation were found to be the three mechanisms that cause D negativity in
our samples. The 1227G>A Del mutation was found to be the major cause of discre-
pant results between genotyping and phenotyping strategies, favouring genotyping
of D-negative samples.
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Introduction
The Rh blood group system is one of the most polymorphic and clinically important
blood group systems in humans. In particular, the highly immunogenic RhD protein
is involved in haemolytic disease of the fetus and newborn (HDFN) and transfusion
reactions. The Rh antigens are encoded by two homologous genes: RHD and
RHCE. It has been demonstrated that different (genetic) forms of D negativity occur
in different ethnic populations. Whilst D-negative white people were almost invaria-
bly found to have a deletion of RHD between the upstream and downstream Rh
Boxes,1 the RHD gene and the RHD (1-3) RHCE (3-7) RHD (8-10) hybrid gene(s)
were found to frequently cause D negativity in Africans.2,3 In Asians, a very weak
expression of the D antigen - the Del phenotype - was found in individuals who were
apparently D negative,4 and represents 10-33% of the Japanese or Chinese serolo-
gically typed D-negative donors.5 Subsequent studies showed that the Del
phenotype was associated with either a deletion of RHD intron 8 to intron 9, inclu-
ding whole exon 9,6 or a missense mutation (1227G>A) in exon 9.7 More recent
studies also revealed new missense mutations and an RHD-RHCE-RHD hybrid
gene in D-negative Chinese subjects.8,9 Recently, the RH locus was explored and it
was found that the RHD gene is flanked by an upstream Rh box (at its 5’-end) and
a downstream Rh box (at its 3’-end). Both Rh boxes have a length of ≈ 9000 bp in
identical orientation and share 98.6% homology. The region (breakpoint region) in
which the RHD deletion occurs is located within a stretch of 1463 bp in which both
Rh boxes have an identical sequence (identity region). The hybrid Rh box, only pre-
sent when the RHD gene is deleted via the proposed mechanism of unequal
crossing over, contains a sequence identical to that of the upstream Rh box in the
5’-part preceding the identity region, and the 3’-part following the identity region is
identical to the downstream Rh box sequence in white people.1 In the present study,
74 D-negative DNA samples from a Chinese Han population were analysed to
explore the genetic background of the D-negative phenotype in this population.
Materials and methods 
Blood samples and DNA isolation 
Blood samples were collected from 74 D-negative and from 11 D-positive unrelated
regular blood donors at Shandong Blood Center (Jinan, China). All donors were of
Chinese Han ethnicity and lived in Shandong Province area. DNA was isolated from
the samples by using a QIAamp DNA blood kit (Qiagen, Valencia, CA).
Serological methods to determine the Rh antigens 
Rh antigens were serologically determined in China by using monoclonal anti-
D,C,c,E,e reagents (Gamma, Houston, TX) according to the manufacturer’s
instructions. For all D-negative samples, the indirect antiglobulin test (IAT) was used
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to retest D-antigen expression to exclude weak D or a partial D phenotype. No
adsorption-elution tests were performed.
Real-time quantitative analyses of the RHD gene 
The presence of RHD exon 7 was determined by real-time quantitative polymerase
chain reaction (RQ-PCR) (7000 Sequence detector; Applied Biosystems,
Nieuwerkerk a/d lJssel, the Netherlands). RHD exon 7 [primers 940S and 1064R
(RHD specific)] was amplified and RHD was detected by using a FAM fluorescently
labelled RHD -specific probe (probe 968; 5’-cccacagctccatcatgggctacaa-3’). Primers
were used at a final concentration of 900 nM, and the probe was used at a final con-
centration of 100 nM , in a total volume of 25 µl of TaqMan Universal Master Mix
(Applied Biosystems). Optimal results were obtained by using a final DNA concen-
tration in the range of 2-4 ng/ml. Each sample was tested in triplicate.
Multiplex PCR analysis of RHD 
As previously described, six primer pairs were used to specifically amplify RHD
exons 3, 4, 5, 6, 7 and 9 in one reaction mixture. PCR products were analysed by
electrophoresis on a 12% acrylamide gel.10
RHD exon-specific sequencing 
RHD-specific primers were designed based on intron sequences, and PCR amplifi-
cations were performed as described previously (Table 1). Amplifications of exons 6
and 10 were performed with the use of the expand high-fidelity PCR system (Roche
Molecular Biochemicals, Mannheim, Germany), as described previously (Table 1).11
Nucleotide sequencing was performed on an automatic 377 DNA sequencer
(Applied Biosystems).
PCR-restriction fragment length polymorphism (PCR-RFLP) for RHD zygo-
sity determination 
According to the method published by Wagner & Flegel,1 a PCR amplification was
performed by using the expand high-fidelity PCR system with primers rez7 (consen-
sus, 5’ of the Rh box identity region) and rnb31 (specific for downstream of the Rh
box, 3’ of the Rh box identity region). PCR products were digested with Pst I for 3h
at 37°C, and the fragments were resolved by electrophoresis on a 1% agarose gel.
Rh box sequencing 
PCR products obtained with primers rez7 and rnb31 (amplifying both the down-
stream and the hybrid Rh boxes) were sequenced with consensus primer pairs
CRBF06/CRBR08 and Rhbox5070/Rhbox557112 (Table 1) to determine the Rh box
sequences.
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Results 
RQ-PCR on RHD exon 7 
All 11 D-positive samples showed the presence of RHD exon 7, indicating the pre-
sence of an RHD gene. Sixty-five of the 74 D-negative samples were analysed for
the presence of RHD exon 7 by RQ-PCR.Twenty-three samples showed the presen-
ce of RHD exon 7, whereas the remaining 42 D-negative samples showed no RHD
exon 7 (D negativity is caused by modification at the genomic level, e.g. by RHD-CE
hybrid genes or by deletion of the whole RHD gene).
Table 1 Primers 
Primer Nucleotide sequence Specificity Position Exona Ref.
re01 atagagaggccagcacaa RHD -149/-131 1 (F) [11] 
RHIN1R tctgtgcccctggagaaccac RHD/CE 84-64 1 (R) [2] 
RHIN2F attgagtgagaggcatc RHD/CE -57/-40 3 (F) 
RHDIN3R tttcaaaaccctggaaac RHD 80/63 3 (R) 
RHIN3F tccagtgagccgagatcg RHD/CE -199/-182 4 (F) 
rb12 tcctgaacctgctctgtgaagtgc RHD 197/174 4 (R) [11] 
rb11 tacctttgaattaagcacttcacag RHD -267/-243 5 (F) [11] 
RHIN5R gtggggaggggcataaat RHD/CE 73/55 5 (R) [2] 
rf51 caaaaacccattcttcccg RHD/CE -332/-314 6 (F) [11] 
re71 acccagcaagctgaagttgtagcc RHD 1008/985 6 (R) [11] 
rb25 agcagggaggatgttacag RHD/CE -111/-93 6 (S) [11] 
re621 catccccctttggtggcc RHD -102/-85 7 (F) [11] 
re75 aaggtaggggctggacag RHD 169/152 7 (R) [11] 
RHin7DF ctggaggctctgagaggttgag RHD -328/307 8 (F) [12] 
RHin8R tatgtgatcctcagggaaggag RHD/CE 97/76 8 (R) [12] 
RHDIN8F gttttgacacacaatatttc RHD -82/-67 9 (F) 
RHDIN9R cagcaagtcaacatatatact RHD 82/62 9 (R) 
re91 caagagatcaagccaaaatcagt RHD/CE -40/-18 10 (F) [11] 
rr4 agcttactggatgaccacca RHD UTR 1541/1552 10 (R) [11] 
rh7 acgtacaaatgcaggcaac RHD/CE UTR 1330/1313 10 (S) [11] 
940S gggtgttgtaaccgagtgctg RHD 7 (F) 
1064R ccggctccgacggtatc RHD 7 (R) 
rez7 cctgtccccatgattcagttacc Rh box Rh box Consensus (F) [1] 
rnb31 cctttttttgtttgtttttggcggtgc Rh box Rh box Downstream (R) [1] 
Rhbox5070 ctacaggcccatgagagtccaaa Rh box Consensus (F) [11] 
Rhbox5571 agtgcaagccccaagccttgaca Rh box Consensus (R) [11] 
CRBF06 gttaatatgggtggctggc Rh box Consensus (F) 
CRBR08 cattaagagatacgcacagg Rh box Consensus (R) 
a The number corresponds to the amplified exon, and the orientation of the primer is shown in paren-
thesis: F for forward; R for reverse; and S for sequence primer. 
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RHD multiplex PCR (MPX PCR) and PCR-RFLP for RHD zygosity deter-
mination 
Of the 11 D-positive samples showing the presence of RHD exon 7 by RQ-PCR,
eight samples were further analysed and showed all RHD-specific exons by RHD
MPX PCR. Seven samples were homozygous for RHD, and one sample was RHD
hemizygous by PCR-RFLP analysis. From the 74 D-negative samples, 46 (62·1%,
including the 42 samples that were negative for RHD exon 7 by RQ- PCR) showed
the absence of RHD-specific exons by RHD MPX PCR and homozygous RHD nega-
tivity by PCR-RFLP. Five samples (6.8%) showed no RHD-specific exons by RHD
MPX PCR, but PCR-RFLP indicated the presence of one RHD gene. From the 23
samples negative for RHD exon 7 by RQ- PCR, 22 (29.7%) showed all RHD-speci-
fic exons by RHD MPX PCR, of which 19 were RHD gene hemizygous and three
were homozygous for RHD. One sample (1.4%) was positive by RHD MPX PCR,
lacking RHD exon 6 and the presence of an RHD gene by PCR-RFLP. Based on
these results, the 74 D-negative samples were divided into groups A, B, C and D
(Table 2).
RHD exon-specific sequencing 
Twenty-one samples from group B (RHD MPX PCR positive and RHD gene hemi-
zygous or homozygous) were further analysed and all showed a 1227G>A mutation
in exon 9. Seven D-positive samples from Chinese subjects were sequenced as con-
trols, and all seven showed normal RHD exon 9 sequences. Based on these results,
the gene frequency of the Del 1227G>A allele is 0.17 among the serologically typed
D-negative samples. The Del phenotype was mainly observed in C-positive sam-
ples, but also sporadically in c-positive samples (Table 2). From four samples of
group C (RHD MPX PCR negative and PCR-RFLP indicating one RHD gene), the
presence of RHD exons 1 and 10 was determined with RHD-specific PCRs (for pri-
mers sequences, see Table 1). The results indicate that the samples from group C
represent hybrid RHD(1)-CE(3-9)-D(10) samples (the origin of RH exon 2 could not
be determined), with a gene frequency of 0.034 among the serologically typed D-
negative samples. Unfortunately, owing to the scarcity of DNA, these samples could
not be analysed further. Sequencing of the RHD exon 6 of the single sample from
group D (RHD MPX PCR positive, but lacking exon 6, and PCR-RFLP indicating one
RHD gene) showed a novel 933C>A nonsense mutation (Fig. 1). RHD-specific
sequencing of exons 1, 3-5 and 7-10 detected no difference from the Chinese con-
trol sample. The 933C>A mutation causes an unstable 3’-end primer annealing,
disabling amplification of RHD exon 6 by RHD MPX PCR analyses.
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Table 2 Results of RHD multiplex polymerase chain reaction (MPX PCR) and
of PCR-restriction fragment length polymorphism (PCR-RFLP) analyses of the 
Chinese RhD-negative population 
Group Number (%) RHD MPX PCR PCR-RFLP RhCcEe Molecular background
A 46 (62·1) Negative All RHD-/RHD- a RHD-negative 
B 22 (29·7) Positive 19 RHD+/RHD- 16 Ccee 1 ccEe RHD 1227G>A 
1 CCee 
1 NT 
3 RHD+/RHD+ 1 CCee 1 ccee 
1 NT 
C 5 (6·8) Negative All RHD+/RHD- 5 Ccee RHD-CE-D hybrids 
D 1 (1·4) RHD exon 6 negative RHD+/RHD- ccee RhD-negative RHD gene
a Unfortunately, RhCcEe phenotyping of group A was not performed. 
Rh box sequencing 
As the samples of group A are RHD negative by RHD MPX PCR analysis, and the
PCR-RFLP indicates no RHD genes, it is expected that only hybrid Rh boxes would
be found on the RH locus. PCR products obtained with primers rez7 and rnb31 (con-
sensus and downstream specific, respectively, amplifying both hybrid and
downstream Rh boxes) were sequenced to study the RHD breakpoint region in
Chinese people. With primers CRBF06 and CRBR08 (both consensus primers, loca-
ted at the 3’ end of the identity region), 27 samples showed downstream sequences
in the 3’ part following the identity region of the hybrid Rh box. Thirteen samples
were further sequenced with primers Rhbox5070 and Rhbox5571 (both consensus
primers, located in the 5’ part preceding the identity/breakpoint region) and all sam-
ples showed upstream-specific sequences in the 5’ part preceding the
identity/breakpoint region, indicating the presence of hybrid Rh boxes, as described
in white people. Because the samples from group B were RHD MPX PCR positive
and showed the presence of an RHD gene hemizygous or homozygously, it was
expected to find no hybrid Rh boxes in the RHD homozygous samples and both a
downstream and a hybrid Rh box in the RHD hemizygous samples. Eleven samples
and four D-positive control samples were sequenced by using primers Rhbox5070
and Rhbox5571. Nine samples hemizygous for RHD showed both upstream and
downstream sequences in the 5’ part preceding the identity region of the Rh box
(confirming the presence of both the downstream and the hybrid Rh box). The two
samples homozygous for RHD showed only downstream Rh box sequences. The
four D-positive samples, homozygous for RHD, also showed only downstream Rh
box sequences.
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Figure 1 In one of the samples one novel 933C>A mutation (the upper sequence) in RHD exon 6 was
found to lead to the formation of a premature stop codon.
The lower sequence is that of the Chinese RhD-positive control sample.
Discussion 
The presence of an RHD gene in serologically D-negative individuals hampers reli-
able genotyping of RHD by introducing false-positive results. False-positive
(geno)typing for the RHD gene may frequently occur in African populations owing to
the presence of RHD and of the RHD(1-3)RHCE(3-7)RHD(8-10) hybrid
gene(s).9,13,14,15 In Japanese people, Okuda et al. found different RHD genes in
apparent D-negative individuals.16 Subsequent studies demonstrated all types of
partial or intact RHD genes to be present in Chinese or Japanese D-negative blood
donors.5,6,8,9,14,17,18 It was also found that a grossly intact RHD gene is present in the
Del phenotype (which was first described in 1984)4 in apparent D-negative donors.
The very weak D antigen of Del can only be detected by adsorption elution tests,
which are not used as part of the routine testing for the D antigen. There is no con-
sistent agreement regarding whether or not the Del phenotype should remain in the
D-negative group. Chang et al. found a large deletion of RHD in all of their 21 Del
phenotype individuals from Taiwan.6 This deletion covers 1013 bp between intron 8
and intron 9, including the whole of RHD exon 9. However, several other groups
found an intact RHD gene in the Del phenotype, and sequencing showed three mis-
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sense mutations, of which one is the 1227G>A mutation that probably disrupts nor-
mal intron splicing.7,8,14 More recently, two groups from Taiwan studied the Del
phenotype and one group demonstrated the 1013-bp deletion in all of their Del
donors (they encountered 13 Del samples in 204 RhD-negative samples),9 while the
other group only found 20% of their Del lacking exon 9, with the remaining 80% sho-
wing the presence of RHD exons 3, 4, 5, 7 and 9 by PCR-SSP (Sequence Specific
Primer) (they encountered 34 Del samples in 156 D-negative samples).19
Apparently, different molecular mechanisms underlie the Del phenotype. In our
study, sequence analysis of 21 D-negative samples from the Chinese HAN popula-
tion, which showed all RHD exons by RHD MPX PCR analysis, revealed only the
1227G>A Del mutation. As shown in this study, individuals with the Del phenotype
frequently occur (often in association with RhCe) and are not recognized as D-posi-
tive in daily practice in blood banks in China. In fact, our study group consists of
regular Chinese blood donors. Therefore, blood of the Del phenotype is frequently
transfused into D-negative patients, apparently without giving rise to immunization.
However, how the splicing site mutation causes the very weak expression of D anti-
gen, and whether this weak antigen causes D immunization when transfused to
D-negative patients, needs further investigation. D negativity owing to a deletion of
the RHD gene is the most common form of D negativity in Chinese people. In 46
samples that were negative in the RHD MPX PCR and contained no RHD gene
according to PCR-RFLP analysis, it is shown that D negativity is caused by a dele-
tion of the RHD gene. Further sequencing of parts of the Rh box in this group
indicates that also in Chinese people the RHD gene deletion has taken place within
the defined breakpoint region, as previously described in white people.1 Therefore,
it is possible to determine the RHD zygosity by using the PCR-RFLP in a Chinese
Han population. Five D-negative samples were negative when analysed by the RHD
MPX PCR (indicating the absence of RHD exons 3, 4, 5, 6, 7 and 9) but PCR-RFLP
analysis indicated the presence of one RHD gene. Further analysis of four samples
revealed that they had at least RHD exons 1 and 10 and were associated with the
DCe haplotype. This result was in concordance with previous studies in Chinese
populations in which the RHD(1)- RHCE(2-9)-RHD(10) hybrid gene was always des-
cribed in association with the DCe haplotype.8,9,18 However, the presence of RHCE
exon 2, and therefore the exact junction point between RHD and RHCE in our sam-
ples, could not be determined. Similar hybrid genes were also described in
Europeans.20 In these European samples the exact junction point between RHD and
RHCE was not described. One novel RHD 933C>A nonsense mutation, which
results in a stop codon, was found in one of the D-negative samples. Missense
mutations are not frequently encountered in D-negative Chinese people, except for
the recent cases reported by Shao et al.8 However, RHD missense mutations are
more frequent in Chinese people than in Europeans, stressing the advantage of
their specific detection by using molecular methods. In summary, the RHD gene
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deletion, a RHD-RHCE-RHD hybrid gene and one novel 933C>A mutation were
found to be the three mechanisms that cause D negativity in our samples (with gene
frequencies of 0.79, 0.034 and 0.006, respectively, in the Chinese Han population
serologically typed as D-negative). Specific sequencing of the Rh boxes indicated
that the physical structure of the hybrid Rh box on the RHD-negative RH locus in
Chinese people is identical to the structure previously described in white people.
Furthermore, our data support that genotyping RHD to predict the D phenotype is
hampered by the presence of the described RHD genes in a Chinese population. In
particular, the highly frequent 1227G>A mutation (allele frequency of 0.17 in D-
negative Chinese donors), characteristic for the Del phenotype should be taken into
account when typing a Chinese (Asian) population. Serologically, this phenotype will
only be detected by the absorption elution technique, which is not part of routine tes-
ting and therefore results in a false-negative test result for D in donors from Asian
descent.
Acknowledgements
The authors would like to thank Lotte Douglas-Berger and Judith van Drunen for
their help in the development of the RHD-specific sequencing assays.
96
Chapter 4
110094_Binnen  08-11-2005  09:15  Pagina 96
References 
1. Wagner FF, Flegel WA: RHD gene deletion occurred in the Rhesus box. Blood
2000; 95:3662-3668.
2. Singleton BK, Green CA, Avent ND, Martin PG, Smart E, Daka A, Narter-
Olaga EG: The presence of an RHD pseudogene containing a 37 bp
duplication and a nonsense mutation in Africans with the Rh D-negative blood
group phenotype. Blood 2000; 95:12-18.
3. Faas BHW, Beckers EA, Wildoer P, Ligthart PC, Overbeeke MA, von
Zondervan HA, dem Borne AE, van der Schoot CE: Molecular background of
VS and weak C expression in blacks. Transfusion 1997; 37:38-44.
4. Okubo Y, Yamaguchi H, Tomita T, Nagao N: A D variant, Del? Transfusion
1984; 24:542.
5. Sun CF, Chou CS, Lai NC, Wang WT: RHD gene polymorphisms among RhD-
negative Chinese in Taiwan. Vox Sang 1998; 75:52- 57.
6. Chang JG, Wang JC, Yang TY, Tsan KW, Shih MC, Peng CT, Tsai CH: Human
RhDel is caused by a deletion of 1013 bp between introns 8 and 9 including
exon 9 of RHD gene. Blood 1998; 92:2602-2604.
7. Wagner FF, Frohmajer A, Flegel WA: RHD positive haplotypes in D negative
Europeans. BMC Genet 2001; 2:10.
8. Shao CP, Maas JH, Su YQ, Kohler M, Legler TJ: Molecular background of Rh
D-positive, D-negative, Del and weak D phenotypes in Chinese. Vox Sang
2002; 83:156-161.
9. Peng CT, Shih MC, Liu TC, Lin IL, Jaung SJ, Chang JG: Molecular basis for
the RhD negative phenotype in Chinese. Int J Mol Med 2003; 11:515-521.
10. Maaskant-van Wijk PA, Faas BH, de Ruijter JA, von Overbeeke MAM, dem
Borne AEG, Kr van Rhenen DJ, van der Schoot CE: Genotyping of RHD by
multiplex polymerase chain reaction analysis of six RHD-specific exons.
Transfusion 1998; 38:1015- 1021.
11. Wagner FF, Flegel WA: Molecular basis of weak D Phenotypes. Blood 1999;
93:385-393.
12. Matheson KA, Denomme GA: Novel 3’Rhesus Box sequences confound RHD
zygosity assignment. Transfusion 2002; 42:645- 650.
13. Tax GHM, van der Schoot CE, van Doorn R, Douglas-Berger L, van Rhenen
DJ, Maaskant-van Wijk PA: RHC and RHc genotyping in different ethnic
groups. Transfusion 2002; 42:634-644.
14. Lan JC, Chen Q, Wu DL, Ding H, Pong DB, Zhao TM: Genetic polymorphism
of RhD-negative associated haplotypes in the Chinese. J Hum Genet 2000;
45:224-227.
15. Wagner FF, Moulds JM, Tounkara A, Kouriba B, Flegel WA: RHD allele distri-
bution in Africans of Mali. Biomed Central Genet 2003; 4:14.
16. Okuda H, Kawano M, Iwamoto S, Tanaka M, Seno T, Okubo Y, Kajii E: The
97
D negativity in Chinese people
110094_Binnen  08-11-2005  09:15  Pagina 97
RHD gene is highly detectable in RhD-negative Japanese donors. J Clin
Invest 1997; 100:373-379.
17. Fukumori Y, Hori Y, Ohnoki S, Nagao N, Shibata H, Okuba Y, Yamaguchi H:
Further analysis of Del (D-elute) using polymerase chain reaction (PCR) with
RHD-gene specific primers. Transfus Med 1997; 7:227-231.
18. Singleton BK, Green CA, Kimura K, Minami A, Okubo Y, Daniels GL: Two new
RHD mutations associated with Del phenotype [Abstract]. Transfus Clin Biol
2001; 8:9s.
19. Lee YL, Chiou HL, Hu SN, Wang L: Analysis of RHD genes in Taiwanese RhD-
negative donors by the multiplex PCR method. J Clin Lab Anal 2003;
17:80-84.
20. Wagner FF, Frohmajer A, Flegel WA. RHD positive haplotypes in D negative
Europeans. Biomed Central Genet 2001; 2:10.
98
Chapter 4
110094_Binnen  08-11-2005  09:15  Pagina 98
99
110094_Binnen  08-11-2005  09:15  Pagina 99
100
110094_Binnen  08-11-2005  09:15  Pagina 100
Chapter 5
RHD(T201R, F223V) cluster analysis in five different ethnic
groups and serological characterization of a new Ethiopian
variant DARE, the DIII type 6 and the RHD(F223V)
Martine GHM Grootkerk-Tax, Joyce D van Wintershoven, Peter C Ligthart, Dick J van Rhenen, C Ellen
van der Schoot, Petra A Maaskant-van Wijk. RHD(T201R, F223V) cluster analysis in five different
ethnic groups and serological characterization of a new Ethiopian variant DARE, the DIII type 6 and
the RHD(F223V). Accepted for publication in Transfusion.
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Abstract
Background: The RHD phylogeny in humans shows 4 main clusters of which 3 are
predominantly observed in (African)Blacks. Each of the African clusters is characte-
rized by specific animo acid substitutions relative to the Eurasian RHD allele. RH
phylogeny defines the framework for identification of clinically relevant aberrant alle-
les. This study focuses on the weak D type 4 cluster (characterized by RHD(T201R,
F223V)(602C>G, 667T>G)) in five ethnic groups.
Study design and methods: 1702 samples were screened for the presence of
602C>G and 667T>G by PCR-SSP. 80 Samples were assigned to the weak D type
4 cluster and were molecularly characterized by PCR-SSP and RHD sequencing.
Antigens of aberrant alleles were characterized with monoclonal anti-D antibodies
according to the 37 epitope model when possible.
Results: Five new aberrant alleles DIII type 6, DIII type 7, DARE, RHD(T201R,
F223V)(without 819G>A) and RHD(F223V) were identified and DIII type 6, DARE
and RHD(F223V) were serologically characterized with monoclonal anti-D. Both the
DARE and RHD(F223V) showed epitope loss. We postulate  the 1136C>T nucleoti-
de substitution (characterisic for the DAU allele cluster) to be present on the
DVa(KOU) allele.
Conclusion: Identification of the new variant alleles refines the phylogeny of RHD
in humans. The proposed DVa(KOU) allele with 1136C>T (DVa(KOU)T379M) is pro-
bably caused by conversion of the DAU0 allele and the DVa(KOU) allele, forming a
phylogenetic link between the DV allele and the DAU cluster. By describing the
RHD(F223V)(667T>G) and RHD(T201R, F223V)(602C>G, 667T>G) alleles we give
formal proof for the origin of the non-Eurasian cluster.
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Introduction
The RhD blood group antigen is a highly immunogenic polypeptide present on the
Red Blood Cell (RBC) membrane in RhD-positive individuals. In transfusion medici-
ne, RhD incompatibility may cause hemolytic transfusion reactions and hemolytic
disease of the foetus and newborn (HDFN) and anti-Rh antibodies are often invol-
ved in autoimmune hemolytic anemia.The RhD protein is encoded by the RHD gene
(chromosome 1, p34.3-p36.1). RhD-negativity in Caucasians is mostly caused by a
deletion of the RHD gene.1 In blacks, RhD-negativity is frequently caused by RHD
and (C)cdes alleles (allele frequencies of 0.0714 and 0.036, respectively).2-4 Both
alleles carry RHD specific sequences and therefore hamper RHD genotyping stra-
tegies. Variant RhD-antigens encoded by aberrant RHD alleles, have been found
with high frequencies in blacks and, with much lower frequencies, in whites.5-7 These
aberrant RHD alleles are mainly caused by gene rearrangements and point mutati-
ons, often between RHD and the highly homologous RHCE gene. The Rh system
contains eight basic haplotypes which were formed by a series of duplication, muta-
tion and recombination events.8
The ancestral RH haplotype was formed by the cDe haplotype which is still frequent
in blacks.8 The most recently proposed phylogeny of RHD in humans, based on a
previously defined phylogeny,6 shows 4 main clusters, the DIVa, DAU and weak D
type 4 clusters are predominantly observed in (African)blacks and occur in the cDe
haplotype.9 The fourth cluster of Eurasian alleles is predominantly observed in the
CDe and cDE haplotypes. Each of the African clusters is characterized by a speci-
fic animo acid substitution relative to the Eurasian RHD allele. The amino acid
substitutions are T379M (1136C>T) in the DAU cluster, F223V (667T>G) in the
weak D type 4 cluster and D350H (1048G>C) in the DIVa cluster (including DIII
types 4 and 5 and (C)cdes). The alleles presented by the DIVa cluster share 3 amino
acid substitutions: L62F (186G>T), A137V (410C>T) and N152T (455A>C), that are
ancestral because they were also observed in chimpanzee RH.10 The weak D type
4 cluster is thought to have an ancestral allele characterized by RHD(F223V)
(667T>G), although the existence of this allele is only postulated and has never
been described. The weak D type 4 cluster encompasses RHD(T201R, F223V)
(602C>G, 667T>G), the weak D types 4.0, 4.1, 4.2.1 and 4.2.2, DAR, DOL and
RHD. Both weak D types 4.2.1 and 4.2.2 are functionally equal to DAR but differ
molecularly from DAR by 957G>A and 957G>A;744C>T respectively.11
This study’s focus is mainly on the RHD(T201R, F223V) (602C>G, 667T>G) cluster
in five different ethnic groups, which includes the whole of the weak D type 4 clus-
ter and, because of a recombination event between the weak D type 4.0 and DIII
type 4 alleles resulting in the DIII type 5 allele, part of the DIVa cluster. This focus
was chosen since these clusters encompass most RHD alleles encoding for partial
D antigens (which are clinically most relevant) and are most interesting regarding
phylogenetics due to the high percentage of polymorphism.
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The analysis of the alleles belonging to the DIVa cluster which are not included in
this study (Ccdes and DIVa alleles) is described by Tax et al.12 and the DAU allele
cluster has been intensively studied by Wagner et al.9 In the present study we give
the formal proof for the phylogenetic origin of the weak D type 4 cluster by demon-
strating the presence of the RHD(F223V) and RHD(T201R, F223V) alleles. The
phylogeny of RHD in humans was refined by describing the new RHD alleles DARE,
DIII type 6 and DIII type 7. The proteins expressed by the DARE, DIII type 6 and
RHD(F223V) alleles have been serologically characterized with monoclonal anti-D.
The proposed DVa(KOU)T379M allele may form a phylogenetic link between the
DVa(KOU) allele and the DAU allele cluster, allowing speculation on the possibility
of a DV allele cluster.
Materials and methods
Samples
Ethylenediaminetetraacetate-anticoagulated blood samples from blood bank donors
were obtained from five different ethnic groups by The South African Blood
Transfusion Service, Johannesburg (South African blacks and Asians), The
Ethiopian Red Cross Society Trandfusion Service, Addis Ababa (Ethiopian blacks),
The Red Cross Blood Bank Curacao, Willemstad (Curacao blacks) and The Sanquin
Blood Bank South West Region, Rotterdam (Caucasian whites). All methods descri-
bed in this study were performed at the Sanquin Blood Bank South West Region,
Rotterdam and Sanquin Research at CLB, Amsterdam.
Serology
Red blood cells (RBCs) were Rh phenotyped according to standard serological pro-
tocols with a monoclonal IgM antibody anti-D (GAMA401, RhD epitope 6/7), a
polyclonal IgG anti-D antibody and monoclonal IgM antibodies (from Gamma
Biologicals INC., Houston, TX, USA) recognizing C (MS24), c (MS33), E
(GAMA402) and e (MS16, MS21, MS63 (blend)). Extended serology was performed
with monoclonal anti-D reagents as provided by the third and fourth Workshop on
Monoclonal Antibodies Against Human Red Blood Cells and Related Antigens.13-14
Extended RhD serology to obtain the 37 epitope model was performed complying to
workshop protocols.15 Samples were tested by direct (IgM) and indirect (IgG) agglu-
tination using the antibodies listed in tabel 3.
Antibody identification of the RHD(F223V) (667T>G) sample was performed with
untreated cells by IAGT with PEG. The ether-eluate of patient cells was also inves-
tigated with untreated cells by IAGT with PEG.
104
Chapter 5
110094_Binnen  08-11-2005  09:15  Pagina 104
Genomic DNA analysis 
Genomic DNA was isolated from peripheral white blood cells by a salting-out
method according to standard protocol.16 PCR reactions were performed in a ther-
mal cycler (model 9700, Applied Biosystems, Nieuwerkerk aan de IJssel, The
Netherlands).
All DNA samples were screened for the presence of 602G in combination with 667G
in RHD with the RHD(201R/223V) Sequence Specific PCR (PCR-SSP) as descri-
bed before with primerset R581/R66717 (700 whites from The Netherlands, 310
blacks from South-Africa (part of the group of 326 blacks from South-Africa previou-
sly studied by Hemker et al),17 319 Asians from South-Africa, 197 blacks from
Curacao and 176 blacks from Ethiopia). 80 Samples carried an RHD-(T201R,
F223V) allele and were further analyzed.
They were screened for nt. 383A (RHD) combined with nt. 455C (RHCE) (hybrid
exon 3) by RHC/c/hex3 Multiplex (MPX) PCR  and for nt. 1048 C>G by intron4/exon7
MPX PCR as described before12 for the identification of DIII, DIV or (C)cdes (r’s) alle-
les.
The RHD MPX PCR was performed as described by Maaskant-van Wijk et al.18
Minor modification were the use of HPLC-purified primers and Amplitaq (Applied
Biosystems). With this MPX PCR, RHD exons 3, 4, 5, 6, 7 and 9 are amplified in one
reaction mixture.
The 1025T>C nucleotide change, specific for the DAR variant RHD allele was detec-
ted by PCR-SSP as previously described by Hemker et al. (primerset
R973/R1044).17
The RHD PCR-SSP was used for detection of nt. 654C and nt. 674T, characteris-
tic for the RHD- as described by Grootkerk-Tax et al.19
The 1136C>T nucleotide change (DAU0) was detected by PCR-SSP with primers
RHin7DF (ctggaggctctgagaggttgag) and 8D1136Tmm (GACCTGTCAGGAGACCA-
TACA).
RHD zygosity was determined by RQ-PCR as previously described by Grootkerk-
Tax et al.19
RH-specific amplification of exon 2 (DIII type 7 sample) was performed with primers
Rex2S (ctccccaccgagcag) and rex2A (ccaccatcccaatac).
RHD-specific sequencing
The RHD exons were sequenced according to our previously published protocol.20
Modifications to this protocol were the use of sequence primers RH-58in4F (ctcatc-
caaaacccctcgag) for exon 5, RH52in6R (gcccatcaggtcccagcg) for exon 6 and
RH-193in7F (cacaatcttggaatctccgtcg) for exon 8. Additionally, RHD exon 2 was
amplified with primers re12d and re23 and sequenced with primers re13 and
RH28in2R (tccattccctctatgaccca), RHD exon 10 was amplified with primers re91 and
rr41 and sequenced with primers re91 and rh7, the RHD promotor region was ampli-
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fied with primers rb13 and rb11d and sequenced with only one primer, re02.11 All
samples were sequenced on an automatic 377 DNA sequencer (Applied
Biosystems).
All previously known aberrant alleles were confirmed by single primer sequencing.
New alleles were identified by bi-directional sequencing.
RESULTS
1702 DNA samples derived from five different ethnic groups (Caucasian whites,
South-African blacks, South-African Asians, Ethiopian blacks and Curacao blacks)
were screened for the presence of nt. 602G in combination with nt. 667G in RHD
with the RHD(201R/223V) PCR-SSP. 80 Samples carried both nucleotide changes
on the same allele (i.e. 2 whites (2.5%), 57 South-African blacks (71%), 4 South-
African Asians (5%), 15 Ethiopian blacks (19%) and 2 Curacao blacks (2.5%)).
Wagner et al. postulated that in the weak D type 4 cluster at least two sub clusters
can be recognized by the presence of either nt. 819A or nt. 1025C.9 Therefore all 80
samples were tested for the presence of these mutations by RHD-specific sequen-
cing of exon 6 and the 1025T>C PCR-SSP, respectively (table 1). In addition, the
samples were analysed by RHC/c/hex3 MPX PCR for nt. 383A (RHD) combined
with nt. 455C (RHCE) in exon 3, a combination characteristic for the DIII category
(table 1). None of the 80 samples in the RHD(T201R, F223V) cluster carried a DIVa
allele since all samples were negative for the characteristic nt. 1048C by
intron4/exon7 MPX PCR analysis. All samples were screened for the presence of an
RHD by PCR-SSP. Results of the genotyping assays are shown in table 1. Based
on the reaction patterns, groups I to VII were defined.
Table 1. PCR-SSP analysis of nts 455 and 1025 and sequencing results of RHD
exon 6 (nt 819) of 80 samples carrying RHD(T201R, F223V) (602C>G, 667T>G)
Group (n) 455C 1025C 819A Phenotype (n)
I (1) pos pos NT CcDee(1)
II (23) pos - pos Table 2
III (21) pos - NT ccDee(16), CcDee(3), ccDEe(2)
IV (3) - pos - ccDee(3)
V (22) - pos NT ccDee(14), CcDee(4), ccDEe(4)
VI (9) - - pos ccDee(6), CcDee(2), CcDEe(1)
VII (1) - - - ccDee(1)
Analysis of RHD(T201R, F223V)-positive/nt. 455C-positive (groups I, II and
III)
To refine identification of the alleles belonging to the weak D type 4 cluster
(RHD(T201R, F223V)) all groups as defined in table 1 were further analyzed. RHD
specific sequencing analysis of exons 3, 4 and 5 of the group I sample (South-
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African black) showed 410C+T and 455A+C in exon 3, 602C>G in exon 4, 667T>G
and 744C>T in exon 5 and the DAR PCR-SSP indicated the presence of 1025C in
exon 7. Therefore this sample carries both a DAR17 allele and a DIII type 5 9 or 6
allele (see group II, subgroup B) (figure 1).
The sequencing results of group II are shown in table 2. Based on the sequencing
results this group was further subdevided in 9 subgroups, A to I.
The presence of 455C in group II could either be derived from a Ccdes allele or from
alleles belonging to the DIII category. The presence of a Ccdes allele could be exclu-
ded from subgroups A-E due to RHD-specific sequencing analysis of exons 5 and 6
which showed the presence of two exons.
The subgroup A sample (South-African black) carries an RHD and a DIII type 6
allele (see group II, subgroup B).
Subgroup B (2 South-African blacks and 2 South-African Asians) sequencing ana-
lysis showed 410C+T and 455A+C in exon 3, 602 C+G in exon 4, 667 G+T in exon
5 and 819 G+A in exon 8. All other RHD exons showed normal RHD sequences
(including exon 2). Standard RhD serology did not indicate weak RhD expression.
This group most likely carries a (normal) RHD allele and an allele very similar to the
alleles of the DIII category, without the 186T in exon 2. Therefore this allele is named
DIII type 6 allele.
Subgroup C (South-African blacks) carries most likely a DAU0 9 allele (1136C>T)
and a DIII type 5 or 6 allele. Based on the mutation pattern this sample could also
carry a weak D type 4.0 21 and a DIII type 411 allele. However, this is not likely due
to the 1136C>T nucleotide change characteristic for the DAU allel cluster, which has
not previously been identified outside this cluster.
The subgroup D sample (South-African black) carries a DIII type 5 or 6 allele com-
bined with a DAU3 (RHD 835G>A and 1136C>T)9 allele.
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Figure 1. Previously and newly identified aberrant RHD alleles
Depicted are RHD exons 2 to 7 of multiple RHD alleles found in the RHD(T201R, F223V) analysis.
Above the dotted line, schematic representation of previously identified alleles. 
Below the dotted line, schematic representation of all 5 new RHD alleles as identified in the present
study.
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In the subgroup E sample (South-African black) we identified the presence of a DIII
type 6 and a DVa (KOU)22 allele. In this sample we also found a 1136T by PCR-SSP.
This nucleotide change, characteristic for the DAU allele cluster and subsequently
not previously identified to exist outside this allele cluster, is most probably present
on an allele carrying the DVa (KOU) characteristic nucleotide changes (see also
group VI).
In the subgroup F sample (South-African black), a Weak D type 4.0 allele combined
with a Ccdes allele was identified.
Subgroup G (7 South-African blacks and 1 South-African Asian) showed the presen-
ce of DIII type 5 alleles either next to another DIII type 5 allele or next to an RHD
gene deletion.
DIII type 6 alleles were also identified in subgroup H (South-African blacks) next to
a Ccdes allele.
The subgroup I sample (South-African black) showed an almost identical sequence
analysis as subgroups G and H. However, we were unable to amplify RHD exon 2
in the subgroup I sample. Next to the use of RHD specific primers located in the sur-
rounding introns (as used for all samples) we also amplified exon 2 with consensus
primers (Rex2S and Rex2A). Because the subgroup I sample was RhC-negative we
were able to rule out the presence of RHD exon 2 (we only found  sequences spe-
cific for the c allele of RHCE). RHD zygosity analysis by RQ-PCR showed the
presence of only 1 RHD gene. This sample carries a new partly hybrid RHD allele
very similar to DIII type 5/6 alleles without RHD exon 2 and is named DIII type 7
(figure 1).
All samples of group III (20 South-African blacks and 1 Ethiopian black) showed all
RHD specific exons by RHD MPX PCR analysis and 455C in exon 3, 602G in exon
4 and 667G in exon 5 (amplification of all RHD exons by RHD MPX PCR in a sam-
ple with 602G in exon 4 and 667G in exon 5 indicates the presence of two RHD
alleles). If all nucleotide changes are present on the same allele, these samples
carry a DIIIa 23 or a DIII type 5 (or 6) allele next to a normal RHD or, if the nucleoti-
de changes are distributed over two alleles, a weak D type 4 and a DIII type 4 are
also possible. By genomic DNA analyses it is not possible to make a distinction
between these allele combinations.
Analysis of RHD(T201R, F223V)-positive, nt. 455C-negative (groups IV, V,
VI and VII)
All RHD specific exons and the RHD promotor region of the group IV samples (3
Ethiopian blacks) were sequencened revealing the nucleotide changes: 602C>G in
exon 4, 667T>G and 697G>C in exon 5 and 957G>A and 1025T>C in exon 7. These
samples seem to carry a weak D type 4.2/DAR allele with an additional nucleotide
change in exon 5 697G>C, leading to E233Q. Therefore, this newly identified allele
was named DARE (E for Ethiopian).
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All group V samples (14 South-African blacks, 7 Ethiopian blacks and 1 Curacao
black) were positive for the 1025T>C nucleotide change, indicating the presence of
an DAR allele. 15 Samples showed amplification of all RHD exons by RHD MPX
analyses, these samples carry a normal RHD next to the DAR allele.The 7 Ethiopian
samples were not sequenced for exon 5, therefore more DARE alleles (with RHD
alleles) might be present in this group. One sample (South-African black) lacked the
RHD exon 5 amplicon by RHD MPX analysis, RHD specific sequencing revealed
509C+T and 602G+C in exon 4 and 667T>G in exon 5, suggesting the presence of
both a DOL 24 and a DAR allele. Three samples of group V were also positive for nt.
654C and nt. 674T by RHD PCR-SSP analysis, suggesting the presence of both a
DAR and an RHD allele. Of three samples of which RHD exons 4 and 5 failed to
amplify by RHD MPX analysis, sequencing analysis of exons 4 and 5 showed the
presence of 602C>G and 667T>G respectively, Additional sequencing of RHD exon
7 of two samples showed 957G>A and 1025T>C. Therefore these samples carry a
weak D type 4.2/DAR allele only.
In group VI (4 Ethiopian blacks, 2 South-African blacks, 1 South-African Asian, 1
Curacao black and 1 Caucasian white), 7 samples showed amplification of all RHD
exons by RHD MPX analysis. Therefore, of these samples all RHD specific exons
and the RHD promotor region were sequencened revealing: 602C+G in exon 4,
667T+G in exon 5 and 819G+A in exon 6 in all samples and 48G>C in two samples,
indicating the presence of a weak D type 4.0 and RHD in 5 samples (2 Ethiopian
blacks, 1 South-African black, 1 Curacao black and 1 South-African Asian) and a
weak D type 4.1 and RHD in 2 samples (both Ethiopian blacks). Of one group VI
sample (Caucasian white) amplification of RHD exons 4 and 5 by RHD MPX analy-
sis failed. Sequencing of all RHD exons (including the promotor region) showed:
602C>G in exon 4, 667T>G in exon 5 and 819G>A in exon 6, characteristic for a
weak D type 4.0 allele. Of one group VI sample (South-African black) the amplifica-
tion of only RHD exon 5 failed by RHD MPX analysis. This sample was also
completely sequenced showing: 602G+C in exon 4, 667T>G and 697C+G in exon
5, 819G+A in exon 6 and 1136C+T in exon 8, indicating the presence of a weak D
type 4.0 and a DVa(KOU) allele. The 1136C>T nucleotide change, characteristic for
the DAU alleles and not previously identified to exist outside this allele cluster, is
most probably present on the allele that also shows DVa (KOU) characteristics (see
also group II, subgroup E).
The RHD MPX analysis of the group VII sample (Caucasian white) failed the ampli-
fication of exons 4 and 5. This sample was completely sequenced for RHD and
showed only the 602G>C in exon 4 and 667T>G in exon 5 nucleotide changes. This
sample represents the not previously identified RHD(T201R, F223V) allele (that is
without the 819G>A nucleotide substitution characteristic for weak D type 4).
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Serological characterisation of DIII type 6 and DIII type 7 antigenic proteins
The genomic organization of the sample identified in group IIA in which the DIII type
6 is present opposite to an RHD (ccDee) allowed us to determine the 37 epitope
pattern of the newly identified DIII type 6 (table 3). Like DIII type 4, only weak reac-
tions were seen and no epitope loss was indicated.
The DIII type 7 sample identified in group II, subgroup I showed a 2+ reaction
strength with monoclonal anti-D and a 1+ reaction strength with polyclonal anti-D in
standard serology. Unfortunately it was not possible to perform extended serology
on this sample.
Serological analysis of African DAR versus Ethiopian DARE antigenic pro-
teins
The 697G>C nucleotide change in RHD (leading to E233Q) has not previously been
described to be present in a DAR-like protein. Nt 697 is located on the fourth extra-
cellular loop of the RhD protein. All 3 Ethiopian DARE samples were serologically
analysed for their RhD epitope expression pattern accoding.
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Table 3. Monoclonal anti-D reaction patterns of an R1r and DAR control cell
and the newly identified RhD-variants DIII type 6, RHD(F223V)and DARE 
according to the 37 epitope model for RhD
Epitope MoAb R1r DIII type 6 RHD(F223V) DAR DAREI DAREII DAREIII
1.1 IV-1-82 3 nt 3 0 0 0 0
1.2 III-1-83 2-3 1 nt 0 1 0 0
1.3 IV-1-50 1-2 0.5 0 0 0 0 0
2.1 IV-1-23 3-4 4 2 1 1 0 0
IV-1-24 3 4 2 0 0 0 0
IV-1-34 3-4 3 2 1 1 0 0
III-1-51 3-4 3 nt 0 0 0 0
2.2 IV-1-60 3-4 3 3 0 0 0 0
IV-1-51 3-4 3 3 0 0 0 0
3.1 IV-1-33 3 3 3 1 1 0 0
IV-1-67 3-4 4 2 2 3 3 1
IV-1-72 2-4 3 2 1 1 0.5 0.5
IV-1-95 3-4 4 3 2 3 3 2
4.1 III-1-45 2-3 3 nt 0 2 1 1
5.1 IV-1-76 4 4 4 1 1 0 0
III-1-116 4 4 nt 1 0 0 0
5.2 IV-1-79 3-4 4 3 1 1 0 0
IV-1-25 2-4 3 3 1 2 0 0
5.3 IV-1-86 4 4 nt 1 0 0 0
5.4 IV-1-32 3-4 3 3 0 0 0 0
IV-1-44 2-3 3 nt 0 0 0 0
5.5 III-1-69 3-4 3 nt 0.5 0 0 0
6.1 IV-1-87 4 4 3 3 3 3 3
IV-1-98 4 4 4 2 2 2 1
III-1-35 4 4 nt 1 1 1 0
III-1-103 3 3 nt 3 2 2 0
6.2 IV-1-55 3 3 3 2 2 1 0
IV-1-48 3-4 4 3 2 3 2 1
IV-1-30 3-4 3 3 3 3 2 2
IV-1-144 3-4 4 3 0 0 0 0
6.3 IV-1-52 4 4 nt 1 1 0 0
IV-1-68 4 4 nt 2 3 0 0
6.4 IV-1-94 3 nt 3 nt nt nt nt
IV-1-62 3 nt 2 nt nt nt nt
IV-1-69 4 4 nt 1 1 0 0
IV-1-83 3-4 4 nt 1 0 0 0
IV-1-36 4 4 nt 1 0 0 0
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IV-1-43 4 3 nt 1 1 0 0
6.5 III-1-30 3 3 nt 2 3 2 2
III-1-84 3-4 3 nt 1 0 0 0
III-1-119 4 4 nt 2 3 2 2
IV-1-100 4 4 nt 3 2 0 0
6.6 IV-1-31 3 nt 2 nt nt nt nt
IV-1-40 4 nt 4 nt nt nt nt
IV-1-37 4 4 4 1 0.5 1 0
IV-1-85 2-4 3 3 0 0 0 0
IV-1-77 4 4 3 0 1 0 0
6.7 IV-1-74 3-4 nt 3 1 1 0 0
IV-1-75 3-4 nt 3 1 1 0 0
6.8 IV-1-53 3 3 3 0 0 0 0
IV-1-49 3-4 4 2 0.5 0 0 0
8.1 IV-1-22 2-3 1 1 0 0 0 0
III-1-74 4 3 nt 3 3 0 0
III-1-78 4 nt 4 0 nt nt nt
IV-1-145 2 nt 0 nt nt nt nt
8.2 IV-1-39 4 4 nt 0 0 0 0
9.1 IV-1-88 3 3 nt 2 3 3 3
IV-1-47 2-4 3 2 0.5 1 1 0.5
IV-1-38 4 4 4 0 0 0 0
10.1 III-1-57 1 0 nt 0 0 0 0
12.1 III-1-38 2-4 4 nt 0 0 0 0
13.1 IV-1-21 3 3 nt 1 1 0 0
IV-1-80 3 3 3 2 1 0 0
14.1 IV-1-63 4 nt 4 nt nt nt nt
15.1 III-1-72 3 3 nt 1 2 2 1
III-1-53 3-4 3 nt 0 0 1 0
III-1-55 3-4 3 nt 1 1 2 1
III-1-76 3-4 3 nt 3 3 3 3
16.1 IV-1-99 4 4 3 3 2 1 1
III-1-117 3-4 3 nt 3 3 3 2
The scoring system is based on 0 (negative), 0,5 (weak) to 4 (strong positive) scale.
to the 37 epitope model and compared with a DAR expression pattern (table 3). The
serological analysis shows a difference in epitope expression between the DAR and
the DARE I reaction pattern on epitope 5.1 (MoAb III-1-116), 5.3 (MoAb IV-1-86), 5.5
(MoAb III-1-69), 6.4 (MoAbs IV-1-83 and IV-1-36), 6.5 (MoAb III-1-84) and 6.8
(MoAb IV-1-49) (table 3). In all cases the DAR sample shows a reaction strength of
1 (maximal) and the DARE samples show no reaction. Interestingly, the DARE sam-
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ples gained epitope 4.1 (MoAb III-I-45) as compared with the DAR reaction pattern.
The differences between the DARE I on one side and DARE II and III on the other
side (table 3) are most probably due to a weaker expression of the RhD antigen of
the DARE II and III samples which was also observed by standard serology.
Serological and RHD sequencing analysis of RHD(F223V)
A blood sample of an apparently RhD-positive patient (Rh phenotype CcDee) of
Indian descent was referred to Sanquin Diagnostics (Amsterdam) because of an allo
anti-D formation following an RhD-positive transfusion. In the patient’s serum, the
anti-D was confirmed besides the presence of other antibodies. No antibodies were
detectable in the patient’s eluate. To exclude the possibility of an auto anti-D, the
patient’s plasma and cells were incubated for 1h. at 370C and a new eluate was pre-
pared. In this eluate no anti-D was detectable by PEG-IAT or direct agglutination with
papain treated cells. Sequencing analysis of all RHD exons including the RHD pro-
motor region showed only a 667T>G nucleotide change, leading to F223V. Amino
acid 223 is located at the end of the seventh transmembrane domain (towards the
fourth exofacial loop) of the RhD protein. Extensive serology was performed accor-
ding to the 37 epitope RhD model of which the results are shown in table 3. The
RHD(F223V) sample showed loss of RhD epitopes 1.3 and 8.1 (with MoAb IV-1-
145) as compared with a R1r control sample. Unfortunately, the alloanti-D of the
patient was too weak to prove the epitope loss on RBCs carrying the 667T>G nucle-
otide change.
Discussion
The present study describes the analysis of the RHD(T201R, F223V) or weak D
type 4 allele cluster.9 As expected we found all aberrant alleles (except the
RHD(T201R, F223V) allele and a weak D type 4.0 allele) in non-Caucasian indivi-
duals and in association with the ancestral cDe haplotype. Surprisingly, the
RHD(T201R, F223V) allele was identified in a Caucasian white individual and in a
cDe haplotype. However, the familial ethnic background of this individual is
unknown. The RHD(F223V) allele was identified in a individual from India in most
probably a CDe haplotype. The familial ethnic background of this individual is also
unknown. The RHD(F223V) allele was the unidentified allele on which the non-eura-
sian phylogeny is based.6, 9 By the identification of this allele we now give the formal
proof for the line of evolution of the non-eurasian abberant RHD alleles (figure 2).
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Figure 2. Refined phylogeny of RHD in humans
The extended phylogeny of RHD in humans is described by Wagner et al.9 This figure shows the
DIVa, weak D type 4 and DAU clusters only. The DIVa cluster now includes the DIII type 6 and 7 alle-
les. The weak D type 4 cluster now includes the DARE allele. The DVa(KOU)T379M allele is now
depicted as the phylogenetic link between the DVa(KOU) allele and the DAU allele cluster.
Within the non-eurasian allele cluster we identified 3 new RHD alleles (figure 2). The
DIII type 6 allele carries the DIII type 5 characteristics 410C>T and 455C>A in exon
3, 602C>G in exon 4, 667T>G in exon 5 and 819G>A in exon 6 but lacks the
186G>T nucleotide change in exon 2 (figure 1). The DIII type 6 allele has an estima-
ted allele frequency of 0,031 in South-African blacks and 0,003 in South-African
Asians (assuming an equal distribution of types 5 and 6 in the undetermined sam-
ples) and was not found in the other populations. Extended serology of the newly
identified DIII type 6 showed many weaker reactions with the MoAbs as compared
to the control sample but no evidence of epitope loss (table 3), as expected from the
results of the previously identified DIII type 4 allele.23
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The DIII type 7 allele is also very similar to the DIII type 5 allele. The only differen-
ce is that the DIII type 7 allele as found in this study has no RHD specific sequences
in exon 2 and no RHD exon 2 could be amplified with intron primers specific for RHD
and the C allele of RHCE (figure 1). The DIII type 7 allele was only found once in a
South-African black population of 310 donors.The absence of RHD exon 2 suggests
the presence of RHCE exon 2 since this allele is most likely the result of a gene con-
version in cis during hairpin formation. The exon conversion has slightly affected the
standard RhD serology (a 2+ reaction strength with monoclonal anti-D and a 1+
reaction strength with polyclonal anti-D). The whole of loop 2 of the RhD expression
model as proposed by Avent et al. consists of exon 2.25 However, the sequences of
RHD and the C allele of RHCE are identical in this exon. Loop 2 is proposed to play
a role in the expression of epitope 8. DIIIb also lacks RHD exon 2 and lacks expres-
sion of the G antigen. Unfortunately it was not possible to perform extended serology
of the DIII type 7.
In the black Ethiopian population we identified a new variant RHD allele, very simi-
lar to the DAR allele with the additional 697G>C nucleotide change, leading to
E233Q on the fourth extracellular loop of the RhD protein (figure 1). The DARE alle-
le has an estimated frequency of at least 0,0085 in Ethiopian blacks. The serological
analysis shows a difference in epitope expression between the DAR and all three
DARE reaction patterns on epitope 5.1 (MoAb III-1-116), 5.3 (MoAb IV-1-86), 5.5
(MoAb III-1-69), 6.4 (MoAbs IV-1-83 and IV-1-36), 6.5 (MoAb III-1-84) and 6.8
(MoAb IV-1-49) (table 3). These observations are in concordance with the model
proposing six different RhD epitope clusters.25 This model predicts that the expres-
sion of epitopes 5 and 6/7 is dependent on a combination of loops 3 and 4 which
may explain why only 2 of 8 epitope 5 monoclonals and 4 of 32 epitope 6 monoclon-
als show a complete loss of reactivity. However, the DAR control sample showed a
maximal reaction strength of 1+ on these epitopes. Interestingly, the DARE samples
seem to have gained the expression of epitope 4.1 (MoAb III-1-45) as compared to
DAR.
The DAR allele was identified in blacks from South-Africa, Ethiopia and Curacao with
estimated allele frequencies of 0,024, 0,020 and 0,0025 respectively.The weak D type
4.0 alleles were found in blacks from South-Africa (estimated allele frequency 0,005)
and Ethiopia (estimated allele frequency 0,006) and the Asian population from South-
Africa (estimated allele frequency 0,0016). Weak D type 4.1 was only seen in
Ethiopians (estimated allele frequency 0,006). Compared to the previously published
weak D type 4 allele frequency in whites (0,001) we can conclude that the weak D type
4 allele is more frequent in black populations. The higher frequency of weak D type 4
in black populations was expected since the highly related DAR allele is also found in
black populations. Surprisingly, the weak D type 4 allele has been found in white popu-
lations whereas the DAR allele has not been identified in white populations.
The primordial DAU type, DAU0 is characterized by 1136C>T nucleotide change.
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Based on this primordial DAU type, the DAU alleles 0 to 4 form a separate allele
cluster. All enumerated DAU alleles occurred in a cDe haplotype and were predomi-
nantly found in Africans.9 In this study, the 1136C>T change was found in two
samples, one carried a DIII type 6 and a DVa(KOU) allele (group IIE) and one car-
ried a weak D type 4.0 and a DVa(KOU) allele (group VI). Since both samples show
an allele carrying the DVa(KOU) characteristics, we postulate that the 1136C>T
nucleotide change is present on the DVa(KOU) allele and is dubbed
DVa(KOU)T379M because this allele shows more molecular similarity to the
DVa(KOU) allele than the DAU0 allele. Both samples were drawn from phenotypic
ccDee (genomic ccDDee), South-African black donors. The DVa(KOU)T379M allele
probably represents a conversion between the DAU0 and DVa(KOU) allele, which
would create a phylogenetic link between the proposed fifth allele cluster of DV alle-
les and the DAU allele cluster (figure 3). The DV cluster is characterized by the
DVa-associated SM allele or RHD233E>Q.
Figure 3. Proposed fifth allele cluster of DV alleles
This figure shows the extended phylogeny of RHD in humans concerning the DV alleles. The DV allele
cluster is characterized by RHD(233E>Q) (nt 697G>C), relative to the eurasian RHD allele and shows
interaction with both the weak D type 4 cluster (by means of the RHD(F223V)allele) and the DAU clus-
ter (by means of the DAU0 allele).
118
Chapter 5
RHD(T201R;F223V)
RHD(223V)
DAU0
DVa(KOU)T379M
DVa(KOU)
DVa(HUS)
DV type VII
Dva-like YH/TT
Dva(TO)
Dva-associated SM
RHD (in cDe)
W
eakD type 4 cluster
DV cluster
186T>G
;410T>C;455C>A
602C>G
667T>G
1136C>T
800A>T
733G>C;787G>A
712G>A
697G>C
DAU cluster
110094_Binnen  08-11-2005  09:15  Pagina 118
Knowledge about the phylogeny of RHD in humans enables the prediction of poten-
tial clinically important RhD variants in any population. It may be postulated that
interactions (e.g. by gene conversions) between the defined clusters will eventually
change this classification into one (non-eurasian) cluster. New aberrant RHD alleles
are identified, refining our understanding of the phylogeny of RHD in humans.
After the reviewing process of the present manuscript a manuscript was published
by Chen and Flegel in which the presence of the 1136C>T nucleotide change in a
DVa(KOU) characteristic allele was also demonstrated (Q. Chen and W.A. Flegel.
Random survey for RHD alleles among D+ European persons. Transfusion
2005;45:1183-1191). Chen and Flegel however dubbed this allele DAU5 and assig-
ned this allele to the DAU cluster whereas in the present manuscript this allele is
dubbed DVa(KOU)T379M and is assigned to the proposed DV cluster.
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Chapter 6
Fragmented cell-free fetal DNA in the maternal circulation may
hamper prenatal genotyping strategies; evaluation of a prenatal
RHD genotyping strategy on cell-free plasma DNA
Martine GHM Grootkerk-Tax, Aicha Ait Soussan, Masja de Haas, Petra A Maaskant-van Wijk, C Ellen
van der Schoot. Fragmented cell-free fetal DNA in the maternal circulation may hamper prenatal
genotyping strategies; evaluation of a prenatal RHD genotyping strategy on cell-free plasma DNA.
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Abstract
Background: The discovery of cell-free fetal DNA in maternal plasma led to the
development of assays to predict the fetal D-status using  RHD-specific sequences.
Few assays are designed in such a way that the fetus can be typed in RHD (pre-
sent in the majority of D-negative African blacks) mothers, and that RHD fetuses
are correctly typed. Due to the limited knowledge about the mechanism responsible
for the presence of fetal DNA in maternal plasma, precautions in developing prena-
tal genotyping strategies have to be made.
Study design and methods: Real-time PCR (RQ-PCR) assays were developed for
prenatal diagnostic use with cell-free plasma DNA. An RQ-PCR assay on RHD
exon-5 (amplicon 361 bp), negative on RHD was developed with gDNA and eva-
luated with cell-free plasma DNA. Furthermore, a previously published RHD exon-5
RQ-PCR was duplexed with an in-house developed RHD exon-7 RQ-PCR and eva-
luated with cell-free plasma DNA samples from pregnant D-negative RHD-positive
women.
Results: The in-house, with gDNA developed RHD exon-5 assay showed on cell-
free plasma DNA samples from D-negative women pregnant with a D-positive fetus,
too low amplification levels, resulting in high Ct values and false negative results.
Apparently, due to fragmentation of cell-free plasma DNA, too few RHDexon-5 stret-
ches of sufficient length (>360 bp) are present. The RHD exon-5 and -7 RQ-PCR
duplex was evaluated with RHD-positive cell-free plasma DNA samples and show-
ed complete specificity and maximal sensitivity.
Conclusion: Assays designed for prenatal genotyping should be developed and
evaluated on cell-free plasma DNA. Prenatal RHD-genotyping is accurate with the
RHD exon-5 and -7 duplex strategy.
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Introduction
Once a clinically relevant antibody with the potential to cause hemolytic disease of
the fetus and/or newborn (HDFN) is found in the plasma of pregnant women (such
as anti-D) it becomes important to determine the phenotype of the fetus, especially
when laboratory parameters such as the antibody titer or tests on the biological acti-
vity are indicative of significant fetal hemolysis. The elucidation of the molecular
basis of various blood group systems has allowed the development of genotyping
methods, mostly by PCR, for fetal blood group phenotype prediction. Molecular
assays can be performed on fetal DNA obtained by invasive means, such as amni-
ocentesis or chorionic villus sampling. These procedures however are associated
with a pregnancy loss rate of about 0.3%.1 The procedures themselves may in fact
further sensitize the mother against fetal red cell antigens.2 More recently, it has
become clear that invasive sampling can be avoided by the use of fetal cells or cell-
free fetal DNA present in the maternal circulation, leading to a virtually risk-free
means of prenatal blood group testing in women negative for the target antigen.3,4
Fetal DNA can already be detected at the 5th week of gestation.4 The fetal DNA con-
centration increases with gestational age with a sharp increase during the last 8
weeks of pregnancy.4 On average, 25 fetal genome equivalents/ml maternal plasma
can be detected in the first trimester, increasing to 100 genome equivalents in the
third trimester.5 Furthermore, because of the rapid clearing of DNA, fetal DNA is not
detectable in plasma of women outside pregnancy.6,7,8 Because of the high number
of maternal DNA copies compared to the low number of fetal DNA copies (fetal DNA
makes up an average of 3,4% and 6,2% of total DNA in maternal circulation in early
and late gestation, respectively),4 a genotyping strategy using fetal cell-free plasma
DNA should be more specific (amplification of the desired DNA sequence only) and
sensitive (able to detect a very low DNA copy number) than a strategy developed for
use on gDNA.
The fetal D-status can be predicted by RHD genotyping on cell-free fetal DNA obtai-
ned from maternal plasma.9,10,11 To accurately predict the fetal D-status it is
important to distinguish functional RHD from non-functional RHD sequences. A
deletion of the RHD gene is the most common form of D-negativity in Caucasian
populations. However, the majority of D-negative black persons carry either an
RHD (allele frequency 0.0714)12 or an (C)cdes allele (allele frequency 0.036).13,14
In both alleles, RHD-specific sequences are present but due to the presence of a
translation termination codon (RHD) or the substitution of RHD-specific coding
sequences by RHCE-specific coding sequences ((C)cdes), no detectable D epitopes
are present on the RBC surface. Finning et al. developed a fetal RHD genotyping
strategy that detects only RHD (and not RHD or (C)cdes) using fetal DNA in mater-
nal plasma.15 With this strategy, RHD exon 4, 5 or 6 is amplified in Real-Time and
compared with the control amplicon of RHD exon 10. When either an RHD or an
(C)cdes allele is present, exon 4, 5 or 6 will not be amplified whereas exon 10 will
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be amplified.
In this paper, we demonstrate the importance of specificity and sensitivity for geno-
typing strategies using fetal cell-free plasma DNA and we describe the evaluation of
a duplex combination of an in-house developed assay with a previously published
method15 on (the clinically relevant) RHD-positive cell-free plasma DNA samples.
Material and methods
Control samples
Red blood cells (RBCs) were Rh phenotyped according to standard serological pro-
tocols with a monoclonal IgM antibody anti-D (GAMA401, RhD epitope 6/7), a
polyclonal IgG anti-D antibody and monoclonal IgM antibodies (from Gamma
Biologicals INC., Houston, TX, USA) recognizing C (MS24), c (MS33), E
(GAMA402) and e (MS16, MS21, MS63 (blend)).
Donor blood samples were obtained with informed consent, according to the rules
of Sanquin. Genomic DNA was isolated from EDTA-anticoagulated blood samples
from black blood bank donors from Curacao (RHD controls) and from Caucasian
blood bank donors from The Netherlands according to a standard protocol.16
Maternal and fetal blood samples 
EDTA-anticoagulated blood samples of D-negative pregnant women (around 28-30
weeks of gestation) were sent to Sanquin Diagnostics for routine D antibody scree-
ning. D blood group typing was performed either on a WADIANA system (Diamed,
Cressier sur Morat, Switzerland) or Autovue system (Ortho Clinical Diagnostics,
Tilburg, The Netherlands), using the appropriate manufacturer’s card systems. The
D status of the fetuses were confirmed by standard serology protocols.
All blood samples were centrifuged 1200 g for 10 minutes. The plasma was centri-
fuged again at 2400 g for 20 min, and the supernatant was collected in fresh tubes
and stored at -20°C until it was used for DNA isolation. 200 ul of buffy coat was
removed and DNA was isolated using MagNA Pure LC (Roche Biochemicals, Basel,
Switerland) with the MagNA Pure LC DNA Isolation Kit 1 according to the “DNA I
Blood_Cells Fast” protocol (Roche Biochemicals). DNA was eluted in 100 µl H2O.
Fetal cell-free DNA extraction from maternal plasma.
Fetal cell-free DNA was extracted  from 1 ml maternal plasma using the MagNA
Pure LC (Roche Biochemicals) with the “Total Nucleic Acid Large Volume” reagent
set (Roche Biochemicals) according to manufacturer’s instructions. For a control on
the fetal DNA-isolation, in each run a plasma pool of D-negative women, pregnant
of a D-positive fetus was included. The isolated DNA was eluted in 55ul. Within 8 hrs
after isolation the DNA was automatically dispersed into a 96 wells plate by the
MagNA Pure LC for real-time quantitative (RQ)-PCR analysis. Samples 5539797
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and 5539929 were obtained from a large cohort of D-negative pregnant women tes-
ted for the presence of fetal RHD sequences, and were initially recognized because
of the extremely high amount of RHD exon-7 sequences.
PCR assays
The RHD status of the control samples and samples 5539797 and 5539929 was
determined by serology and by RHD multiplex (MPX) PCR analysis as described
before.17
The presence of an RHD was confirmed by PCR-SSP with forward primer RexWs,
specific on nt 654C (RHD) and reverse primer Rex5Was, specific on nt 674T
(RHD) and an internal control on the ß-actin gene as previously published.18
RQ-PCR assays
All primers used are listed in table 1. Oligonucleotides were purchased from
Invitrogen (Carlsbad, CA) and fluorescent probes were purchased from Applied
Biosystems (Nieuwerkerk a/d IJssel, The Netherlands). All RQ-PCRs were develo-
ped based on the Taqman technology by using a 7000 Sequence detector (Applied
Biosystems).
Table 1. Name, type (primer or probe), nucleotide sequence, location and 
specificity of all oligonucleotides used in this study.
Name/type Sequence Location Specificity
Rex5Ws/primer CGCCCTCTTCTTGTGGATC exon 5 RHD
Rex5Was/primer TGGACTTCTCAGCAGAGCAA exon5 RHD
FDTin4-A/primer gtgtctgaagcccttccatc intron 4 RH 
RDTex5-Aprimer gagttgaaacttggcctgaac exon5 RHD+RHCE
RHDin4/VIC labelled probe agcacttcacagagcag intron 4 RHD/ RHD
EX5F/primer CGCCCTCTTCTTGTGGATG exon 5 RHD/RHCE
EX5R/primer GAACACGGCATTCTTCCTTTC exon 5 RHD/ RHD
EX5P/VIC labelled probe TCTGGCCAAGTTTCAACTCTGCTCGCT exon 5 RHD
940S/primer GGGTGTTGTAACCGAGTGCTG exon 7 RHD
1064R/primer CCGGCTCCGACGGTATC exon 7 RHD
968/FAM labelled probe cccacagctccatcatgggctacaa exon 7 RHD
All primers have been previously published, see Materials and Methods section for the appropriate
references. 
For the RQ-PCR on RHD exon 5-361 bp the consensus forward primer (FDTin4-A)
is located in intron 4 before the 650 bp insertion present in RHCE. The reverse pri-
mer (RDTex5-A) is specific on nt 654 G (negative on RHD due to nt 654 G>C in
RHD) and therefore only hybridizes with RHD and RHCE specific DNA. With these
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primers, only RHD will be amplified since the RHCE product is too large to be ampli-
fied (RHD product is 361 bp whereas the RHCE product would be 1011 bp). The
FAM fluorescent labeled probe (RHDin4) is located in intron 4, covering the junction
point of the RHCE 650 bp insertion and will therefore only hybridize with RHD spe-
cific DNA. Variable concentrations of DNA were analyzed in a mixture of 25 ul of
Universal Mastermix (Applied Biosystems), 300nM of each primer and 100nM
probe. PCR was started with 2 minutes at 500C and 10 minutes at 950C followed by
50 cycles of denaturation for 15 seconds at 950C, primer annealing 1 minute at 580C
and primer extension 1 minute at 720C. All samples were tested in triplicate.To deve-
lop the assay, samples from donors with the following phenotypes were used: R1R1
(n=2), R2R2 (n=1), R1r (n=2) and rr (n=2); all Caucasian, and 4 rr samples positive
for the RHD (all blacks from Curacao) by PCR-SSP.
The RHD exon-5 RQ PCR from Finning et al. is also based on detection of RHD and
not RHD exon 5 but is generating an 82-bp product (primers EX5F and EX5R and
a VIC-labeled, probe EX5P).15 EX5F amplifies RHD and RHCE but not RHD, EX5R
amplifies RHD and RHD but not RHCE (the PCR amplicon is RHD) and EX5P
hybridizes with RHD only. This PCR was combined with a previously developed RQ-
PCR for RHD exon-7 (primers 940S and 1064R and a FAM-labeled probe 968
(generating a 122 bp product),9 into an RHD exon-5 and -7 duplex PCR. If cell-free
plasma DNA was analysed the RHD exon-5 and -7 duplex PCR was used, but if
genomic DNA was tested the assays were not combined. For both assays the reac-
tion mixtures contained 25 ul Universal Mastermix, 300nM of each primer and
100nM probe. PCR was started with 2 minutes at 500C and 10 minutes at 950C fol-
lowed by 50 cycles of denaturation for 15 seconds at 950C and primer annealing and
elongation for 1 minute at 600C. All RQ-PCR data were compared to an RHD homo-
zygous standard.18
Results
RHD exon 5-361 bp RQ-PCR
The RHD exon 5-361 bp RQ-PCR was developed using genomic DNA (gDNA) with
known Rh phenotypes and RHD genotypes as described in the Materials and
Methods section. gDNA of an RHD gene positive sample and heterozygous RHD
gene positive sample were tested both in concentrations ranging from 0 to 10000
pg. The RQ-PCR was completely specific as no signal of the RHD sample was
detected. Furthermore, the RQ-PCR was sensitive enough to detect gDNA derived
from one heterozygous RHD-positive cell (median Ct value of 39.43). Serial diluti-
ons of the RHD heterozygous sample in a constant concentration of 1000 pg of
RHD gene positive gDNA or in H2O demonstrated identical results.
The sensitivity and specificity for fetal DNA of the RHD exon 5-361 bp RQ-PCR was
tested with 45 plasma samples from D-negative pregnant women. These samples
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were also tested with the RQ-PCR on RHD exon 7, that has previously been shown
to have maximal sensitivity for detection of fetal RHD sequences.6 In 26 of the 45
cases the RHD exon-7 RQ-PCR showed Ct values in the expected range for the pre-
sence of fetal RHD (all triplicates positive, all samples Ct values between 33 and 37,
figure 1A). The D-positivity of these 26 fetuses was confimed by cord blood serolo-
gy. The remaining samples were all RHD-negative (data not shown). The RHD exon
5-361 bp RQ-PCR however, showed a much lower sensitivity (Ct values of 40 and
higher), and was negative in 11 of the 26 exon 7 positive plasma samples (figure
1B). Although the RHD exon 5-361 bp RQ-PCR showed to be a specific and sensi-
tive assay when used on gDNA, this assay, when performed on cell-free fetal DNA
derived from maternal plasma, it is not applicable because of a far too low sensitivi-
ty.
RHD genotyping by RQ-PCR on RHD exon-5 and -7 in duplex on cell-free
fetal DNA derived from maternal plasma.
The RQ-PCR on RHD exon 5, as developed by Finning et al.15 was tested with cell-
free fetal DNA derived from maternal plasma. A total cell-free plasma DNA (isolated
from a heterozygous D-positive donor) input of 100 pg generates Ct values between
33 and 36 for all triplicates and 10 pg cell-free plasma DNA input generates a Ct
value of about 36 in one of the triplicates. The specificity of the assay was tested on
gDNA of an RHD sample in serial dilutions ranging from 0 to 100 ng and showed
no amplification of the RHD DNA. The RQ-PCR on RHD exon-5 and the RQ-PCR
on RHD exon-7 assays were duplexed by using a different fluorochrome label for
each probe (a VIC labeled exon-5 probe and a FAM labeled exon-7 probe) and sub-
sequently tested on cell-free fetal DNA from maternal plasma. RQ-PCR results of 55
duplexed cell-free plasma DNA samples are shown in figure 1C (RHD exon-7) and
figure 1D (RHD exon-5). In 35 of the 55 cases both RHD exon-7 and RHD exon-5
specific products were amplified, indicating D-positivity. Of the remaining 20 sam-
ples, neither RHD exon-5 nor RHD exon-7 amplicons were obtained, indicating
D-negativity. The median Ct values of the RHD exon-7 RQ-PCR performed as sin-
gle assay (median Ct 36.4) and in duplex with RHD exon-5 (median Ct 36.0) show
that both approaches are (equally) sensitive.
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Figure 1 A to D. RQ-PCRs on RHD exon-7 (A) and RHD exon 5-361 bp (B) and RQ-PCR duplex on
RHD exon-5 (D) and-7 (C) on cell-free fetal DNA derived from maternal plasma
The horizontal lines depict the median Ct value of each RQ-PCR assay.
Figures 1A and 1B show the Ct values from fetal cell-free plasma DNA of 26 (RHD exon-7) or 11 (RHD
exon-5) D-positive fetusses of 45 D-negative pregnant women, tested in triplicate. Figure 1A shows
the Ct values from RQ-PCR on RHD exon-7, performed on the same samples as used for 1B. Figure
1B clearly shows the low sensitivity by high Ct values obtained with the RQ-PCR on RHD exon 5-361
bp.
Figures 1C and 1D show the Ct values of RHD exon-5 (D) and-7 (C) tested in duplex from fetal cell-
free plasma DNA of 35 D-positive fetusses of 55 D-negative pregnant women, tested in triplicate.
Figure 1C shows the Ct values obtained with the RHD exon -7 when performed in duplex with RHD
exon-5. Figure 1D shows that the Ct values of the RQ-PCR on RHD exon-5 (as developed by Finning
et al.)15 are within a reliable area and is much more sensitive than 1B.
The diagnostic value of the RHD exon-5 and -7 duplex genotyping method was eva-
luated with two special samples. Sample no. 5539797 represents a D-negative
RHD-positive pregnant woman, carrying a D-negative fetus. Sample no. 5539929
represents a D-negative RHD-positive pregnant woman carrying a D-positive fetus.
Both samples were subjected to the RQ-PCR duplex on RHD exon-5 and -7. Of both
maternal samples, gDNA was isolated from WBCs and subjected to the RQ-PCR on
RHD exon 5-361 bp, the RQ-PCR on RHD exon-7 and the RHD Multiplex (MPX)
PCR. In this PCR assay, exons 3, 4, 5, 6, 7 and 9 are amplified with RHD specific pri-
mers in one reaction mixture. In case of an RHD, RHD exon 5 will not be amplified
by the RHD MPX PCR. The amplification plots of samples 5539797 and 5539929 by
RQ-PCR duplex on RHD exon-5 and -7 are shown in figures 2 and 3, respectively.
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Fig. 2. RQ-PCR MPX on RHD exon-5 and -7 amplification plot of sample no. 5539797
The amplification plot shows the real time amplification of RHD exon-7 (Ct values of 28.33, 28.36 and
28.36, threshold set at 0.10), the exon-5 fluorescent signal does not cross the threshold (Ct values of
50).
Figure 3. RQ-PCR MPX on RHD exon-5 and -7 amplification plot of sample no. 5539929
The amplification plot shows the real time amplification of RHD exon-7 (Ct values of 24.45, 24.75 and
24.74, threshold set at 0.10) and RHD exon-5 (Ct values of 36.44, 37.41 and 36.89, threshold set at
0.03).
The amplification plot of sample 5539797 shows amplification of RHD exon 7 and
not of RHD exon 5, indicating the presence of an RHD. Furthermore, the low Ct
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value (28.35, corresponding with about 54ng DNA/ml plasma) of the exon 7 RQ-
PCR suggests that maternal DNA is amplified, hence, the D-negative mother is
carrying an RHD. Indeed, the maternal origin of the RHD is confirmed by analy-
sis of maternal leukocyte-derived gDNA, again showing negativity of the RQ-PCR
on RHD exon 5-361 bp assay (Ct value of 50) and positivity of the RQ-PCR on RHD
exon-7 assay (Ct value of 23.71). The RHD MPX PCR, amplifying exons 3, 4, 5, 6,
7 and 9, shows only the absence of the RHD exon 5 amplicon, which is also indica-
tive for the presence of an RHD. The cord blood serology was indeed D-negative.
The amplification plot of sample 5539929 shows early amplification of RHD exon-7
(Ct 24.64 corresponding with about 570ng DNA/ml) and late amplifcation of RHD
exon-5 (Ct 36.91). These results point to the presence of a maternal RHD gene
(RHD exon-5 negative and exon-7 positive) and an RHD-positive fetus (RHD exon-
5 and -7 positive). Again, the maternal origin of the RHD was shown upon analysis
of maternal gDNA with the RHD exon 5 and 7 RQ PCRs and the RHD MPX PCR.
After delivery, cord blood serology showed that the fetus was indeed D-positive.
The results indicate that the RHD exon-5 and-7 duplex can be used for fetal RHD
typing in the presence of a maternal RHD gene on fetal cell-free DNA derived from
maternal plasma in a diagnostic setting.
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Discussion
Despite the rapid introduction of diagnostic assays that use fetal DNA isolated from
maternal plasma in clinical settings, the molecular characteristics of cell-free plas-
ma DNA in pregnant women are not completely known. In the present study we
found that a newly developed RQ-PCR on RHD exon 5, generating a 361 bp pro-
duct, showed high specificity and sensitivity on genomic DNA, but not on cell-free
fetal DNA isolated from maternal plasma (figure 1). The same cell-free plasma DNA
samples showed normal Ct values in the RQ-PCR on RHD exon 7. Recently, Chan
et al. analyzed plasma DNA samples from 21 pregnant women, who were carrying
male fetuses, for the size distribution of DNA fragments encoding the SRY gene.19
They reported that the median relative concentration of the SRY gene determined
with primers producing amplicons longer than 313 bps was <1%. They also suggest
that most of the circulating DNA molecules are in the range of 145-201 bp. Several
studies have demonstrated a correlation between plasma DNA concentrations and
apoptosis of tumor cells in cancer patients,20,21 and several studies have also shown
that the lengths of plasma DNA molecules in cancer patients are very short and are
in multiples of nucleosomal DNA.20,22 Whether the DNA fragmentation is random is
not known. The presence of only small sized fetal DNA in maternal plasma caused
the RQ-PCR on RHD exon 5-361 bp to fail when performed on cell-free fetal DNA
isolated from maternal plasma.The RQ-PCR’s on RHD exon 5 developed by Finning
et al., and the in-house developed RHD exon 7 RQ PCR have amplicons of 82 bps
and 122 bps, respectively. However, not only the size of the DNA fragments may be
important, because if the cell-free fetal DNA is not randomly fragmented, it is possi-
ble that the digestion site is located within the chosen stretch of DNA for
amplification and the PCR will fail or will be less sensitive independent of the ampli-
con size.
This study also presents an RQ-PCR duplex on RHD exon-5 (as developed by
Finning et al)15 and -7 for prenatal genotyping on cell-free plasma DNA and has
been evaluated with two samples carrying a maternal RHD gene. In the original
publication of Finning et al. no maternal RHD positive samples were tested for the
presence of D-negative or D-positive fetal cell-free plasma DNA. However, during
routine screening, one fetal RHD gene was detected in an RHD-negative woman.15
The present study however, shows the importance of including maternal RHD
samples in the evaluation phase of assays developed for diagnostic purposes. In
The Netherlands, the frequency of serologically D-negative pregnant women carry-
ing an RHD gene is 0.25% (unpublished results). Therefore, these samples will be
encountered if the fetal RHD status will be determined routinely to direct the gift of
antenatal anti-D prophylaxis.23 The combination of RHD exon-5 and -7 will prevent
amplification of RHD specific sequences (false positive results) when an (C)cdes
allele is present (RHD1-3, CE3-7, D hybrid allele without D-antigen expression).
More importantly, the accuracy of D-negative typing by the absence of both ampli-
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cons (neither exon 5 nor exon 7) of this strategy has been reported to be 100% 15,
and was confirmed by this study. However, some aberrant RHD alleles may give
results similar to RHD by RQ-PCR on RHD exon-5 and -7 duplex (e.g. Dva) and
therefore complicate interpretation of the RHD genotyping assay. Therefore, when a
fetal sample negative for RHD exon 5 and positive for RHD exon 7 is identified, furt-
her (molecular) analysis of the fetus or the father may be desired. The DIVa variant
will cause an amplicon of exon 5 only, and those fetuses should be regarded as D-
positive. Also D-positive haplotypes have been described to be present in a
D-negative European population which may hamper genotyping with this assay due
to the possible presence of such an allele in the mother, and might lead to false posi-
tive results.24 However, all other known D-variant haplotypes will be (correctly)
recognized as D-positive by the described strategy.
Many fundamental questions remain concerning the characteristics of the circulating
DNA in maternal plasma and the release and elimination of plasma DNA. The pre-
sent study shows that it is very important to develop and evaluate a diagnostic assay
on the relevant cell-free fetal DNA, especially since it is not known whether RHD is
randomly fragmented.
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Rh is the most complex blood group system. The Rh blood group system comprises
46 antigens. Of the RhD antigen alone, more than 50 partial RhD and 40 weak D
types have been described, all caused by molecular alteration(s). The RHD and
RHCE genes, which encode for the RhD and RhCE proteins respectively, are evi-
dently prone to molecular changes. Especially the high homology between the two
genes and the proposed hairpin formation during RNA synthesis cause a great num-
ber of aberrant RHD alleles carrying RHCE nucleotides or RHCE exon(s). Other
causes of molecular alterations that give rise to an altered RhD protein include mis-
sense mutations, nonsense mutations and nucleotide deletions causing a frameshift
and premature stopcodon.1
Most aberrant RHD alleles encode an abnormal (or partial) RhD protein. Carriers of
such partial RhD may form alloantibodies against epitopes of the normal RhD anti-
gen that they lack. Many of the partial RhD phenotypes react weakly with anti-D
reagents. Some aberrant RHD alleles may encode an RhD protein with only a redu-
ced expression of RhD on the red cell surface (the so-called weak D alleles or, when
RhD is only detectable by adsorption elution techniques, Del alleles). Weak D phe-
notypes are caused by amino acid substitutions in the intracellular (cytoplasmic) or
transmembrane-spanning domains of the protein and do not produce alloanti-D.
Weak D phenotypes are treated as regular RhD-positive phenotypes in transfusion
medicine.
The frequency of partial RhD depends on the population. Most aberrant RHD alle-
les caused by multiple missense mutations are more frequently found in (African)
black populations than in Eurasian populations, probably because the alleles that
evolved in blacks have a longer phylogenetic distance from standard RhD (introduc-
tion, figure 4 and chapter 5).
Ethnic variability of RhD-negativity 
The RhD-negative phenotype is found in 15% of the Caucasian population, where-
as only about 5% of the black population is RhD-negative.2 In the Asian population,
RhD-negativity is even more rare (about 0,5%(including Del)).3 The frequency of the
RHD deletion (RhD-negative haplotype) in a white English population is about 0.39.2
The RHD gene deletion is caused by an unequal crossing over event, triggered by
the high homology of the upstream and downstream Rhesus boxes that flank the
RHD gene, resulting in an RH locus without an RHD gene but with a newly created
hybrid Rhesus box.4
Homozygosity for the RHD gene deletion is the main cause of the RhD-negative
phenotype in Caucasians. In non-Caucasian populations, RhD-negativity is associ-
ated with a grossly intact RHD gene. In RhD-negative African blacks, both the
(C)cdes (or r’s) allele and RHD allele are frequently present.5,6 In RhD-negative
Asians, the Del allele is often present.7,8 Due to the extreme low RhD-antigen
expression, which can only be seen by adsorption elution techniques, these pheno-
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types are often classified as RhD-negative. Because of the presence of RhD-nega-
tive RHD genes in non-Caucasian RhD-negative individuals, the true RHD
gene-negative haplotype has a low frequency in non-Caucasians.
Sequencing analysis of the hybrid Rhesus box of the RH locus in RhD-negative
blacks, Asians and Caucasians showed that the hybrid Rhesus box is present in all
populations and that only in blacks, a second hybrid Rhesus box is present (chap-
ter 2). The presence of an identical hybrid Rhesus box indicates that the mechanism
causing the RHD gene deletion is most probably the same for all ethnic groups stu-
died.
Ethnic variability of partial RhD, weak D and Del
The most frequently occurring aberrant RH alleles have been fully explored in black
and Caucasian populations. Studies exploring the RH alleles of Asian populations
and the development of matching RH diagnostic strategies have been published to
a lesser extent.9,10 Between 82% and 88% of Europeans and around 95% of black
Africans are RhD-positive. Among Europeans, the frequency of all (known) partial
RhD combined is less than 1%.11,12 In Africans, the occurrence of aberrant RHD
alleles and anti-D immunizations in RhD-positive individuals is much higher. For
example, 11% of anti-D in pregnancies in the Cape Town area (South-Africa) occur-
red in RhD-positive women.13 Appendix I shows the molecular and ethnic
characteristics of partial RhDs. Although the number of different aberrant RHD alle-
les is higher in Caucasians than in blacks, the population frequencies (or the number
of probands) of the aberrant alleles are considerably higher in blacks. Only a few
aberrant RHD alleles as found in blacks are also identified in Caucasians (like weak
D type 4 and DAU 0) (chapter 5). It is currently unknown whether these alleles were
present during the primary bottleneck (the migration out of Africa) or entered the
Caucasian allele pool by secondary migrations. Many of the Caucasian aberrant
alleles have only been identified in single individuals.The current knowledge of aber-
rant RHD alleles in non-Caucasian populations may be distorted by the limited
amount of research in this area. Extensive knowledge of the aberrant RHD alleles
enables the reconstruction of the evolutionary pathway of RHD by means of RH phy-
logeny. Knowledge about the RH phylogenetics in humans is of practical importance
because it defines the framework for determining clinically relevant RH alleles in any
population.14
Weak D red cells are considered to have all epitopes of RhD expressed weakly, are
not able to produce anti-D and are caused by amino acid substitutions in the int-
racellular (cytoplasmic) or membrane-spanning domains of RhD. Currently, 41
different weak D alleles have been identified.15 However, some individuals classified
as weak D have developed anti-D and are therefore now considered partial RhD (as
recently described for weak D types 4.2, 15 and 26).16,17 Interestingly, we recently
found that the weak D phenotypes 1, 2 and 3, most frequently occurring in
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Caucasians, are not present in blacks from Ethiopia, Curacao and South-Africa or in
Asians from South-Africa.18 The absence of weak D in these groups implies that the
weak D allele is, from an evolutionary point of view, a relatively young type of allele,
which has its origin in Caucasians and has not spread out to other populations yet.
In contrast, the weak D type 4 allele was identified more frequently in blacks than in
Caucasians and Asians.18 The weak D type 4 allele shares two nucleotide substitu-
tions with the partial RhDs DAR and DOL (602C>G, 667T>G) and together these
alleles form the phylogenetical African weak D type 4 cluster. While analyzing this
weak D type 4 cluster we identified an RHD allele with the 667T>G only in a patient
who made an anti-D after a RhD-positive transfusion (chapter 5). Because of the
molecular similarities and serological consequences, it is debatable whether the
weak D type 4 alleles should be classified as weak D.
RhD is a high incidence antigen in the Far-East, even reaching 100% in some popu-
lations. RhD-positivity has been reported to reach 99,7% in Hong-Kong Chinese and
Japanese populations.3 However, a substantial proportion of those classified as
RhD-negative express the Del phenotype. The molecular background for the Del
phenotype is variable (appendix III). Del phenotypes were initially proposed to be
non-immunogenic because the amount of RhD was supposed to be too low to trig-
ger an immune response. However, recently a case was described wherein anti-D
was produced by an RhD-negative patient after transfusion with red cells carrying
the Del phenotype, strongly suggesting that the Del phenotype is immunogenic.19
This finding has great implications for transfusion medicine in those geographical
regions where Del is a frequently occurring phenotype, like most Asian countries.20
The recent identification of anti-D formation by weak D indicates that the original
classification of aberrant Rh proteins in “weak D” and “partial RhD” based on the
location of the amino acid substitution(s) and the presence of anti-D (at the time of
molecular identification) is not very accurate anymore. Maybe all RhD phenotypes
encoded by aberrant RHD alleles should rather be initially regarded as having the
potential to generate anti-D antibodies (partial D) unless proven otherwise.
Ethnic variability of RhCcEe
The RhC and Rhc antigens have Caucasian allele frequencies of 0.44 and 0.56, res-
pectively. In blacks, the frequency of Rhc is much higher and the frequency of RhC
is lower, whereas in Asians RhC and Rhc expression approaches an allele frequen-
cy of 0.75 and  0.25, respectively (table 1).2
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Table 1. Haplotype distributions (in % occurrence) in Caucasian, black and
Asian populations.
Haplotype Caucasians Blacks Asians
CDe (R1) 42 17 70
Cde (r’) 2 2 2
cDE (R2) 14 11 21
cdE (r’’) 1 0 0
cDe (R0) 4 44 3
cde (r) 37 26 3
CDE (Rz) 0 0 1
CdE (ry) 0 0 0
RHC differs from RHc at only 6 nucleotide positions, 4 of which lead to an actual
amino acid substitution. This means that variant RhC and Rhc proteins are rare and
aberrant RHC and RHc alleles are also less frequent. RHC differs from RHD at only
1 coding nucleotide position (nt 48).
The most frequently occurring aberrant RHc allele is caused by a single nucleotide
substitution (48G>C), hampering RHC genotyping.21 The RHce 48G>C allele is
highly frequent in black populations (identified in 67%, 48% and 42% of RhC-positi-
ve blacks from South-Africa, Ethiopia and Curacao, respectively) but does not affect
the expression of Rhc (chapter 3). Most deviant RhC and Rhc antigens are caused
by nucleotide substitutions in the RHD allele rather than in the RHCE alleles (e.g. Dc
and r’s).5,22 The very rare D-- phenotype, in which the red cells express RhD but not
RhC, Rhc, RhE or Rhe, has a heterogeneous molecular genetic background but is
mostly seen in combination with RHD-CE-D hybrid alleles.23
Serological identification of partial RhD and weak D and clinical aspects
Partial RhDs usually lack the expression of one or more RhD epitopes. Therefore,
human monoclonal antibodies can be used for the classification of partial RhD in
terms of expressed epitopes. The current model consists of 37 different epitopes.24
Partial RhD phenotypes differ in their ability to form alloanti-D against the lacking
epitopes. Many partial RhDs give weak reactions with anti-D reagents and can only
be classified by 37 epitope model analysis. The application of this model however, is
dependent on the availability of monoclonal antibodies and the analysis is very com-
plicated and laborious.
In populations with little African admixture (like Caucasians, Asians and Arabs) par-
tial RhD phenotypes are likely to be rare and to derive from the limited and
serologically well-defined set of alleles of the Eurasian allele cluster. Typing strate-
gies for African populations and those with African admixture may take account of
the various frequently occurring alleles of the “African” clusters (chapter 5).14 Several
of these alleles are difficult to discern by serological means and may in the future
143
Discussion
110094_Binnen  08-11-2005  09:15  Pagina 143
warrant genotyping approaches for detection in patients and donors.
Some partial RhD phenotypes are associated with Low Frequency Antigens (LFA).25
These antigens are expressed due to novel structures on the RBC surface and can
be useful markers for the identification of partial RhD.
The predictive value of a method used for medical diagnostics should be as accura-
te as possible. The raw outcome of a test can only be correctly interpreted when the
subject is well defined. When an altered RhD protein is identified in a blood donor,
its products must be labelled RhD-positive. When RBCs with an altered RhD protein
are administered to an RhD-negative recipient, the chance of an immune response
(primary immunization) is present. However, if an altered RhD protein is identified in
a recipient, this recipient must be regarded as RhD-negative. If this recipient recei-
ves RhD-positive blood the chance that antibodies against the missing RhD
epitopes are produced is present.
Weak D blood products should only be administered to RhD-positive patients.
Ongoing research shows that some of the non-frequently occurring phenotypes pri-
marily identified as weak D can develop anti-D when transfused with RhD-positive
red blood cells.16,17 Therefore, recipients identified with weak D phenotypes type 4
and higher, should be regarded as RhD-negative.
The multi-ethnic character of our (Dutch) society is reflected in the population of
blood recipients but unfortunately not in the blood donor population. This may cause
problems with the availability of RhD-negative blood products for people with altered
Rh proteins or antigen combinations that are rare in the donor population. Moreover,
the reliability of standard typing assays is influenced by the ethnic origin of the
donor/recipient.
Molecular identification of RHD
Blood group identification using molecular rather than serological methods is most
often seen when serological typing is difficult. When patients have received multiple
transfusions, it can be very hard to determine the patient’s original blood group due
to the presence of donor red cells in the patient’s circulation. The blood group of a
multiple transfused patient can be obtained by molecular methods. When the Direct
Agglutination Test (DAT) is found positive with the patient’s red blood cells, it is diffi-
cult to serologically type for blood groups by direct agglutination. Molecular tests can
also be of use for donor selection when serological typing reagents are not availa-
ble or of poor quality. Currently, the most reliable method for the determination of
RHD zygosity is molecular analysis (chapter 2).26 Blood group genotype analysis
can also be used to improve the quality of red blood cells to be used as reagent27 or
in cases where no red blood cells are available. Currently, fetal molecular RHD
typing (and in lesser extent K1 and RHc and occasionally other blood groups) is
used for the prediction of the risk of the fetus for Hemolytic Disease of the Fetus and
Newborn (HDFN) in RhD-negative women.28,29 Cell-free fetal DNA can be obtained
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from maternal plasma, eliminating the need for invasive procedures such as amnio-
centesis or chorionic villus sampling for fetal DNA extraction.30,31 The chances of a
(potential) fetus for being RHD-positive and therefore being at risk for HDFN when
the RhD-negative mother-to-be has an anti-D can be elucidated from the RHD zygo-
sity of the father. Therefore, RHD zygosity determination can be used as a
diagnostic tool in prenatal counseling.
High throughput molecular typing methods can be applied to large scale donor
typing for many blood groups.32,33,34 With a large donor population typed for many
blood groups it becomes easier to find a matching blood product for patients with
uncommon antibodies. If blood products are matched for more than just the standard
blood groups the formation of additional antibodies will decrease as well.
Furthermore, large scale donor typing will identify donors that are negative for high
frequency antigens (HFA) which is important for transfusion of patients with anti-HFA
antibodies due to prior transfusion(s) or pregnancy.
Molecular methods are increasingly used in patient diagnostics. For instance, when
an antibody is identified in a recently transfused patient, the origin (allo or auto) of
the antibody can be determined by molecular analysis of the corresponding antigen.
The use of molecular typing methods in patient diagnostics to supplement serologi-
cal testing has been reported to increase the overall accuracy.35
The research presented in this thesis has provided a deeper insight into the ethnic
variability of the RH genes, enabling the development of molecular typing methods
that are reliable in multi-ethnic (heterogeneous) societies. Knowledge of the ethnic
variability of the RH genes is important for the development of molecular screening
methods, like a DNA array (DNA chip technology). However, the research presented
in this thesis is limited by the number of populations studied. It can be anticipated
that more research among populations residing in Africa (like Ghana) and Asia will
show even more variability concerning RH. Mediterranean populations are also rela-
tively unexplored concerning RH.
The molecular typing methods available for RH are complex. Therefore, application
of these methods by blood group identification laboratories is a difficult task when
no in house experts are available. For the accurate development of RH genotyping
strategies it is of great importance that genetic variation is well documented.
The importance of accurate and reliable genotyping by RH variant identification is
dependent on the patient population. In this thesis we have described several mole-
cular typing assays which take into account the most frequently occurring variant
RH genes in blacks. Like for RHC and RHc genotyping on genomic DNA (chapter 3)
and RhD phenotype prediction on cell-free plasma DNA (fetal DNA) (chapter 6). We
also analyzed the molecular background of RhD-negativity in a Chinese Han popu-
lation (chapter 4) in order to facilitate the development of reliable genotyping
strategies. Molecular analysis of the Rhesus boxes flanking the RHD gene in diffe-
rent ethnic groups showed a high variability of the RH locus in nonwhite persons,
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hampering RHD zygosity determination by Rhesus box analysis. Therefore, we
developed a real-time quantitative PCR method on RHD exon 7 to reliably determi-
ne RHD zygosity in different ethnic groups (chapter 2).
In Dutch society, the different ethnicities are now emerging in the patient population
because the first generation of different ethnic groups within Dutch society are now
reaching old age which often comes with ailment and also because pregnancies
with parents from different ethnic backgrounds are becoming more common.
Therefore, the coming years will clarify the clinical importance of accurate RH
typing. So far, the general feeling has been that the variant RH genes were only rare-
ly involved in immunization events. However, only systematic review of unresolved
anti-D immunization in combination with the availability of the typing assays as des-
cribed in this thesis will resolve this issue.17,36 The recent observations of alloanti-D
in weak D type 4 recipients and the induction of alloanti-D by the Del phenotype indi-
cate that this problem might be underestimated.
Evolutionary aspects
The frequency of the aberrant RHD alleles is high in black populations when com-
pared to Asian and Caucasian populations (appendix I). Some aberrant alleles are
only present in a single population whereas other aberrant alleles may be present in
several populations, with different frequencies. This implies that many aberrant RHD
alleles have evolved from the same template. As a template RHD allele is present in
all populations this can be regarded as an H. Sapiens-specific characteristic that has
propagated from its population of origin to all other populations. The population dif-
ference (or ethnic variability) in aberrant alleles can be regarded as part of the
characteristics responsible for regional continuity that have remained restricted to
the population of their origin. The presence of identical aberrant RHD alleles in dif-
ferent ethnic populations may indicate that these alleles were present in H. sapiens
before the expansion of H. sapiens to the diferent regions, strongly supporting the
plausibility of the uniregional hypothesis (see chapter 1, introduction, page 16).
The above also implies that there must be some evolutionary advantage in changing
the RhD protein. It has been postulated that an altered amino acid sequence might
prevent parasites, like Plasmodia that causes malaria, from using the transmembra-
ne Rh proteins for invasion of the red cell. However, a causal relationship has not
been demonstrated. Recently, Rh-related proteins (including RhAG) have been
shown to export ammonia.37,38 It may therefore be speculated that amino acid sub-
stitutions located in transmembraneous Rh protein segments may affect the function
of the Rh protein.
Developments
Large scale (molecular) typing methods are now being developed.32,33,34 For the
identification of aberrant RH alleles so many different areas of the RH genes should
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be investigated, that the DNA microarray seems to be the best format. The aim of
large scale donor typing is to have a fully typed donor population in order to be able
to match for more antigens and subsequently diminish (additional) antibody forma-
tion. Avoiding antibody formation is especially important for women of child bearing
age and patients that regularly need transfusions, like people who suffer from hemo-
globinopathies (like sickle cell anaemia and thalassemia, not uncommon in
non-Caucasian populations) and patients who suffer from hemolytic anaemias. Most
blood groups other than ABO and Rh are encoded by Single Nucleotide
Polymorphisms (or SNPs). Because these blood group systems have no homologue
genes present on the same chromosome (except the MNSs blood group system)
they are less prone to genetic variation within the coding allele. SNP-based blood
groups may be suitable candidates to include in large scale molecular typing
methods.The RH system however, is very complex and not fully explored (yet). Even
in Caucasian/European populations, RhD-negative RHD alleles and new variant
alleles are continuously identified.17,39 With the current knowledge of the RH system
most aberrant alleles can be identified. It is, however, virtually impossible to map all
low frequency aberrant alleles because the emerging of aberrant alleles is infinite
(intrinsic to evolution).
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Appendix I 
Characteristics of partial RhDs.
DII 1060C>G A354D EC Ce One C
1061C>A A354D EC
DIIIa 455A>C N152T TM ce, Many B
602C>G T201R IC G+
667T>G F223V TM
DIIIb 90T>C 30F ce, Few B
178A>C I60L TM G-
203G>A S68N TM
307T>C S103P EC
DIIIc 361T>A L121M TM Ce, Many C
380T>C V127A TM G+
383A>G D128G TM
455A>C N152T TM
DIII 186G>T L62F TM - Few C
Type 4 410C>T 137A
455A>C N152T TM
DIII 186G>T L62F TM ce One
Type 5 410C>T 137A
455A>C N152T TM
602C>G T201R IC
667T>G F223V TM
819G>A 273A
DIII 410C>T 137A B
type 6 455A>C N152T TM
602C>G T201R IC
667T>G F223V TM
819G>A 273A
153
N
am
e
N
ucleotide
Change
Protein
Sequence
M
em
bra
n
e
Localization
M
olecular Basis
Associated 
H
aplotype
N
um
ber of
Probands
Ethnic
O
rigin*
s
s
s
s
s
s
110094_Binnen  08-11-2005  09:15  Pagina 153
DIII exon 2D>C EC B
type 7 410C>T 137A
455A>C 152N>T TM
602C>G 201T>R IC
667T>G 223F>V TM
819G>A 273A
DIVa 186G>T L62F TM ce Many B
455A>C N152T TM
1048G>C D350H EC
DIVb 1048G>C D350H EC
type 2 1053C>T 351T
1057G>T G353T EC
1059A>G G353T EC
1060G>A A354N EC
1061C>A A354N EC
1170T>C 389L
1193A>T E398V IC
DIVb DIVb type 2DIVb type 2 Ce One C
type 3 916G>A V306I TM
932A>G Y311C IC
941G>T G314V IC
968C>A P323H IC
974G>T S325I IC
979A>G I327V IC
985G>C G329H IC
986G>A G329H IC
989A>C Y330S IC
992A>T N331I IC
1025T>C I342T TM
DIVb 1048G>C D350H EC Ce Several
type 4 1057G>T G353T EC
1059A>G G353T EC
1060G>A A354N EC
1061C>A A354N EC
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DVI Dva(HUS) Dva(HUS)EC/TM/IC cE Many C
type 1 505A>C M169L EC
509T>G M170R EC
514A>T I172F EC
544T>A S182T TM
577G>A E193K IC
594A>T K298N IC
602C>G T201R IC
DVI DVI type 1 DVI type 1 EC/TM/IC Ce Many C,
type 2 916G>A V306I IC J
932A>G Y311C IC
DVI DVI type 2 DVI type 2 EC/TM/IC Ce Few C
type 3 361T>A L121M TM
380T>C V127A TM
383A>G D128G TM
455A>C N152T TM
DVII 329T>C L110P EC Ce Many C
DAR 602C>G T201R IC ce Many B
667T>G F223V TM
1025T>C I342T TM
DAU-0 1136C>T T379M TM ce Few C
DAU-1 DAU-0 DAU-0 TM ce One B
689G>T S230I EC
DAU-2 DAU-0 DAU-0 TM ce One B
209G>A R70Q TM
998G>A S333N IC
DAU-3 DAU-0 DAU-0 TM ce One B
835G>A V279M TM
DAU-4 DAU-0 DAU-0 TM ce One B
697G>A E233K EC
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DBT DVa (HUS) DVa (HUS) EC/TM/IC
Ce> Several C,
type 1 916G>A V306I TM (C) B,
932A>G Y311C IC (e) J
941G>T G314V IC and
968C>A P323H IC ce
974G>T S325I IC
979A>G I327V IC
985G>C G329H IC
986G>A G329H IC
989A>C Y330S IC
992A>T N331I IC
1025T>C I342T TM
1048G>C D350H EC
1053C>T 351T EC
1057G>T G353T EC
1059A>G G353T EC
1060G>A A354N EC
1061C>A A354N EC
DBT DBT type 1 DBT type 1EC/TM/IC Ce  Several J
type 2 1170T>C 389L
1193A>T E398V IC
DFR 505A>C M169L EC Ce> Many C
509T>G M170R EC cE
514A>T I172F EC
DFW 497A>C H166P EC Ce One C
DHMi 848C>T T283I TM cE  Several C
DHO 704A>C K235T Ce C
DHR 686G>A R229K cE C
DIM 854G>A C285Y cE One C
DMH 161T>C L54P ce C
DNB 1063G>A G355S Ce Many C
DNU 1057G>A G353R Ce Few C
DOL 509T>G M170T EC ce  Several B
667T>G F223V TM
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DHAR/ RHCE- multiple c(e) Many C
R0HARRHD exon5- G-
RHCE
* B=blacks, C=Caucasian and J=Japanese.
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Appendix II 
Characteristics of the RhD category V phenotype
Name Nucleotide Protein Membrane Molecular Basis
Change Sequence Localization RHD exon 5
DVa (KOU)/FH 667T>G 223F>V TM
697G>C 233E>Q EC
DVa (HUS) 667T>G 223F>V TM
697G>C 233E>Q EC
712G>A 238V>M EC or
733G>C 245V>L TM
787G>A 263G>R IC
800A>T 267K>M TM
DVa (TO) 697G>C 233E>Q EC
712G>A 238V>M EC
DVa-like YH/TT 667T>G 223F>V TM
697G>C 233E>Q EC
712G>A 238V>M EC
DV type VII 667T>G 223F>V TM
697G>C 233E>Q EC
712G>A 238V>M EC
733G>C 245V>L TM
787G>A 263G>R IC
Dva-associated 697G>A 233E>K EC
HK/DYO
Dva-associated 697G>C 233E>Q EC
SM
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Appendix III 
Characteristics of the Del phenotype
Name Nucleotide Protein Associated Number of Ethnic Origin*
Change Sequence Haplotype Probands
Del IVS3+1G>A - Ce Few C
Del IVS8+1G>A - Ce One C
Del 885G>T 295M>I Ce Few C
Del 1227G>A - Ce many A
Del 1013 bp deletion, - - Few A
including exon 9
* A=Asian and C=Caucasian
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Summary
The RhD bloodgroup was first described by Levine en Stetson in 1939 after the
manifestation of a hemolytic transfusion reaction in a woman who recently gave
birth, after transfusion with her husbands red cells. The RhD-negative woman pro-
duced antibodies against the RhD present on the red cells of her child. The child
inherited the antigenic character from her father. Nowadays, the initial antibody pro-
duction in pregnant women is prevented by means of anti-D prophylaxis because
this antibody may cause severe hemolytic disease of the newborn in a next preg-
nancy. Also, the presence of anti-D in a patient who is transfused with RhD-positive
red cells may give rise to a severe hemolytic transfusion reaction. The Rh phenoty-
pe can be determined by means of serological techniques based on agglutination of
a known antibody (anti-D in this case) with the erythrocytes. In cases where no red
cells are available  (like in prenatal diagnostics) or when serological testing is ham-
pered (like after a recent transfusion or when it is difficult to obtain the antibody) the
Rh phenotype can be predicted from DNA analysis. To be able to make a reliable
prediction of the Rh phenotype, it is important to genotype on those DNA stretches
that are the least prone to changes and that are equal among different ethnic
groups. The research described in this thesis has tried to map the ethnic differences
in RH genes and to develop reliable genotyping methods that can be applied in a
multi-ethnic society.
The discovery of the physical structure of the RH locus and the mechanism causing
the RHD gene deletion in RhD-negative white populations has made it possible to
genotype for the absence of the RHD gene (RhD-negativity) by means of the hybrid
Rhesus box (PCR-RFLP). Knowledge about RHD zygosity is of clinical interest for
prenatal counselling when a woman has developed anti-D and the father is RhD-
positive. The chance of a RhD-positive child is 50% when the father carries one
RHD gene (hemizygous for RHD) and 100% when the father carries two RHD genes
(homozygous for RHD). Chapter 2 describes the analysis of the RH locus among dif-
ferent ethnic populations (blacks from South-Africa, Curaçao and Ethiopia, Asians
fom South-Africa and Caucasians from The Netherlands). Apart from the confirma-
tion of the known fact that RhD-negativity in non-Caucasians is frequently caused
by the RHD and/or the r’s gene, we showed that the DNA sequence of Rhesus
boxes is highly variable in non-Caucasians (aberrant sequences of Rhesus boxes
were found with a frequency of 0.22 in RhD-positive RHD homozygous black popu-
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lations). These aberrant Rhesus boxes cause a false negative prediction for the pre-
sence of an RHD gene by PCR-RFLP.To be able to reliably predict the RHD zygosity
in a multi-ethnic society, a real time quantitative PCR method on RHD exon 7 was
developed and evaluated. The real time quantitative PCR method gives more relia-
ble results than the PCR-RFLP method and is the preferred method for RHD
zygosity determination.
In chapter 3 the reliability of the prediction of the RhC and Rhc phenotypes by geno-
typing among different ethnic groups was studied. Blood samples of people from five
different ethnic groups (blacks from South-Africa, Curaçao and Ethiopia, Asians fom
South-Africa and Caucasians from The Netherlands) were genotyped for RHC and
RHc and the genotyping results were compared with the results from serological
analysis. RHc genotyping was performed on two different coding nucleotide positi-
ons, namely nt 178C (RHc ASPA) and 307C (RHC/c MPX PCR). No discrepancies
were found between genotyping and serology. Therefore, both nucleotide positions
are a reliable predictor for the Rhc phenotype. However, because of the existence of
the Dc allele (variant RHD gene with Rhc expression because of a 307T>C mutati-
on) genotyping on 307C is the preferred method. RHC genotyping was performed
on the RHC coding nt 48C (RHC ASPA) and on a RHC specific 109 bp insert in
intron 2 of the RHC allele (RHC/c/MPX PCR). When compared with serology, 43.3%
of the serological RhC-negative samples showed a false positive prediction of the
RhC phenotype (false positive for RhC) with the nt 48C method. This discrepancy
was caused by the presence of an RHce allele with a nt 48G>C substitution which
was identified in all ethnic groups that were analyzed. The nt 48G>C substitution
does not influence the expression of Rhc. False negative predictions of the RHC
phenotype were not made with this method. The RHC genotyping method on the
109 bp insert in RHC intron 2 generated a false negative prediction of the RhC phe-
notype in 7.3% of the RhC-positive samples. This discrepancy was caused by the
presence of an r’s allele that was only identified in blacks from Curaçao and South-
Africa and in one Caucasian blood donor. To improve the reliability of the present
RHC genotyping techniques, the existing RHC/c MPX PCR method was extended
with specific PCRs for the detection of the r’s allele (RHC/c/hex3 method, possibly
in combination of the intron4/exon7 MPX PCR) and validated on the same samples.
This method resulted in a correct predictive value of 100% for the Rhc phenotype
and 99.8% for the RhC phenotype.
Chapter 4 describes the RHD gene analysis and RHD zygosity determination in a
selected group of RhD-negative Chinese Han blood donors (n=74). No specific RHD
sequences were identified in 46 RhD-negative samples (62%) that also showed the
hybrid Rhesus box only (indicative for the RHD gene deletion). 22 Samples (30%)
showed the presence of the Del genotype (nt 1227G>A) which causes a very weak
164
Summary
110094_Binnen  08-11-2005  09:15  Pagina 164
expression of RhD. In 5 samples (7%), a hybrid RHD-RHCE-RHD gene was identi-
fied. In 1 sample (1.4%) a new nonsense mutation was identified (933C>A).
RhD-negativity in the presence of an RHD specific sequences is often found in the
Chinese Han population. The main cause for the discrepancy between serology and
genotyping was caused by the Del phenotype which is typed RhD-negative by stan-
dard serological methods. Therefore, in a RhD-negative Chinese Han population,
genotyping is preferable to serological typing.
Chapter 5 describes the analysis of the weak D type 4 cluster (characterized by nts
602G and 667G) from a phylogenetic perspective. For this purpose, 80 samples
were selected (from a total of 1702 samples from 5 different ethnic groups) for the
presence of nt 602G in combination with 667G and were analyzed further. Apart
from the known and expected variant RHD alleles, three new variant RHD alleles
were identified using molecular methods, and where possible serological methods.
By identifying new variant RHD alleles it is possible to refine the existing RH phylo-
geny. In this analysis we also identified the RHD(F223V)(602C>G) and RHD(T201R,
F223V)(602C>G, 667T>G) alleles which gave us formal proof for the origin of the
weak D type 4 cluster. Furthermore, we identified the 1136C>T nucleotide substitu-
tion (characteristic for the DAU allele cluster) to be present on two DVa(KOU) alleles.
This “new” allele is probably caused by gene conversion of the DAU0 allele and the
DVa(KOU) allele, most probably forming a phylogenetic link between the DAU clus-
ter and the DV allele cluster, proposed in this chapter.
Knowledge about the RhD-status of a fetus is important for the prevention of RhD
immunization in RhD-negative women. Also the administration of anti-D prophylaxis
can be based on whether the fetus is positive or negative for RhD. This prevents the
administration of anti-D to those mothers that carry an RhD-negative fetus. The dis-
covery of cell-free fetal DNA in maternal plasma led to the development of several
assays to predict the fetal D-status using RHD-specific sequences. Few assays are
designed in such a way that RhD-negative RHD genes are taken into account (like
the RHD, present in the majority of D-negative African blacks) hampering correct
genotyping of the fetus in RHD-positive mothers and leading to a false positive pre-
diction of the RhD-status when the fetus carries an RHD. Chapter 6 describes the
development of a reliable prenatal genotyping method on genomic DNA and the
evaluation of this method on cell-free plasma DNA. During the course of events, the
importance of the use of the proper material (in this case cell-free plasma DNA)
during the development of a genotyping method on cell-free plasma DNA was
emphasized because of the different characteristics of genomic DNA and cell-free
plasma DNA and due to the limited knowledge in this area. Chapter 6 describes an
RHD genotyping method that generates a product of 361 base pairs (bp) and shows
a high specificity and sensitivity on genomic DNA but does not generate a product
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when used with cell-free plasma DNA. During this research, it was published that the
majority of cell-free plasma DNA present in the maternal circulation has a size dis-
tribution of 145 to 201 bp, which explained why no 361 bp product was amplified.
Eventually, a previously published RHD genotyping method was evaluated on cell-
free plasma DNA of RhD-negative RHD-positive pregnant women and showed
maximal specificity and sensitivity.
In chapter 7, the discussion, the findings as described in the previous chapters are
shown in a broader perspective based on the present knowledge about the (ethnic)
variability of the Rh blood group system. Also, attention is given to the advantages
and disadvantages of possible future genotyping methods for both blood donors and
blood recipients.
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Samenvatting
De RhD bloedgroep werd voor het eerst beschreven door Levine en Stetson in 1939
nadat een hemolytische transfusie reactie was opgetreden in een pas bevallen
vrouw na transfusie met bloed van haar man. De RhD-negatieve vrouw bleek anti-
stoffen gemaakt te hebben tegen het RhD dat aanwezig was op de cellen van haar
kind. Het kind had deze antigene eigenschap geërfd van de vader. Tegenwoordig
wordt geprobeerd deze initiële antistofvorming in zwangere vrouwen te voorkómen
door middel van anti-D prophylaxe omdat deze antistofvorming aanleiding kan
geven tot ernstige hemolytische ziekte van de pasgeborene bij een volgende zwan-
gerschap. Ook kan de aanwezigheid van anti-D in een patiënt die getransfundeerd
wordt met RhD-positief bloed leiden tot een ernstige hemolytische transfusiereactie.
Het Rh fenotype kan worden vastgesteld met behulp van serologische technieken
op basis van agglutinatie van een bekende antistof (in dit geval anti-D) met de te
typeren erytrocyten. In die gevallen waarin geen rode cellen voorhanden zijn (bij-
voorbeeld in prenatale diagnostiek) of wanneer serologische bepalingen worden
bemoeilijkt (bijvoorbeeld na recente transfusie of wanneer een antistof moeilijk ver-
krijgbaar is) kan het Rh fenotype worden voorspeld uit DNA analyse. Om een goede
voorspelling van het Rh fenotype te kunnen doen, is het van belang om te genoty-
peren op die delen van het DNA die zo min mogelijk onderhevig zijn aan
veranderingen en die gelijk zijn binnen verschillende etnische groepen. Het onder-
zoek zoals beschreven in dit proefschrift heeft getracht om de etnische verschillen
tussen de RH genen in kaart te brengen en betrouwbare genotypeer methoden te
ontwikkelen die kunnen worden toegepast in een multi-etnische samenleving.
Door de ontdekking van de fysieke structuur van de RH locus en het mechanisme
dat de RHD gen deletie veroorzaakt in Kaukasische RhD-negatieven is het mogelijk
geworden om te genotyperen voor de afwezigheid van het RHD-gen (RhD-negativi-
teit) met behulp van de hybride Rhesus box (PCR-RFLP). Kennis over RHD
zygositeit is van klinisch belang voor prenatale counseling bij een vrouw die anti-D
heeft ontwikkeld en de vader RhD-positief is. De kans op een RhD-positief kind is
50% wanneer de vader één RHD gen draagt (hemizigoot voor RHD) en 100% wan-
neer de vader twee RHD genen draagt (homozygoot voor RHD). Hoofdstuk 2
beschrijft de analyse van de RH locus in verschillende etnische populaties (negroï-
den uit Zuid-Afrika, Curaçao en Ethiopië, aziaten uit Zuid-Afrika en kaukasiërs uit
Nederland). Naast het bevestigen van het reeds bekende feit dat in niet-kaukasische
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populaties RhD-negativiteit vaak wordt veroorzaakt door het RHD en/of het r’s gen,
hebben we aangetoond dat de DNA sequentie van de Rhesus boxen in niet-kauka-
siërs zeer variabel is (afwijkende sequenties in de Rhesus boxen werden gevonden
met een frequentie van 0.22 in RhD-positieve RHD homozygote negroïde popula-
ties). Deze afwijkende Rhesus boxen geven een vals negatieve voorspelling voor de
aanwezigheid van een RHD gen met de PCR-RFLP methode. Om toch de RHD
zygositeit betrouwbaar te kunnen bepalen in een multi-etnische samenleving is een
kwantitatieve real-time PCR methode op RHD exon 7 ontwikkeld en geëvalueerd.
De kwantitatieve real-time PCR methode geeft beter betrouwbare resultaten dan de
PCR-RFLP en is de aanbevolen methode voor het bepalen van de RHD zygositeit.
In hoofdstuk 3 is de betrouwbaarheid van de voorspelling van het Rhc en RhC feno-
type middels genotypering in verschillende etnische groepen bestudeerd.
Bloedmonsters afkomstig van mensen uit 5 verschillende etnische groepen (negro-
ïden uit Zuid-Afrika, Curaçao en Ethiopië, aziaten uit Zuid-Afrika en kaukasiërs uit
Nederland) zijn gegenotypeerd voor RHc en RHC en deze resultaten zijn vergele-
ken met de resultaten van de serologische analyse. Voor RHc genotypering zijn
twee verschillende coderende nucleotiden (nt) bekeken, namelijk nt. 178C (RHc
ASPA) en nt. 307C (RHC/c MPX PCR). Er werden geen discrepanties gevonden tus-
sen het genotyperen en de serologie, daarom zijn beide RHc specifieke nucleotiden
een betrouwbare voorspeller voor het Rhc fenotype. Vanwege het voorkomen van
een Dc allel (variant RHD allel met Rhc expressie als gevolg van een 307T>C muta-
tie) geniet genotyperen van RHc op nt 307C de voorkeur. De RHC genotypering is
uitgevoerd op basis van het RHC specifieke nt. 48C (RHC ASPA) en op basis van
een RHC specifiek 109 bp insert in intron 2 van het RHC allel (RHC/c MPX PCR).
Vergeleken met de serologie gaf 43.3% van de serologisch RhC-negatieven een
vals positieve voorspelling van het fenotype (onterecht RhC-positief) met de nt. 48C
methode. Deze discrepantie werd veroorzaakt door de aanwezigheid van een RHce
allel met een nt. 48G>C substitutie welke voorkomt in alle bestudeerde etnische
groepen. De 48G>C substitutie heeft geen invloed op de expressie van Rhc. Vals
negatieve voorspellingen kwamen met deze assay niet voor. Met de assay geba-
seerd op het 109 bp insert in RHC intron 2 gaf 7.3% van de serologisch
RhC-positieven een vals negatieve voorspelling van het fenotype. Deze discrepan-
tie werd veroorzaakt door de aanwezigheid van een r’s allel welke alleen werd
geïdentificeerd in negroïden uit Curaçao en Zuid-Afrika en in één kaukasische
bloeddonor. Om de betrouwbaarheid van de huidige RHCc genotypeertechniek te
verhogen, is de RHC/c MPX PCR uitgebreid met specifieke PCRs welke tevens het
r’s allel aantonen (RHC/c/hex3 methode, wel of niet in combinatie met intron4/exon
7 MPX PCR) en gevalideerd op dezelfde monsters. Dit heeft geresulteerd in een
juiste voorspellingswaarde van 100% voor het Rhc en 99.8% voor het RhC fenotype.
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Hoofdstuk 4 beschrijft de RHD gen analyse en RHD zygositeitsbepaling in een
geselecteerde RhD-negatieve Chinese Han populatie van bloeddonoren (n=74). In
46 RhD-negatieve monsters (62%) werden geen RHD-specifieke exonen gevonden
en werd ook alleen de hybride Rhesus box aangetoond (karakteristiek voor RHD
gen deletie). In 22 monsters (30%) werd het Del genotype dat gepaard gaat met een
zeer zwakke RhD expressie (nt 1227G>A) vastgesteld. In 5 monsters (7%) werd een
hybride RHD-RHCE-RHD gen geïdentificeerd. In 1 monster (1.4%) werd een nieu-
we nonsense mutatie geïdentificeerd (933C>A). RhD-negativiteit in de
aanwezigheid van RHD specifieke sequenties komt veel voor binnen de Chinese
Han populatie. De grootste discrepantie tussen serologie en genotypering werd ver-
oorzaakt door het Del fenotype welke met de standaard serologische technieken als
RhD-negatief wordt getypeerd. Daarom verdient in de RhD-negatieve Chinese Han
populatie het genotyperen de voorkeur boven serologische typering.
Hoofdstuk 5 beschrijft de analyse van het zwak D type 4 cluster (gekenmerkt door
nts 602G en 667G) vanuit fylogenetisch perspectief. Hiertoe zijn 80 monsters (uit
1702 monsters afkomstig van vijf etnische groepen) geselecteerd op de aanwezig-
heid van nt 602G in combinatie met nt 667G en moleculair gekarakteriseerd. Naast
de bekende variant RHD allelen werden ook drie nieuwe variant RHD allelen mole-
culair, en wanneer mogelijk tevens serologisch, geïdentificeerd. Middels de
identificatie van nieuwe variant RHD allelen is het mogelijk om de fylogenetische
boom voor RH te verfijnen. Tevens werden in deze analyse de twee allelen geïden-
tificeerd die de grondslag leggen voor het gehele zwak D type 4 cluster
(RHD(F223V)(602C>G) en RHD(T201R, F223V)(602C>G, 667T>G), de hoofdtak-
ken). In twee DVa(KOU) variant allelen werd een mutatie gevonden die voorheen
exclusief werd toegeschreven aan het DAU0 allel. Dit “nieuwe” allel is zeer waar-
schijnlijk ontstaan door een gen conversie van het DAU0 allel en het DVa(KOU) allel
waardoor deze zeer waarschijnlijk een fylogenetische link vormt tussen het DAU
allel cluster en het in dit hoofdstuk voorgestelde DV allel cluster.
Kennis omtrent de RhD-status van een foetus is van belang voor de preventie van
RhD-immunizatie bij RhD-negatieve vrouwen. Tevens kan, wanneer bekend is of de
foetus RhD-positief danwel negatief is, het geven van anti-D profylaxe hierop afge-
stemd worden. Dit voorkomt onnodige toedienning van anti-D in geval van een
RhD-negatieve foetus. Sinds de ontdekking van foetaal DNA in de maternale circu-
latie zijn meerdere RHD genotypeerstrategieën ontwikkeld op cel-vrij plasma
(foetaal) DNA dat wordt geïsoleerd uit maternaal plasma. Slechts weinig strategieën
houden rekening met RhD-negatieve RHD genen (zoals het in negroïden zeer fre-
quent voorkomende RHD waardoor foetale genotypering bij RHD-positieve
aanstaande moeders wordt bemoeilijkt en de foetus alsnog ten onrechte als RhD-
positief kan worden beschouwd wanneer deze zelf een RHD draagt. Hoofdstuk 6
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beschrijft het opzetten van een betrouwbare prenatale RHD genotypeerassay op
genomisch DNA en de evaluatie van deze test op cel vrij plasma DNA. Hierbij kwam
het belang naar voren van het gebruik van het eigenlijke uitgangsmateriaal (in dit
geval cel-vrij plasma DNA) bij het opzetten van een genotypeer assay op cel-vrij
plasma DNA omdat gebleken is dat genomisch DNA en cel-vrij plasma DNA ver-
schillende eigenschappen hebben en de kennis op dit gebied beperkt is. Hoofdstuk
6 beschrijft een RHD genotypeerassay die een produkt genereert van 361 basepa-
ren (bp) en een hoge specificiteit en sensitiviteit kent op genomisch DNA maar geen
product genereert wanneer cel-vrij plasma DNA wordt gebruikt. Ten tijde van deze
bevinding werd door anderen gepubliceerd dat het meeste in maternaal plasma cir-
culerende DNA een grootte heeft tussen 145-201 bp hetgeen verklaarde waarom
geen 361 bp product werd gegenereerd. Een elders gepubliceerde RHD genoty-
peermethode werd uiteindelijk geëvalueerd op het celvrij plasma DNA van
RhD-negatieve RHD-positieve zwangere vrouwen en liet een maximale specifici-
teit en sensitiviteit zien.
In hoofdstuk 7, de discussie, worden de bevindingen zoals beschreven in de voor-
gaande hoofdstukken van dit proefschrift in een breder daglicht geplaatst aan de
hand van de huidige kennis op het gebied van de (etnische) vaiabiliteit van het Rh
bloedgroepsysteem. Daarnaast wordt ook aandacht besteed aan de voor- en nade-
len van mogelijk toekomstige genotypeermethoden voor zowel de donors als
ontvangers van bloed.
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Een promovendus met meerdere werkplekken heeft vreselijk veel vrije dagen.
Wanneer ik na een paar weken zwoegen in Dordrecht weer eens in Amsterdam
kwam kijken was de vaste vraag: “Hé, daar ben je weer, fijne vakantie gehad?”
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Joyce, hoewel nog niet zo lang op O&O werkzaam heb je bergen werk verzet. Weet
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te worden, ik wil jullie bedanken voor jullie inzet. Ook mijn nieuwe collega’s op het
IHD-RES lab. wil ik graag bedanken voor hun interesse in het onderzoek en geduld
als ik nog “even iets moest aftypen”, het is nu echt klaar hoor!
Ook buiten het lab zijn er vele mensen die mij hebben geholpen door hun interesse
te tonen en begrip te hebben voor het afzeggen van afspraken of het er stiekem tus-
senuitknijpen wanneer er weer een of andere deadline dreigde te passeren. Bedankt
allemaal!
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